<?xml version='1.0' encoding='utf-8'?>
<ns0:drugbank xmlns:ns0="http://www.drugbank.ca" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.drugbank.ca http://www.drugbank.ca/docs/drugbank.xsd" version="5.1" exported-on="2026-01-04"><ns0:drug type="small molecule" created="2020-09-10" updated="2023-12-05">
  <ns0:drugbank-id primary="true">DB15822</ns0:drugbank-id>
  <ns0:name>Pralsetinib</ns0:name>
  <ns0:description>Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity.[A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, L15986]

Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment of metastatic RET-fusion positive non-small cell lung cancer. It is currently marketed under the brand name GAVRETO™ by Blueprint Medicines.[L15986]</ns0:description>
  <ns0:cas-number>2097132-94-8</ns0:cas-number>
  <ns0:unii>1WPE73O1WV</ns0:unii>
  <ns0:average-mass>533.612</ns0:average-mass>
  <ns0:monoisotopic-mass>533.266299469</ns0:monoisotopic-mass>
  <ns0:state>solid</ns0:state>
  <ns0:groups>
    <ns0:group>approved</ns0:group>
    <ns0:group>investigational</ns0:group>
  </ns0:groups>
  <ns0:general-references>
    <ns0:articles>
      <ns0:article>
        <ns0:ref-id>A202049</ns0:ref-id>
        <ns0:pubmed-id>32296961</ns0:pubmed-id>
        <ns0:citation>Russo A, Lopes AR, McCusker MG, Garrigues SG, Ricciardi GR, Arensmeyer KE, Scilla KA, Mehra R, Rolfo C: New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1). Curr Oncol Rep. 2020 Apr 16;22(5):48. doi: 10.1007/s11912-020-00909-8.</ns0:citation>
      </ns0:article>
      <ns0:article>
        <ns0:ref-id>A202046</ns0:ref-id>
        <ns0:pubmed-id>31715421</ns0:pubmed-id>
        <ns0:citation>Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, Mehra R, Adamo V, Rolfo C: RET fusions in solid tumors. Cancer Treat Rev. 2019 Dec;81:101911. doi: 10.1016/j.ctrv.2019.101911. Epub 2019 Oct 30.</ns0:citation>
      </ns0:article>
      <ns0:article>
        <ns0:ref-id>A202055</ns0:ref-id>
        <ns0:pubmed-id>32083997</ns0:pubmed-id>
        <ns0:citation>Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F: State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020 Apr 10;38(11):1209-1221. doi: 10.1200/JCO.19.02551. Epub 2020 Feb 21.</ns0:citation>
      </ns0:article>
      <ns0:article>
        <ns0:ref-id>A219746</ns0:ref-id>
        <ns0:pubmed-id>32782485</ns0:pubmed-id>
        <ns0:citation>Stinchcombe TE: Current management of RET rearranged non-small cell lung cancer. Ther Adv Med Oncol. 2020 Jul 26;12:1758835920928634. doi: 10.1177/1758835920928634. eCollection 2020.</ns0:citation>
      </ns0:article>
      <ns0:article>
        <ns0:ref-id>A219751</ns0:ref-id>
        <ns0:pubmed-id>29657135</ns0:pubmed-id>
        <ns0:citation>Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK: Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15.</ns0:citation>
      </ns0:article>
      <ns0:article>
        <ns0:ref-id>A202061</ns0:ref-id>
        <ns0:pubmed-id>2992805</ns0:pubmed-id>
        <ns0:citation>Takahashi M, Ritz J, Cooper GM: Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985 Sep;42(2):581-8. doi: 10.1016/0092-8674(85)90115-1.</ns0:citation>
      </ns0:article>
      <ns0:article>
        <ns0:ref-id>A202073</ns0:ref-id>
        <ns0:pubmed-id>25047660</ns0:pubmed-id>
        <ns0:citation>Qian Y, Chai S, Liang Z, Wang Y, Zhou Y, Xu X, Zhang C, Zhang M, Si J, Huang F, Huang Z, Hong W, Wang K: KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer. Mol Cancer. 2014 Jul 21;13:176. doi: 10.1186/1476-4598-13-176.</ns0:citation>
      </ns0:article>
      <ns0:article>
        <ns0:ref-id>A219756</ns0:ref-id>
        <ns0:pubmed-id>30257958</ns0:pubmed-id>
        <ns0:citation>Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW, Marcoux N, Banwait MK, Digumarthy SR, Su W, Yoda S, Riley AK, Nangia V, Lin JJ, Nagy RJ, Lanman RB, Dias-Santagata D, Mino-Kenudson M, Iafrate AJ, Heist RS, Shaw AT, Evans EK, Clifford C, Ou SI, Wolf B, Hata AN, Sequist LV: Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26.</ns0:citation>
      </ns0:article>
    </ns0:articles>
    <ns0:textbooks />
    <ns0:links>
      <ns0:link>
        <ns0:ref-id>L15986</ns0:ref-id>
        <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
        <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
      </ns0:link>
      <ns0:link>
        <ns0:ref-id>L15988</ns0:ref-id>
        <ns0:title>Pralsetinib product sheet</ns0:title>
        <ns0:url>https://file.medchemexpress.com/batch_PDF/HY-112301/Pralsetinib-DataSheet-MedChemExpress.pdf</ns0:url>
      </ns0:link>
      <ns0:link>
        <ns0:ref-id>L39249</ns0:ref-id>
        <ns0:title>Roche News Release: Gavreto for the treatment of NSCLC</ns0:title>
        <ns0:url>https://www.globenewswire.com/news-release/2021/11/19/2338282/0/en/European-Commission-approves-Roche-s-Gavreto-pralsetinib-for-the-treatment-of-adults-with-RET-fusion-positive-advanced-non-small-cell-lung-cancer.html</ns0:url>
      </ns0:link>
      <ns0:link>
        <ns0:ref-id>L47276</ns0:ref-id>
        <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) capsules, for oral use (July 2023)</ns0:title>
        <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s011lbl.pdf</ns0:url>
      </ns0:link>
      <ns0:link>
        <ns0:ref-id>L47905</ns0:ref-id>
        <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) capsules, for oral use (August 2023)</ns0:title>
        <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf</ns0:url>
      </ns0:link>
    </ns0:links>
    <ns0:attachments />
  </ns0:general-references>
  <ns0:synthesis-reference>Jason D. Brubaker, Joseph L.  Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro, "Inhibitors of ret." U.S. Patent US20170121312A1, issued July 24, 2018.</ns0:synthesis-reference>
  <ns0:indication>Pralsetinib is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients who are confirmed to possess a rearranged during transfection (RET) gene fusion, as determined by an FDA approved test.[L15986] It is also indicated in adult and pediatric patients 12 years of age and older for the treatment of advanced or metastatic _RET_ fusion-positive thyroid cancer who require systemic therapy and for whom radioactive iodine is not appropriate.[L47905] The indication for advanced or metastatic _RET_ fusion-positive thyroid cancer was approved under accelerated approval based on the overall response rate and duration of response, and continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.[L47905] 

</ns0:indication>
  <ns0:pharmacodynamics>Pralsetinib exerts an anti-tumour effect through specific inhibition of the rearranged during transfection (RET) tyrosine kinase, including multiple distinct oncogenic RET fusions, mutated RET kinase domains harbouring gatekeeper mutations, and in RET kinases with a variety of activating single point mutations.[A202049, A202046, A202055, A219746, L15986] Due to pralsetinib's high selectivity for RET over other kinases, both _in vitro_ and _in vivo_,[A219751] pralsetinib has been described as having a better safety profile compared to previously used multi-kinase inhibitors.[A202049, A202046, A202055, A219746] Despite this, pralsetinib use may increase the risk of hypertension, hemorrhagic events, impaired wound healing, hepatotoxicity, interstitial lung disease/pneumonitis, and embryo-fetal toxicity.[L15986]</ns0:pharmacodynamics>
  <ns0:mechanism-of-action>Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase containing extracellular, transmembrane, and intracellular domains whose activity is required for normal kidney and nervous system development.[A202061, A202055] Constitutive RET activation is achieved through chromosomal rearrangements producing 5' fusions of dimerizable domains to the 3' _RET_ tyrosine kinase domain leading to constitutive dimerization and subsequent autophosphorylation; the most common fusions are _KIF5B-RET_ and _CCDC6-RET_, although more than 35 genes have been reported to fuse with _RET_.[A202055, A202049, A202073] Constitutive activation leads to increased downstream signalling and is associated with tumour invasion, migration, and proliferation.[A202046]

Pralsetinib (formerly referred to as BLU-667) was developed through screening more than 10,000 agnostically designed kinase inhibitors followed by extensive chemical modification to improve its properties. Pralsetinib displays _in vitro_ IC&lt;sub&gt;50&lt;/sub&gt; values for both WT RET as well as several mutant forms, including CCDC6-RET, in the range of 0.3-0.4 nmol/L, and is 100-fold more selective for RET kinase over 96% of 371 kinases tested.[A219751] It is this specific inhibition of RET kinase that is associated with anti-tumour activity and clinical benefit in patients.[A219751, A219756, L15986]

Despite increased selectivity for RET over other kinases, pralsetinib has been reported to inhibit DDR1, TRKC, FLT3, JAK1-2, TRKA, VEGFR2, PDGFRb, and FGFR1-2 at clinically relevant concentrations. The significance of these findings remains uncertain.[L15986]</ns0:mechanism-of-action>
  <ns0:toxicity>Pralsetinib administered to rats at 20 mg/kg (roughly 2.5-3.6 times the recommended human exposure) resulted in resorption of litters in pregnant female mice in 92% of pregnancies (82% complete resorption); resorption occurred at doses as low as 5 mg/kg (0.3 times the recommended human exposure). Both male and female rats given 10 mg/kg pralsetinib or more had observable degeneration within the testis/ovaries. In 28-day rat and monkey studies, once-daily pralsetinib resulted in histological necrosis at doses 1.1 or more times the recommended human dose and myocardial hemorrhage at doses 2.6 or more times the recommended human dose. Also, pralsetinib induced hyperphosphatemia (rats only, dose 2.4-3.5 times the recommended human dose) and multi-organ mineralization (dose 0.11 or more times the recommended human dose).[L15986]</ns0:toxicity>
  <ns0:metabolism>Pralsetinib is metabolized _in vitro_ primarily by CYP3A4 and to a lesser extent by CYP2D6 and CYP1A2. Pralsetinib given as a single oral dose of 310 mg in healthy volunteers led to the detection of metabolites from both oxidation (M453, M531, and M549b) and glucuronidation (M709), although these constituted less than 5% of the detected material.[L15986]</ns0:metabolism>
  <ns0:absorption>Pralsetinib given at 400 mg once daily resulted in a mean steady-state C&lt;sub&gt;max&lt;/sub&gt; of 2830 ng/mL (coefficient of variation, CV, 52.5%) and AUC&lt;sub&gt;0-24h&lt;/sub&gt; of 43900 ng\*h/mL (CV 60.2%). The C&lt;sub&gt;max&lt;/sub&gt; and AUC of pralsetinib increased inconsistently with increasing doses between 60 and 600 mg once daily, with a median T&lt;sub&gt;max&lt;/sub&gt; across this range of between two and four hours. At 400 mg once daily, pralsetinib reached steady-state plasma concentration by three to five days.[L15986]

Pralsetinib absorption is affected by food. A single dose of 400 mg given with a high-fat meal (800 to 1000 calories with 50 to 60% of calories coming from fat) increased the mean C&lt;sub&gt;max&lt;/sub&gt; by 104% (95% CI 65-153%), mean AUC&lt;sub&gt;0-∞&lt;/sub&gt; by 122% (95% CI 96-152%), and the median T&lt;sub&gt;max&lt;/sub&gt; from four to 8.5 hours.[L15986]</ns0:absorption>
  <ns0:half-life>Pralsetinib has a plasma elimination half-life of 14.7 ± 6.5 hours following a single dose and 22.2 ± 13.5 hours following multiple doses.[L15986]</ns0:half-life>
  <ns0:protein-binding>Pralsetinib is 97.1% bound to plasma proteins regardless of concentration.[L15986]</ns0:protein-binding>
  <ns0:route-of-elimination>Pralsetinib is primarily eliminated through the fecal route (73%, 66% unchanged) with a small amount found in the urine (6%, 4.8% unchanged).[L15986]</ns0:route-of-elimination>
  <ns0:volume-of-distribution>Pralsetinib has a mean apparent volume of distribution of 228 L (CV 75%).[L15986]</ns0:volume-of-distribution>
  <ns0:clearance>Pralsetinib has a mean apparent steady-state oral clearance of 9.1 L/h (CV 60%).[L15986]</ns0:clearance>
  <ns0:salts />
  <ns0:synonyms>
    <ns0:synonym language="english" coder="inn/usan">Pralsetinib</ns0:synonym>
  </ns0:synonyms>
  <ns0:products>
    <ns0:product>
      <ns0:name>Gavreto</ns0:name>
      <ns0:labeller>Hoffmann La Roche</ns0:labeller>
      <ns0:ndc-id />
      <ns0:ndc-product-code />
      <ns0:dpd-id>02517590</ns0:dpd-id>
      <ns0:ema-product-code />
      <ns0:ema-ma-number />
      <ns0:started-marketing-on>2021-11-12</ns0:started-marketing-on>
      <ns0:ended-marketing-on>2025-02-26</ns0:ended-marketing-on>
      <ns0:dosage-form>Capsule</ns0:dosage-form>
      <ns0:strength>100 mg</ns0:strength>
      <ns0:route>Oral</ns0:route>
      <ns0:fda-application-number />
      <ns0:generic>false</ns0:generic>
      <ns0:over-the-counter>false</ns0:over-the-counter>
      <ns0:approved>true</ns0:approved>
      <ns0:country>Canada</ns0:country>
      <ns0:source>DPD</ns0:source>
    </ns0:product>
    <ns0:product>
      <ns0:name>Gavreto</ns0:name>
      <ns0:labeller>Blueprint Medicines Corporation</ns0:labeller>
      <ns0:ndc-id />
      <ns0:ndc-product-code>72064-210</ns0:ndc-product-code>
      <ns0:dpd-id />
      <ns0:ema-product-code />
      <ns0:ema-ma-number />
      <ns0:started-marketing-on>2020-09-04</ns0:started-marketing-on>
      <ns0:ended-marketing-on>2022-04-30</ns0:ended-marketing-on>
      <ns0:dosage-form>Capsule</ns0:dosage-form>
      <ns0:strength>100 mg/1</ns0:strength>
      <ns0:route>Oral</ns0:route>
      <ns0:fda-application-number>NDA213721</ns0:fda-application-number>
      <ns0:generic>false</ns0:generic>
      <ns0:over-the-counter>false</ns0:over-the-counter>
      <ns0:approved>true</ns0:approved>
      <ns0:country>US</ns0:country>
      <ns0:source>FDA NDC</ns0:source>
    </ns0:product>
    <ns0:product>
      <ns0:name>Gavreto</ns0:name>
      <ns0:labeller>Blueprint Medicines Corporation</ns0:labeller>
      <ns0:ndc-id />
      <ns0:ndc-product-code />
      <ns0:dpd-id />
      <ns0:ema-product-code>EMEA/H/C/005413</ns0:ema-product-code>
      <ns0:ema-ma-number>EU/1/21/1555/001</ns0:ema-ma-number>
      <ns0:started-marketing-on>2022-01-17</ns0:started-marketing-on>
      <ns0:ended-marketing-on>2021-09-16</ns0:ended-marketing-on>
      <ns0:dosage-form />
      <ns0:strength>100 mg</ns0:strength>
      <ns0:route>Oral</ns0:route>
      <ns0:fda-application-number />
      <ns0:generic>false</ns0:generic>
      <ns0:over-the-counter>false</ns0:over-the-counter>
      <ns0:approved>false</ns0:approved>
      <ns0:country>EU</ns0:country>
      <ns0:source>EMA</ns0:source>
    </ns0:product>
    <ns0:product>
      <ns0:name>Gavreto</ns0:name>
      <ns0:labeller>Blueprint Medicines Corporation</ns0:labeller>
      <ns0:ndc-id />
      <ns0:ndc-product-code />
      <ns0:dpd-id />
      <ns0:ema-product-code>EMEA/H/C/005413</ns0:ema-product-code>
      <ns0:ema-ma-number>EU/1/21/1555/002</ns0:ema-ma-number>
      <ns0:started-marketing-on>2022-01-17</ns0:started-marketing-on>
      <ns0:ended-marketing-on>2021-09-16</ns0:ended-marketing-on>
      <ns0:dosage-form />
      <ns0:strength>100 mg</ns0:strength>
      <ns0:route>Oral</ns0:route>
      <ns0:fda-application-number />
      <ns0:generic>false</ns0:generic>
      <ns0:over-the-counter>false</ns0:over-the-counter>
      <ns0:approved>false</ns0:approved>
      <ns0:country>EU</ns0:country>
      <ns0:source>EMA</ns0:source>
    </ns0:product>
    <ns0:product>
      <ns0:name>Gavreto</ns0:name>
      <ns0:labeller>Blueprint Medicines Corporation</ns0:labeller>
      <ns0:ndc-id />
      <ns0:ndc-product-code />
      <ns0:dpd-id />
      <ns0:ema-product-code>EMEA/H/C/005413</ns0:ema-product-code>
      <ns0:ema-ma-number>EU/1/21/1555/003</ns0:ema-ma-number>
      <ns0:started-marketing-on>2022-01-17</ns0:started-marketing-on>
      <ns0:ended-marketing-on>2021-09-16</ns0:ended-marketing-on>
      <ns0:dosage-form />
      <ns0:strength>100 mg</ns0:strength>
      <ns0:route>Oral</ns0:route>
      <ns0:fda-application-number />
      <ns0:generic>false</ns0:generic>
      <ns0:over-the-counter>false</ns0:over-the-counter>
      <ns0:approved>false</ns0:approved>
      <ns0:country>EU</ns0:country>
      <ns0:source>EMA</ns0:source>
    </ns0:product>
    <ns0:product>
      <ns0:name>Gavreto</ns0:name>
      <ns0:labeller>Genentech, Inc.</ns0:labeller>
      <ns0:ndc-id />
      <ns0:ndc-product-code>50242-210</ns0:ndc-product-code>
      <ns0:dpd-id />
      <ns0:ema-product-code />
      <ns0:ema-ma-number />
      <ns0:started-marketing-on>2021-07-01</ns0:started-marketing-on>
      <ns0:ended-marketing-on>2026-09-30</ns0:ended-marketing-on>
      <ns0:dosage-form>Capsule</ns0:dosage-form>
      <ns0:strength>100 mg/1</ns0:strength>
      <ns0:route>Oral</ns0:route>
      <ns0:fda-application-number>NDA213721</ns0:fda-application-number>
      <ns0:generic>false</ns0:generic>
      <ns0:over-the-counter>false</ns0:over-the-counter>
      <ns0:approved>true</ns0:approved>
      <ns0:country>US</ns0:country>
      <ns0:source>FDA NDC</ns0:source>
    </ns0:product>
    <ns0:product>
      <ns0:name>Gavreto</ns0:name>
      <ns0:labeller>RIGEL PHARMA SDN. BHD.</ns0:labeller>
      <ns0:ndc-id />
      <ns0:ndc-product-code>71332-006</ns0:ndc-product-code>
      <ns0:dpd-id />
      <ns0:ema-product-code />
      <ns0:ema-ma-number />
      <ns0:started-marketing-on>2024-06-24</ns0:started-marketing-on>
      <ns0:ended-marketing-on />
      <ns0:dosage-form>Capsule</ns0:dosage-form>
      <ns0:strength>100 mg/1</ns0:strength>
      <ns0:route>Oral</ns0:route>
      <ns0:fda-application-number>NDA213721</ns0:fda-application-number>
      <ns0:generic>false</ns0:generic>
      <ns0:over-the-counter>false</ns0:over-the-counter>
      <ns0:approved>true</ns0:approved>
      <ns0:country>US</ns0:country>
      <ns0:source>FDA NDC</ns0:source>
    </ns0:product>
  </ns0:products>
  <ns0:international-brands />
  <ns0:mixtures />
  <ns0:packagers />
  <ns0:manufacturers />
  <ns0:prices />
  <ns0:categories>
    <ns0:category>
      <ns0:category>Antineoplastic Agents</ns0:category>
      <ns0:mesh-id>D000970</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Antineoplastic and Immunomodulating Agents</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>BCRP/ABCG2 Inhibitors</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>BCRP/ABCG2 Substrates</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>BSEP/ABCB11 Inhibitors</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP1A2 Substrates</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP2C8 Inducers</ns0:category>
      <ns0:mesh-id>D065696</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP2C8 Inducers (strength unknown)</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP2C8 Inhibitors</ns0:category>
      <ns0:mesh-id>D065687</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP2C9 Inducers</ns0:category>
      <ns0:mesh-id>D065698</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP2C9 Inducers (strength unknown)</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP2C9 Inhibitors</ns0:category>
      <ns0:mesh-id>D065688</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP2D6 Substrates</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A Inducers</ns0:category>
      <ns0:mesh-id>D065701</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A Inhibitors</ns0:category>
      <ns0:mesh-id>D065692</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A Substrates</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A4 Inducers</ns0:category>
      <ns0:mesh-id>D065701</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A4 Inducers (strength unknown)</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A4 Inhibitors</ns0:category>
      <ns0:mesh-id>D065692</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A4 Substrates</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A5 Inducers</ns0:category>
      <ns0:mesh-id>D065701</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A5 Inducers (strength unknown)</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A5 Inhibitors</ns0:category>
      <ns0:mesh-id>D065692</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 CYP3A5 Inhibitors (strength unknown)</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 Enzyme Inducers</ns0:category>
      <ns0:mesh-id>D065693</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 Enzyme Inhibitors</ns0:category>
      <ns0:mesh-id>D065607</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Cytochrome P-450 Substrates</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Kinase Inhibitor</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>MATE 1 Inhibitors</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>MATE 2 Inhibitors</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>MATE inhibitors</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>OAT1/SLC22A6 inhibitors</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>OATP1B1/SLCO1B1 Inhibitors</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>OATP1B3 inhibitors</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>P-glycoprotein inhibitors</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>P-glycoprotein substrates</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
    <ns0:category>
      <ns0:category>Protein Kinase Inhibitors</ns0:category>
      <ns0:mesh-id>D047428</ns0:mesh-id>
    </ns0:category>
    <ns0:category>
      <ns0:category>Rearranged during Transfection (RET) Inhibitors</ns0:category>
      <ns0:mesh-id />
    </ns0:category>
  </ns0:categories>
  <ns0:affected-organisms>
    <ns0:affected-organism>Humans and other mammals</ns0:affected-organism>
  </ns0:affected-organisms>
  <ns0:dosages>
    <ns0:dosage>
      <ns0:form />
      <ns0:route>Oral</ns0:route>
      <ns0:strength>100 mg</ns0:strength>
    </ns0:dosage>
    <ns0:dosage>
      <ns0:form>Capsule</ns0:form>
      <ns0:route>Oral</ns0:route>
      <ns0:strength>100 mg</ns0:strength>
    </ns0:dosage>
    <ns0:dosage>
      <ns0:form>Capsule</ns0:form>
      <ns0:route>Oral</ns0:route>
      <ns0:strength>100 mg/1</ns0:strength>
    </ns0:dosage>
  </ns0:dosages>
  <ns0:atc-codes>
    <ns0:atc-code code="L01EX23">
      <ns0:level code="L01EX">Other protein kinase inhibitors</ns0:level>
      <ns0:level code="L01E">PROTEIN KINASE INHIBITORS</ns0:level>
      <ns0:level code="L01">ANTINEOPLASTIC AGENTS</ns0:level>
      <ns0:level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</ns0:level>
    </ns0:atc-code>
  </ns0:atc-codes>
  <ns0:ahfs-codes />
  <ns0:pdb-entries>
    <ns0:pdb-entry>7du9</ns0:pdb-entry>
    <ns0:pdb-entry>7ju5</ns0:pdb-entry>
  </ns0:pdb-entries>
  <ns0:patents>
    <ns0:patent>
      <ns0:number>10030005</ns0:number>
      <ns0:country>United States</ns0:country>
      <ns0:approved>2018-07-24</ns0:approved>
      <ns0:expires>2036-11-01</ns0:expires>
      <ns0:pediatric-extension>false</ns0:pediatric-extension>
    </ns0:patent>
    <ns0:patent>
      <ns0:number>11273160</ns0:number>
      <ns0:country>United States</ns0:country>
      <ns0:approved>2022-03-15</ns0:approved>
      <ns0:expires>2039-04-03</ns0:expires>
      <ns0:pediatric-extension>false</ns0:pediatric-extension>
    </ns0:patent>
    <ns0:patent>
      <ns0:number>11872192</ns0:number>
      <ns0:country>United States</ns0:country>
      <ns0:approved>2024-01-16</ns0:approved>
      <ns0:expires>2039-04-03</ns0:expires>
      <ns0:pediatric-extension>false</ns0:pediatric-extension>
    </ns0:patent>
    <ns0:patent>
      <ns0:number>11963958</ns0:number>
      <ns0:country>United States</ns0:country>
      <ns0:approved>2024-04-23</ns0:approved>
      <ns0:expires>2039-04-03</ns0:expires>
      <ns0:pediatric-extension>false</ns0:pediatric-extension>
    </ns0:patent>
  </ns0:patents>
  <ns0:food-interactions>
    <ns0:food-interaction>Take on an empty stomach. Food affects the absorption of pralsetinib. Patients should take pralsetinib either at least one hour before or at least two hours after a meal.</ns0:food-interaction>
  </ns0:food-interactions>
  <ns0:drug-interactions>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06616</ns0:drugbank-id>
      <ns0:name>Bosutinib</ns0:name>
      <ns0:description>The serum concentration of Bosutinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08870</ns0:drugbank-id>
      <ns0:name>Brentuximab vedotin</ns0:name>
      <ns0:description>The serum concentration of Brentuximab vedotin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00175</ns0:drugbank-id>
      <ns0:name>Pravastatin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Pravastatin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00176</ns0:drugbank-id>
      <ns0:name>Fluvoxamine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Fluvoxamine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00222</ns0:drugbank-id>
      <ns0:name>Glimepiride</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Glimepiride which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00255</ns0:drugbank-id>
      <ns0:name>Diethylstilbestrol</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00270</ns0:drugbank-id>
      <ns0:name>Isradipine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Isradipine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00301</ns0:drugbank-id>
      <ns0:name>Flucloxacillin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00328</ns0:drugbank-id>
      <ns0:name>Indomethacin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Indomethacin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00335</ns0:drugbank-id>
      <ns0:name>Atenolol</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Atenolol which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00412</ns0:drugbank-id>
      <ns0:name>Rosiglitazone</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00439</ns0:drugbank-id>
      <ns0:name>Cerivastatin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00455</ns0:drugbank-id>
      <ns0:name>Loratadine</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Loratadine which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00572</ns0:drugbank-id>
      <ns0:name>Atropine</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Atropine which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00586</ns0:drugbank-id>
      <ns0:name>Diclofenac</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Diclofenac which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00622</ns0:drugbank-id>
      <ns0:name>Nicardipine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Nicardipine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00678</ns0:drugbank-id>
      <ns0:name>Losartan</ns0:name>
      <ns0:description>The metabolism of Losartan can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00693</ns0:drugbank-id>
      <ns0:name>Fluorescein</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Fluorescein which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00698</ns0:drugbank-id>
      <ns0:name>Nitrofurantoin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00788</ns0:drugbank-id>
      <ns0:name>Naproxen</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Naproxen which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00822</ns0:drugbank-id>
      <ns0:name>Disulfiram</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Disulfiram which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00833</ns0:drugbank-id>
      <ns0:name>Cefaclor</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Cefaclor which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00911</ns0:drugbank-id>
      <ns0:name>Tinidazole</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Tinidazole which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00912</ns0:drugbank-id>
      <ns0:name>Repaglinide</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Repaglinide which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00966</ns0:drugbank-id>
      <ns0:name>Telmisartan</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Telmisartan which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00973</ns0:drugbank-id>
      <ns0:name>Ezetimibe</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00975</ns0:drugbank-id>
      <ns0:name>Dipyridamole</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Dipyridamole which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01015</ns0:drugbank-id>
      <ns0:name>Sulfamethoxazole</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01016</ns0:drugbank-id>
      <ns0:name>Glyburide</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Glyburide which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01023</ns0:drugbank-id>
      <ns0:name>Felodipine</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Felodipine which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01039</ns0:drugbank-id>
      <ns0:name>Fenofibrate</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Fenofibrate which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01054</ns0:drugbank-id>
      <ns0:name>Nitrendipine</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Nitrendipine which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01067</ns0:drugbank-id>
      <ns0:name>Glipizide</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Glipizide which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01098</ns0:drugbank-id>
      <ns0:name>Rosuvastatin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01115</ns0:drugbank-id>
      <ns0:name>Nifedipine</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Nifedipine which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01138</ns0:drugbank-id>
      <ns0:name>Sulfinpyrazone</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01165</ns0:drugbank-id>
      <ns0:name>Ofloxacin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Ofloxacin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01222</ns0:drugbank-id>
      <ns0:name>Budesonide</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Budesonide which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01586</ns0:drugbank-id>
      <ns0:name>Ursodeoxycholic acid</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB02123</ns0:drugbank-id>
      <ns0:name>Glycochenodeoxycholic Acid</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Glycochenodeoxycholic Acid which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB02659</ns0:drugbank-id>
      <ns0:name>Cholic Acid</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Cholic Acid which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04348</ns0:drugbank-id>
      <ns0:name>Taurocholic acid</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Taurocholic acid which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05804</ns0:drugbank-id>
      <ns0:name>Prasterone sulfate</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Prasterone sulfate which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09374</ns0:drugbank-id>
      <ns0:name>Indocyanine green acid form</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Indocyanine green acid form which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12319</ns0:drugbank-id>
      <ns0:name>Benzbromarone</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Benzbromarone which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12712</ns0:drugbank-id>
      <ns0:name>Pilsicainide</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Pilsicainide which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13345</ns0:drugbank-id>
      <ns0:name>Dihydroergocristine</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13751</ns0:drugbank-id>
      <ns0:name>Glycyrrhizic acid</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15719</ns0:drugbank-id>
      <ns0:name>Belantamab mafodotin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01394</ns0:drugbank-id>
      <ns0:name>Colchicine</ns0:name>
      <ns0:description>The serum concentration of Colchicine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09075</ns0:drugbank-id>
      <ns0:name>Edoxaban</ns0:name>
      <ns0:description>The serum concentration of Edoxaban can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09027</ns0:drugbank-id>
      <ns0:name>Ledipasvir</ns0:name>
      <ns0:description>The serum concentration of Ledipasvir can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09049</ns0:drugbank-id>
      <ns0:name>Naloxegol</ns0:name>
      <ns0:description>The serum concentration of Naloxegol can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06589</ns0:drugbank-id>
      <ns0:name>Pazopanib</ns0:name>
      <ns0:description>The serum concentration of Pazopanib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06480</ns0:drugbank-id>
      <ns0:name>Prucalopride</ns0:name>
      <ns0:description>The serum concentration of Prucalopride can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06207</ns0:drugbank-id>
      <ns0:name>Silodosin</ns0:name>
      <ns0:description>The excretion of Silodosin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01030</ns0:drugbank-id>
      <ns0:name>Topotecan</ns0:name>
      <ns0:description>The serum concentration of Topotecan can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01238</ns0:drugbank-id>
      <ns0:name>Aripiprazole</ns0:name>
      <ns0:description>The metabolism of Aripiprazole can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14185</ns0:drugbank-id>
      <ns0:name>Aripiprazole lauroxil</ns0:name>
      <ns0:description>The metabolism of Aripiprazole lauroxil can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09039</ns0:drugbank-id>
      <ns0:name>Eliglustat</ns0:name>
      <ns0:description>The metabolism of Eliglustat can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09053</ns0:drugbank-id>
      <ns0:name>Ibrutinib</ns0:name>
      <ns0:description>The metabolism of Ibrutinib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01220</ns0:drugbank-id>
      <ns0:name>Rifaximin</ns0:name>
      <ns0:description>The serum concentration of Rifaximin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01166</ns0:drugbank-id>
      <ns0:name>Cilostazol</ns0:name>
      <ns0:description>The metabolism of Cilostazol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04946</ns0:drugbank-id>
      <ns0:name>Iloperidone</ns0:name>
      <ns0:description>The metabolism of Iloperidone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01256</ns0:drugbank-id>
      <ns0:name>Retapamulin</ns0:name>
      <ns0:description>The metabolism of Retapamulin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08895</ns0:drugbank-id>
      <ns0:name>Tofacitinib</ns0:name>
      <ns0:description>The metabolism of Tofacitinib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00862</ns0:drugbank-id>
      <ns0:name>Vardenafil</ns0:name>
      <ns0:description>The metabolism of Vardenafil can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01198</ns0:drugbank-id>
      <ns0:name>Zopiclone</ns0:name>
      <ns0:description>The metabolism of Zopiclone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00227</ns0:drugbank-id>
      <ns0:name>Lovastatin</ns0:name>
      <ns0:description>The metabolism of Lovastatin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00346</ns0:drugbank-id>
      <ns0:name>Alfuzosin</ns0:name>
      <ns0:description>The metabolism of Alfuzosin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00404</ns0:drugbank-id>
      <ns0:name>Alprazolam</ns0:name>
      <ns0:description>The metabolism of Alprazolam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01181</ns0:drugbank-id>
      <ns0:name>Ifosfamide</ns0:name>
      <ns0:description>The metabolism of Ifosfamide can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08883</ns0:drugbank-id>
      <ns0:name>Perampanel</ns0:name>
      <ns0:description>The metabolism of Perampanel can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00682</ns0:drugbank-id>
      <ns0:name>Warfarin</ns0:name>
      <ns0:description>The serum concentration of Warfarin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01418</ns0:drugbank-id>
      <ns0:name>Acenocoumarol</ns0:name>
      <ns0:description>The serum concentration of Acenocoumarol can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08496</ns0:drugbank-id>
      <ns0:name>(R)-warfarin</ns0:name>
      <ns0:description>The serum concentration of (R)-warfarin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08735</ns0:drugbank-id>
      <ns0:name>R,S-Warfarin alcohol</ns0:name>
      <ns0:description>The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08736</ns0:drugbank-id>
      <ns0:name>S,R-Warfarin alcohol</ns0:name>
      <ns0:description>The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14055</ns0:drugbank-id>
      <ns0:name>(S)-Warfarin</ns0:name>
      <ns0:description>The serum concentration of (S)-Warfarin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00683</ns0:drugbank-id>
      <ns0:name>Midazolam</ns0:name>
      <ns0:description>The serum concentration of Midazolam can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00864</ns0:drugbank-id>
      <ns0:name>Tacrolimus</ns0:name>
      <ns0:description>The serum concentration of Tacrolimus can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01076</ns0:drugbank-id>
      <ns0:name>Atorvastatin</ns0:name>
      <ns0:description>The metabolism of Atorvastatin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09272</ns0:drugbank-id>
      <ns0:name>Eluxadoline</ns0:name>
      <ns0:description>The serum concentration of Eluxadoline can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00541</ns0:drugbank-id>
      <ns0:name>Vincristine</ns0:name>
      <ns0:description>The excretion of Vincristine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00997</ns0:drugbank-id>
      <ns0:name>Doxorubicin</ns0:name>
      <ns0:description>The serum concentration of Doxorubicin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00530</ns0:drugbank-id>
      <ns0:name>Erlotinib</ns0:name>
      <ns0:description>The serum concentration of Erlotinib can be decreased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12364</ns0:drugbank-id>
      <ns0:name>Betrixaban</ns0:name>
      <ns0:description>The serum concentration of Betrixaban can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08881</ns0:drugbank-id>
      <ns0:name>Vemurafenib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Vemurafenib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11901</ns0:drugbank-id>
      <ns0:name>Apalutamide</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Apalutamide.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11642</ns0:drugbank-id>
      <ns0:name>Pitolisant</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Pitolisant.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00201</ns0:drugbank-id>
      <ns0:name>Caffeine</ns0:name>
      <ns0:description>Caffeine may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00213</ns0:drugbank-id>
      <ns0:name>Pantoprazole</ns0:name>
      <ns0:description>Pantoprazole may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00317</ns0:drugbank-id>
      <ns0:name>Gefitinib</ns0:name>
      <ns0:description>Gefitinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00394</ns0:drugbank-id>
      <ns0:name>Beclomethasone dipropionate</ns0:name>
      <ns0:description>Beclomethasone dipropionate may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00396</ns0:drugbank-id>
      <ns0:name>Progesterone</ns0:name>
      <ns0:description>Progesterone may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00448</ns0:drugbank-id>
      <ns0:name>Lansoprazole</ns0:name>
      <ns0:description>Lansoprazole may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00470</ns0:drugbank-id>
      <ns0:name>Dronabinol</ns0:name>
      <ns0:description>The serum concentration of Dronabinol can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00783</ns0:drugbank-id>
      <ns0:name>Estradiol</ns0:name>
      <ns0:description>Estradiol may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00795</ns0:drugbank-id>
      <ns0:name>Sulfasalazine</ns0:name>
      <ns0:description>Sulfasalazine may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00921</ns0:drugbank-id>
      <ns0:name>Buprenorphine</ns0:name>
      <ns0:description>Buprenorphine may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01051</ns0:drugbank-id>
      <ns0:name>Novobiocin</ns0:name>
      <ns0:description>Novobiocin may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01094</ns0:drugbank-id>
      <ns0:name>Hesperetin</ns0:name>
      <ns0:description>Hesperetin may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01129</ns0:drugbank-id>
      <ns0:name>Rabeprazole</ns0:name>
      <ns0:description>Rabeprazole may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01645</ns0:drugbank-id>
      <ns0:name>Genistein</ns0:name>
      <ns0:description>Genistein may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01685</ns0:drugbank-id>
      <ns0:name>Topiroxostat</ns0:name>
      <ns0:description>Topiroxostat may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB02115</ns0:drugbank-id>
      <ns0:name>Daidzin</ns0:name>
      <ns0:description>Daidzin may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB02703</ns0:drugbank-id>
      <ns0:name>Fusidic acid</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Fusidic acid.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB03467</ns0:drugbank-id>
      <ns0:name>Naringenin</ns0:name>
      <ns0:description>Naringenin may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04216</ns0:drugbank-id>
      <ns0:name>Quercetin</ns0:name>
      <ns0:description>Quercetin may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05928</ns0:drugbank-id>
      <ns0:name>Dovitinib</ns0:name>
      <ns0:description>Dovitinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06210</ns0:drugbank-id>
      <ns0:name>Eltrombopag</ns0:name>
      <ns0:description>Eltrombopag may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06654</ns0:drugbank-id>
      <ns0:name>Safinamide</ns0:name>
      <ns0:description>Safinamide may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08828</ns0:drugbank-id>
      <ns0:name>Vismodegib</ns0:name>
      <ns0:description>Vismodegib may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08864</ns0:drugbank-id>
      <ns0:name>Rilpivirine</ns0:name>
      <ns0:description>The serum concentration of Rilpivirine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08880</ns0:drugbank-id>
      <ns0:name>Teriflunomide</ns0:name>
      <ns0:description>Teriflunomide may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09061</ns0:drugbank-id>
      <ns0:name>Cannabidiol</ns0:name>
      <ns0:description>Cannabidiol may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09183</ns0:drugbank-id>
      <ns0:name>Dasabuvir</ns0:name>
      <ns0:description>Dasabuvir may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09297</ns0:drugbank-id>
      <ns0:name>Paritaprevir</ns0:name>
      <ns0:description>Paritaprevir may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11796</ns0:drugbank-id>
      <ns0:name>Fostemsavir</ns0:name>
      <ns0:description>Fostemsavir may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12010</ns0:drugbank-id>
      <ns0:name>Fostamatinib</ns0:name>
      <ns0:description>Fostamatinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12070</ns0:drugbank-id>
      <ns0:name>Letermovir</ns0:name>
      <ns0:description>The excretion of Letermovir can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12141</ns0:drugbank-id>
      <ns0:name>Gilteritinib</ns0:name>
      <ns0:description>Gilteritinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13952</ns0:drugbank-id>
      <ns0:name>Estradiol acetate</ns0:name>
      <ns0:description>Estradiol acetate may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13953</ns0:drugbank-id>
      <ns0:name>Estradiol benzoate</ns0:name>
      <ns0:description>Estradiol benzoate may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13954</ns0:drugbank-id>
      <ns0:name>Estradiol cypionate</ns0:name>
      <ns0:description>Estradiol cypionate may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13955</ns0:drugbank-id>
      <ns0:name>Estradiol dienanthate</ns0:name>
      <ns0:description>Estradiol dienanthate may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13956</ns0:drugbank-id>
      <ns0:name>Estradiol valerate</ns0:name>
      <ns0:description>Estradiol valerate may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14009</ns0:drugbank-id>
      <ns0:name>Medical Cannabis</ns0:name>
      <ns0:description>The metabolism of Medical Cannabis can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14011</ns0:drugbank-id>
      <ns0:name>Nabiximols</ns0:name>
      <ns0:description>Nabiximols may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00158</ns0:drugbank-id>
      <ns0:name>Folic acid</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Folic acid which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00286</ns0:drugbank-id>
      <ns0:name>Conjugated estrogens</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00437</ns0:drugbank-id>
      <ns0:name>Allopurinol</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Allopurinol which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00457</ns0:drugbank-id>
      <ns0:name>Prazosin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Prazosin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00481</ns0:drugbank-id>
      <ns0:name>Raloxifene</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Raloxifene which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00482</ns0:drugbank-id>
      <ns0:name>Celecoxib</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Celecoxib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00495</ns0:drugbank-id>
      <ns0:name>Zidovudine</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Zidovudine which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00526</ns0:drugbank-id>
      <ns0:name>Oxaliplatin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00602</ns0:drugbank-id>
      <ns0:name>Ivermectin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Ivermectin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00624</ns0:drugbank-id>
      <ns0:name>Testosterone</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Testosterone which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00631</ns0:drugbank-id>
      <ns0:name>Clofarabine</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Clofarabine which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00669</ns0:drugbank-id>
      <ns0:name>Sumatriptan</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00688</ns0:drugbank-id>
      <ns0:name>Mycophenolate mofetil</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00709</ns0:drugbank-id>
      <ns0:name>Lamivudine</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Lamivudine which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00740</ns0:drugbank-id>
      <ns0:name>Riluzole</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Riluzole which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00843</ns0:drugbank-id>
      <ns0:name>Donepezil</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Donepezil which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01079</ns0:drugbank-id>
      <ns0:name>Tegaserod</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Tegaserod which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01097</ns0:drugbank-id>
      <ns0:name>Leflunomide</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Leflunomide which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01204</ns0:drugbank-id>
      <ns0:name>Mitoxantrone</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB03496</ns0:drugbank-id>
      <ns0:name>Alvocidib</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Alvocidib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04690</ns0:drugbank-id>
      <ns0:name>Camptothecin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Camptothecin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06228</ns0:drugbank-id>
      <ns0:name>Rivaroxaban</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06605</ns0:drugbank-id>
      <ns0:name>Apixaban</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Apixaban which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06813</ns0:drugbank-id>
      <ns0:name>Pralatrexate</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08930</ns0:drugbank-id>
      <ns0:name>Dolutegravir</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08931</ns0:drugbank-id>
      <ns0:name>Riociguat</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Riociguat which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08934</ns0:drugbank-id>
      <ns0:name>Sofosbuvir</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09078</ns0:drugbank-id>
      <ns0:name>Lenvatinib</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09279</ns0:drugbank-id>
      <ns0:name>Fimasartan</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Fimasartan which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09296</ns0:drugbank-id>
      <ns0:name>Ombitasvir</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Ombitasvir which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09299</ns0:drugbank-id>
      <ns0:name>Tenofovir alafenamide</ns0:name>
      <ns0:description>The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11689</ns0:drugbank-id>
      <ns0:name>Selumetinib</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Selumetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11943</ns0:drugbank-id>
      <ns0:name>Delafloxacin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11952</ns0:drugbank-id>
      <ns0:name>Duvelisib</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Duvelisib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12887</ns0:drugbank-id>
      <ns0:name>Tazemetostat</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Tazemetostat which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13125</ns0:drugbank-id>
      <ns0:name>Lusutrombopag</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13943</ns0:drugbank-id>
      <ns0:name>Testosterone cypionate</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13944</ns0:drugbank-id>
      <ns0:name>Testosterone enanthate</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14649</ns0:drugbank-id>
      <ns0:name>Dexamethasone acetate</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Dexamethasone acetate.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15442</ns0:drugbank-id>
      <ns0:name>Trilaciclib</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06237</ns0:drugbank-id>
      <ns0:name>Avanafil</ns0:name>
      <ns0:description>The serum concentration of Avanafil can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00295</ns0:drugbank-id>
      <ns0:name>Morphine</ns0:name>
      <ns0:description>The serum concentration of Morphine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00300</ns0:drugbank-id>
      <ns0:name>Tenofovir disoproxil</ns0:name>
      <ns0:description>The serum concentration of Tenofovir disoproxil can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00349</ns0:drugbank-id>
      <ns0:name>Clobazam</ns0:name>
      <ns0:description>The serum concentration of Clobazam can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00612</ns0:drugbank-id>
      <ns0:name>Bisoprolol</ns0:name>
      <ns0:description>The serum concentration of Bisoprolol can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00742</ns0:drugbank-id>
      <ns0:name>Mannitol</ns0:name>
      <ns0:description>The serum concentration of Mannitol can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00882</ns0:drugbank-id>
      <ns0:name>Clomifene</ns0:name>
      <ns0:description>The serum concentration of Clomifene can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00950</ns0:drugbank-id>
      <ns0:name>Fexofenadine</ns0:name>
      <ns0:description>The serum concentration of Fexofenadine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01261</ns0:drugbank-id>
      <ns0:name>Sitagliptin</ns0:name>
      <ns0:description>The serum concentration of Sitagliptin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05015</ns0:drugbank-id>
      <ns0:name>Belinostat</ns0:name>
      <ns0:description>The serum concentration of Belinostat can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05039</ns0:drugbank-id>
      <ns0:name>Indacaterol</ns0:name>
      <ns0:description>The serum concentration of Indacaterol can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06403</ns0:drugbank-id>
      <ns0:name>Ambrisentan</ns0:name>
      <ns0:description>The serum concentration of Ambrisentan can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06670</ns0:drugbank-id>
      <ns0:name>Odanacatib</ns0:name>
      <ns0:description>The serum concentration of Odanacatib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09076</ns0:drugbank-id>
      <ns0:name>Umeclidinium</ns0:name>
      <ns0:description>The serum concentration of Umeclidinium can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09079</ns0:drugbank-id>
      <ns0:name>Nintedanib</ns0:name>
      <ns0:description>The serum concentration of Nintedanib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09161</ns0:drugbank-id>
      <ns0:name>Technetium Tc-99m sestamibi</ns0:name>
      <ns0:description>The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11362</ns0:drugbank-id>
      <ns0:name>Selexipag</ns0:name>
      <ns0:description>The serum concentration of Selexipag can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11574</ns0:drugbank-id>
      <ns0:name>Elbasvir</ns0:name>
      <ns0:description>Elbasvir may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11575</ns0:drugbank-id>
      <ns0:name>Grazoprevir</ns0:name>
      <ns0:description>Grazoprevir may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11712</ns0:drugbank-id>
      <ns0:name>Tezacaftor</ns0:name>
      <ns0:description>The serum concentration of Tezacaftor can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11770</ns0:drugbank-id>
      <ns0:name>Talinolol</ns0:name>
      <ns0:description>The serum concentration of Talinolol can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12455</ns0:drugbank-id>
      <ns0:name>Omadacycline</ns0:name>
      <ns0:description>The serum concentration of Omadacycline can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12836</ns0:drugbank-id>
      <ns0:name>Grapiprant</ns0:name>
      <ns0:description>The serum concentration of Grapiprant can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13007</ns0:drugbank-id>
      <ns0:name>Enfortumab vedotin</ns0:name>
      <ns0:description>The serum concentration of Enfortumab vedotin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14126</ns0:drugbank-id>
      <ns0:name>Tenofovir</ns0:name>
      <ns0:description>The serum concentration of Tenofovir can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14631</ns0:drugbank-id>
      <ns0:name>Prednisolone phosphate</ns0:name>
      <ns0:description>The serum concentration of Prednisolone phosphate can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00080</ns0:drugbank-id>
      <ns0:name>Daptomycin</ns0:name>
      <ns0:description>The serum concentration of Daptomycin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16222</ns0:drugbank-id>
      <ns0:name>Loncastuximab tesirine</ns0:name>
      <ns0:description>The serum concentration of Loncastuximab tesirine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06695</ns0:drugbank-id>
      <ns0:name>Dabigatran etexilate</ns0:name>
      <ns0:description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00279</ns0:drugbank-id>
      <ns0:name>Liothyronine</ns0:name>
      <ns0:description>The excretion of Liothyronine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00520</ns0:drugbank-id>
      <ns0:name>Caspofungin</ns0:name>
      <ns0:description>The excretion of Caspofungin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00584</ns0:drugbank-id>
      <ns0:name>Enalapril</ns0:name>
      <ns0:description>The excretion of Enalapril can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00859</ns0:drugbank-id>
      <ns0:name>Penicillamine</ns0:name>
      <ns0:description>The excretion of Penicillamine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00917</ns0:drugbank-id>
      <ns0:name>Dinoprostone</ns0:name>
      <ns0:description>The excretion of Dinoprostone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01053</ns0:drugbank-id>
      <ns0:name>Benzylpenicillin</ns0:name>
      <ns0:description>The excretion of Benzylpenicillin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01092</ns0:drugbank-id>
      <ns0:name>Ouabain</ns0:name>
      <ns0:description>The excretion of Ouabain can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01583</ns0:drugbank-id>
      <ns0:name>Liotrix</ns0:name>
      <ns0:description>The excretion of Liotrix can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06199</ns0:drugbank-id>
      <ns0:name>Atrasentan</ns0:name>
      <ns0:description>The serum concentration of Atrasentan can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06721</ns0:drugbank-id>
      <ns0:name>Gimatecan</ns0:name>
      <ns0:description>The excretion of Gimatecan can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08836</ns0:drugbank-id>
      <ns0:name>Temocapril</ns0:name>
      <ns0:description>The excretion of Temocapril can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08862</ns0:drugbank-id>
      <ns0:name>Cholecystokinin</ns0:name>
      <ns0:description>The excretion of Cholecystokinin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08884</ns0:drugbank-id>
      <ns0:name>Gadoxetic acid</ns0:name>
      <ns0:description>The excretion of Gadoxetic acid can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09137</ns0:drugbank-id>
      <ns0:name>Technetium Tc-99m mebrofenin</ns0:name>
      <ns0:description>The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13139</ns0:drugbank-id>
      <ns0:name>Levosalbutamol</ns0:name>
      <ns0:description>The excretion of Levosalbutamol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00559</ns0:drugbank-id>
      <ns0:name>Bosentan</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Bosentan.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00197</ns0:drugbank-id>
      <ns0:name>Troglitazone</ns0:name>
      <ns0:description>The risk or severity of liver damage can be increased when Troglitazone is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00275</ns0:drugbank-id>
      <ns0:name>Olmesartan</ns0:name>
      <ns0:description>The risk or severity of liver damage can be increased when Olmesartan is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00477</ns0:drugbank-id>
      <ns0:name>Chlorpromazine</ns0:name>
      <ns0:description>The risk or severity of liver damage can be increased when Chlorpromazine is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00501</ns0:drugbank-id>
      <ns0:name>Cimetidine</ns0:name>
      <ns0:description>The risk or severity of liver damage can be increased when Cimetidine is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00977</ns0:drugbank-id>
      <ns0:name>Ethinylestradiol</ns0:name>
      <ns0:description>The risk or severity of liver damage can be increased when Ethinylestradiol is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14057</ns0:drugbank-id>
      <ns0:name>Valinomycin</ns0:name>
      <ns0:description>The risk or severity of liver damage can be increased when Valinomycin is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00694</ns0:drugbank-id>
      <ns0:name>Daunorubicin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14583</ns0:drugbank-id>
      <ns0:name>Segesterone acetate</ns0:name>
      <ns0:description>The metabolism of Segesterone acetate can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04540</ns0:drugbank-id>
      <ns0:name>Cholesterol</ns0:name>
      <ns0:description>Cholesterol may increase the excretion rate of Pralsetinib which could result in a lower serum level and potentially a reduction in efficacy.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00570</ns0:drugbank-id>
      <ns0:name>Vinblastine</ns0:name>
      <ns0:description>The serum concentration of Vinblastine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01254</ns0:drugbank-id>
      <ns0:name>Dasatinib</ns0:name>
      <ns0:description>The serum concentration of Dasatinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06772</ns0:drugbank-id>
      <ns0:name>Cabazitaxel</ns0:name>
      <ns0:description>The metabolism of Cabazitaxel can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08912</ns0:drugbank-id>
      <ns0:name>Dabrafenib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Dabrafenib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00773</ns0:drugbank-id>
      <ns0:name>Etoposide</ns0:name>
      <ns0:description>The serum concentration of Etoposide can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00970</ns0:drugbank-id>
      <ns0:name>Dactinomycin</ns0:name>
      <ns0:description>The serum concentration of Dactinomycin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09330</ns0:drugbank-id>
      <ns0:name>Osimertinib</ns0:name>
      <ns0:description>The serum concentration of Osimertinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11760</ns0:drugbank-id>
      <ns0:name>Talazoparib</ns0:name>
      <ns0:description>The serum concentration of Talazoparib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12483</ns0:drugbank-id>
      <ns0:name>Copanlisib</ns0:name>
      <ns0:description>The metabolism of Copanlisib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00188</ns0:drugbank-id>
      <ns0:name>Bortezomib</ns0:name>
      <ns0:description>The serum concentration of Bortezomib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00877</ns0:drugbank-id>
      <ns0:name>Sirolimus</ns0:name>
      <ns0:description>The serum concentration of Sirolimus can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01396</ns0:drugbank-id>
      <ns0:name>Digitoxin</ns0:name>
      <ns0:description>The serum concentration of Digitoxin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05239</ns0:drugbank-id>
      <ns0:name>Cobimetinib</ns0:name>
      <ns0:description>The serum concentration of Cobimetinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05773</ns0:drugbank-id>
      <ns0:name>Trastuzumab emtansine</ns0:name>
      <ns0:description>The serum concentration of Trastuzumab emtansine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06176</ns0:drugbank-id>
      <ns0:name>Romidepsin</ns0:name>
      <ns0:description>The serum concentration of Romidepsin can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06212</ns0:drugbank-id>
      <ns0:name>Tolvaptan</ns0:name>
      <ns0:description>The serum concentration of Tolvaptan can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08910</ns0:drugbank-id>
      <ns0:name>Pomalidomide</ns0:name>
      <ns0:description>The serum concentration of Pomalidomide can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09063</ns0:drugbank-id>
      <ns0:name>Ceritinib</ns0:name>
      <ns0:description>The serum concentration of Ceritinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11641</ns0:drugbank-id>
      <ns0:name>Vinflunine</ns0:name>
      <ns0:description>The serum concentration of Vinflunine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06769</ns0:drugbank-id>
      <ns0:name>Bendamustine</ns0:name>
      <ns0:description>The serum concentration of Bendamustine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11967</ns0:drugbank-id>
      <ns0:name>Binimetinib</ns0:name>
      <ns0:description>The serum concentration of Binimetinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00726</ns0:drugbank-id>
      <ns0:name>Trimipramine</ns0:name>
      <ns0:description>The serum concentration of Trimipramine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00441</ns0:drugbank-id>
      <ns0:name>Gemcitabine</ns0:name>
      <ns0:description>The serum concentration of Gemcitabine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00458</ns0:drugbank-id>
      <ns0:name>Imipramine</ns0:name>
      <ns0:description>The serum concentration of Imipramine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00540</ns0:drugbank-id>
      <ns0:name>Nortriptyline</ns0:name>
      <ns0:description>The serum concentration of Nortriptyline can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09046</ns0:drugbank-id>
      <ns0:name>Metreleptin</ns0:name>
      <ns0:description>The metabolism of Pralsetinib can be increased when combined with Metreleptin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00294</ns0:drugbank-id>
      <ns0:name>Etonogestrel</ns0:name>
      <ns0:description>The metabolism of Etonogestrel can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00304</ns0:drugbank-id>
      <ns0:name>Desogestrel</ns0:name>
      <ns0:description>The metabolism of Desogestrel can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00351</ns0:drugbank-id>
      <ns0:name>Megestrol acetate</ns0:name>
      <ns0:description>The metabolism of Megestrol acetate can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00367</ns0:drugbank-id>
      <ns0:name>Levonorgestrel</ns0:name>
      <ns0:description>The metabolism of Levonorgestrel can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00603</ns0:drugbank-id>
      <ns0:name>Medroxyprogesterone acetate</ns0:name>
      <ns0:description>The metabolism of Medroxyprogesterone acetate can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00717</ns0:drugbank-id>
      <ns0:name>Norethisterone</ns0:name>
      <ns0:description>The metabolism of Norethisterone can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00823</ns0:drugbank-id>
      <ns0:name>Ethynodiol diacetate</ns0:name>
      <ns0:description>The metabolism of Ethynodiol diacetate can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01357</ns0:drugbank-id>
      <ns0:name>Mestranol</ns0:name>
      <ns0:description>The metabolism of Mestranol can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01395</ns0:drugbank-id>
      <ns0:name>Drospirenone</ns0:name>
      <ns0:description>The metabolism of Drospirenone can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04574</ns0:drugbank-id>
      <ns0:name>Estrone sulfate</ns0:name>
      <ns0:description>The metabolism of Estrone sulfate can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04682</ns0:drugbank-id>
      <ns0:name>Octylphenoxy polyethoxyethanol</ns0:name>
      <ns0:description>The metabolism of Octylphenoxy polyethoxyethanol can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04839</ns0:drugbank-id>
      <ns0:name>Cyproterone acetate</ns0:name>
      <ns0:description>The metabolism of Cyproterone acetate can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05830</ns0:drugbank-id>
      <ns0:name>Trestolone</ns0:name>
      <ns0:description>The metabolism of Trestolone can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06713</ns0:drugbank-id>
      <ns0:name>Norelgestromin</ns0:name>
      <ns0:description>The metabolism of Norelgestromin can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06730</ns0:drugbank-id>
      <ns0:name>Gestodene</ns0:name>
      <ns0:description>The metabolism of Gestodene can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06789</ns0:drugbank-id>
      <ns0:name>Hydroxyprogesterone caproate</ns0:name>
      <ns0:description>The metabolism of Hydroxyprogesterone caproate can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08867</ns0:drugbank-id>
      <ns0:name>Ulipristal</ns0:name>
      <ns0:description>The metabolism of Ulipristal can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09123</ns0:drugbank-id>
      <ns0:name>Dienogest</ns0:name>
      <ns0:description>The metabolism of Dienogest can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09371</ns0:drugbank-id>
      <ns0:name>Norethynodrel</ns0:name>
      <ns0:description>The metabolism of Norethynodrel can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09389</ns0:drugbank-id>
      <ns0:name>Norgestrel</ns0:name>
      <ns0:description>The metabolism of Norgestrel can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11619</ns0:drugbank-id>
      <ns0:name>Gestrinone</ns0:name>
      <ns0:description>The metabolism of Gestrinone can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11636</ns0:drugbank-id>
      <ns0:name>Nomegestrol</ns0:name>
      <ns0:description>The metabolism of Nomegestrol can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12474</ns0:drugbank-id>
      <ns0:name>Lynestrenol</ns0:name>
      <ns0:description>The metabolism of Lynestrenol can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13044</ns0:drugbank-id>
      <ns0:name>Gossypol</ns0:name>
      <ns0:description>The metabolism of Gossypol can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13310</ns0:drugbank-id>
      <ns0:name>Ormeloxifene</ns0:name>
      <ns0:description>The metabolism of Ormeloxifene can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13528</ns0:drugbank-id>
      <ns0:name>Chlormadinone</ns0:name>
      <ns0:description>The metabolism of Chlormadinone can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13563</ns0:drugbank-id>
      <ns0:name>Norgestrienone</ns0:name>
      <ns0:description>The metabolism of Norgestrienone can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13685</ns0:drugbank-id>
      <ns0:name>Quingestanol</ns0:name>
      <ns0:description>The metabolism of Quingestanol can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13857</ns0:drugbank-id>
      <ns0:name>Demegestone</ns0:name>
      <ns0:description>The metabolism of Demegestone can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13866</ns0:drugbank-id>
      <ns0:name>Etynodiol</ns0:name>
      <ns0:description>The metabolism of Etynodiol can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13981</ns0:drugbank-id>
      <ns0:name>Nomegestrol acetate</ns0:name>
      <ns0:description>The metabolism of Nomegestrol acetate can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14678</ns0:drugbank-id>
      <ns0:name>Norethindrone enanthate</ns0:name>
      <ns0:description>The metabolism of Norethindrone enanthate can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00155</ns0:drugbank-id>
      <ns0:name>Citrulline</ns0:name>
      <ns0:description>The excretion of Citrulline can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00229</ns0:drugbank-id>
      <ns0:name>Cefotiam</ns0:name>
      <ns0:description>The excretion of Cefotiam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00345</ns0:drugbank-id>
      <ns0:name>Aminohippuric acid</ns0:name>
      <ns0:description>The excretion of Aminohippuric acid can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00365</ns0:drugbank-id>
      <ns0:name>Grepafloxacin</ns0:name>
      <ns0:description>The excretion of Grepafloxacin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00369</ns0:drugbank-id>
      <ns0:name>Cidofovir</ns0:name>
      <ns0:description>The excretion of Cidofovir can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00432</ns0:drugbank-id>
      <ns0:name>Trifluridine</ns0:name>
      <ns0:description>The excretion of Trifluridine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00535</ns0:drugbank-id>
      <ns0:name>Cefdinir</ns0:name>
      <ns0:description>The excretion of Cefdinir can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00649</ns0:drugbank-id>
      <ns0:name>Stavudine</ns0:name>
      <ns0:description>The excretion of Stavudine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00718</ns0:drugbank-id>
      <ns0:name>Adefovir dipivoxil</ns0:name>
      <ns0:description>The excretion of Adefovir dipivoxil can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00863</ns0:drugbank-id>
      <ns0:name>Ranitidine</ns0:name>
      <ns0:description>The excretion of Ranitidine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00900</ns0:drugbank-id>
      <ns0:name>Didanosine</ns0:name>
      <ns0:description>The excretion of Didanosine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00943</ns0:drugbank-id>
      <ns0:name>Zalcitabine</ns0:name>
      <ns0:description>The excretion of Zalcitabine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01197</ns0:drugbank-id>
      <ns0:name>Captopril</ns0:name>
      <ns0:description>The excretion of Captopril can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01327</ns0:drugbank-id>
      <ns0:name>Cefazolin</ns0:name>
      <ns0:description>The excretion of Cefazolin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01332</ns0:drugbank-id>
      <ns0:name>Ceftizoxime</ns0:name>
      <ns0:description>The excretion of Ceftizoxime can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01414</ns0:drugbank-id>
      <ns0:name>Cefacetrile</ns0:name>
      <ns0:description>The excretion of Cefacetrile can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01415</ns0:drugbank-id>
      <ns0:name>Ceftibuten</ns0:name>
      <ns0:description>The excretion of Ceftibuten can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01606</ns0:drugbank-id>
      <ns0:name>Tazobactam</ns0:name>
      <ns0:description>The excretion of Tazobactam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB02527</ns0:drugbank-id>
      <ns0:name>Cyclic adenosine monophosphate</ns0:name>
      <ns0:description>The excretion of Cyclic adenosine monophosphate can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB03553</ns0:drugbank-id>
      <ns0:name>Glutaric Acid</ns0:name>
      <ns0:description>The excretion of Glutaric Acid can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08846</ns0:drugbank-id>
      <ns0:name>Ellagic acid</ns0:name>
      <ns0:description>The excretion of Ellagic acid can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09008</ns0:drugbank-id>
      <ns0:name>Cefaloridine</ns0:name>
      <ns0:description>The excretion of Cefaloridine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09298</ns0:drugbank-id>
      <ns0:name>Silibinin</ns0:name>
      <ns0:description>The excretion of Silibinin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00567</ns0:drugbank-id>
      <ns0:name>Cephalexin</ns0:name>
      <ns0:description>The metabolism of Cephalexin can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00207</ns0:drugbank-id>
      <ns0:name>Azithromycin</ns0:name>
      <ns0:description>The metabolism of Azithromycin can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00246</ns0:drugbank-id>
      <ns0:name>Ziprasidone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ziprasidone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00247</ns0:drugbank-id>
      <ns0:name>Methysergide</ns0:name>
      <ns0:description>The metabolism of Methysergide can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00454</ns0:drugbank-id>
      <ns0:name>Meperidine</ns0:name>
      <ns0:description>The metabolism of Meperidine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00518</ns0:drugbank-id>
      <ns0:name>Albendazole</ns0:name>
      <ns0:description>The metabolism of Albendazole can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00590</ns0:drugbank-id>
      <ns0:name>Doxazosin</ns0:name>
      <ns0:description>The metabolism of Doxazosin can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01431</ns0:drugbank-id>
      <ns0:name>Allylestrenol</ns0:name>
      <ns0:description>The metabolism of Allylestrenol can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01624</ns0:drugbank-id>
      <ns0:name>Zuclopenthixol</ns0:name>
      <ns0:description>The metabolism of Zuclopenthixol can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01656</ns0:drugbank-id>
      <ns0:name>Roflumilast</ns0:name>
      <ns0:description>The serum concentration of Roflumilast can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06218</ns0:drugbank-id>
      <ns0:name>Lacosamide</ns0:name>
      <ns0:description>The metabolism of Lacosamide can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06717</ns0:drugbank-id>
      <ns0:name>Fosaprepitant</ns0:name>
      <ns0:description>The metabolism of Fosaprepitant can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09071</ns0:drugbank-id>
      <ns0:name>Tasimelteon</ns0:name>
      <ns0:description>The metabolism of Tasimelteon can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11273</ns0:drugbank-id>
      <ns0:name>Dihydroergocornine</ns0:name>
      <ns0:description>The metabolism of Dihydroergocornine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11742</ns0:drugbank-id>
      <ns0:name>Ebastine</ns0:name>
      <ns0:description>The metabolism of Ebastine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12515</ns0:drugbank-id>
      <ns0:name>9-aminocamptothecin</ns0:name>
      <ns0:description>The metabolism of 9-aminocamptothecin can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12952</ns0:drugbank-id>
      <ns0:name>Methylprednisone</ns0:name>
      <ns0:description>The metabolism of Methylprednisone can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13385</ns0:drugbank-id>
      <ns0:name>Dihydroergocryptine</ns0:name>
      <ns0:description>The metabolism of Dihydroergocryptine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15444</ns0:drugbank-id>
      <ns0:name>Elexacaftor</ns0:name>
      <ns0:description>The metabolism of Elexacaftor can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00604</ns0:drugbank-id>
      <ns0:name>Cisapride</ns0:name>
      <ns0:description>The metabolism of Cisapride can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05154</ns0:drugbank-id>
      <ns0:name>Pretomanid</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Pretomanid.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05316</ns0:drugbank-id>
      <ns0:name>Pimavanserin</ns0:name>
      <ns0:description>The metabolism of Pimavanserin can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12235</ns0:drugbank-id>
      <ns0:name>Estetrol</ns0:name>
      <ns0:description>The metabolism of Estetrol can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00637</ns0:drugbank-id>
      <ns0:name>Astemizole</ns0:name>
      <ns0:description>The metabolism of Astemizole can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01229</ns0:drugbank-id>
      <ns0:name>Paclitaxel</ns0:name>
      <ns0:description>The metabolism of Paclitaxel can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01268</ns0:drugbank-id>
      <ns0:name>Sunitinib</ns0:name>
      <ns0:description>The metabolism of Sunitinib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09074</ns0:drugbank-id>
      <ns0:name>Olaparib</ns0:name>
      <ns0:description>The metabolism of Olaparib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11363</ns0:drugbank-id>
      <ns0:name>Alectinib</ns0:name>
      <ns0:description>The metabolism of Alectinib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11817</ns0:drugbank-id>
      <ns0:name>Baricitinib</ns0:name>
      <ns0:description>The excretion of Baricitinib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12001</ns0:drugbank-id>
      <ns0:name>Abemaciclib</ns0:name>
      <ns0:description>The serum concentration of Abemaciclib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12267</ns0:drugbank-id>
      <ns0:name>Brigatinib</ns0:name>
      <ns0:description>The metabolism of Brigatinib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00444</ns0:drugbank-id>
      <ns0:name>Teniposide</ns0:name>
      <ns0:description>The metabolism of Teniposide can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00563</ns0:drugbank-id>
      <ns0:name>Methotrexate</ns0:name>
      <ns0:description>The metabolism of Methotrexate can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00762</ns0:drugbank-id>
      <ns0:name>Irinotecan</ns0:name>
      <ns0:description>The metabolism of Irinotecan can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09054</ns0:drugbank-id>
      <ns0:name>Idelalisib</ns0:name>
      <ns0:description>The metabolism of Idelalisib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06603</ns0:drugbank-id>
      <ns0:name>Panobinostat</ns0:name>
      <ns0:description>The serum concentration of Panobinostat can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06626</ns0:drugbank-id>
      <ns0:name>Axitinib</ns0:name>
      <ns0:description>The serum concentration of Axitinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01100</ns0:drugbank-id>
      <ns0:name>Pimozide</ns0:name>
      <ns0:description>The metabolism of Pimozide can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12371</ns0:drugbank-id>
      <ns0:name>Siponimod</ns0:name>
      <ns0:description>The metabolism of Siponimod can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00204</ns0:drugbank-id>
      <ns0:name>Dofetilide</ns0:name>
      <ns0:description>The metabolism of Dofetilide can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00248</ns0:drugbank-id>
      <ns0:name>Cabergoline</ns0:name>
      <ns0:description>The serum concentration of Cabergoline can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00277</ns0:drugbank-id>
      <ns0:name>Theophylline</ns0:name>
      <ns0:description>The metabolism of Theophylline can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00309</ns0:drugbank-id>
      <ns0:name>Vindesine</ns0:name>
      <ns0:description>The metabolism of Vindesine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00361</ns0:drugbank-id>
      <ns0:name>Vinorelbine</ns0:name>
      <ns0:description>The metabolism of Vinorelbine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00946</ns0:drugbank-id>
      <ns0:name>Phenprocoumon</ns0:name>
      <ns0:description>The metabolism of Phenprocoumon can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01008</ns0:drugbank-id>
      <ns0:name>Busulfan</ns0:name>
      <ns0:description>The metabolism of Busulfan can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01223</ns0:drugbank-id>
      <ns0:name>Aminophylline</ns0:name>
      <ns0:description>The metabolism of Aminophylline can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01248</ns0:drugbank-id>
      <ns0:name>Docetaxel</ns0:name>
      <ns0:description>The metabolism of Docetaxel can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04572</ns0:drugbank-id>
      <ns0:name>Thiotepa</ns0:name>
      <ns0:description>The metabolism of Thiotepa can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05109</ns0:drugbank-id>
      <ns0:name>Trabectedin</ns0:name>
      <ns0:description>The metabolism of Trabectedin can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08877</ns0:drugbank-id>
      <ns0:name>Ruxolitinib</ns0:name>
      <ns0:description>The metabolism of Ruxolitinib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09143</ns0:drugbank-id>
      <ns0:name>Sonidegib</ns0:name>
      <ns0:description>The metabolism of Sonidegib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09289</ns0:drugbank-id>
      <ns0:name>Tianeptine</ns0:name>
      <ns0:description>The metabolism of Tianeptine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09570</ns0:drugbank-id>
      <ns0:name>Ixazomib</ns0:name>
      <ns0:description>The metabolism of Ixazomib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11703</ns0:drugbank-id>
      <ns0:name>Acalabrutinib</ns0:name>
      <ns0:description>The metabolism of Acalabrutinib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12978</ns0:drugbank-id>
      <ns0:name>Pexidartinib</ns0:name>
      <ns0:description>The metabolism of Pexidartinib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15035</ns0:drugbank-id>
      <ns0:name>Zanubrutinib</ns0:name>
      <ns0:description>The metabolism of Zanubrutinib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00531</ns0:drugbank-id>
      <ns0:name>Cyclophosphamide</ns0:name>
      <ns0:description>The metabolism of Cyclophosphamide can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00575</ns0:drugbank-id>
      <ns0:name>Clonidine</ns0:name>
      <ns0:description>The metabolism of Clonidine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00320</ns0:drugbank-id>
      <ns0:name>Dihydroergotamine</ns0:name>
      <ns0:description>The metabolism of Dihydroergotamine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01128</ns0:drugbank-id>
      <ns0:name>Bicalutamide</ns0:name>
      <ns0:description>The metabolism of Bicalutamide can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01242</ns0:drugbank-id>
      <ns0:name>Clomipramine</ns0:name>
      <ns0:description>The metabolism of Clomipramine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01227</ns0:drugbank-id>
      <ns0:name>Levacetylmethadol</ns0:name>
      <ns0:description>The metabolism of Levacetylmethadol can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04896</ns0:drugbank-id>
      <ns0:name>Milnacipran</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Milnacipran.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08918</ns0:drugbank-id>
      <ns0:name>Levomilnacipran</ns0:name>
      <ns0:description>The metabolism of Levomilnacipran can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11886</ns0:drugbank-id>
      <ns0:name>Infigratinib</ns0:name>
      <ns0:description>The metabolism of Infigratinib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01095</ns0:drugbank-id>
      <ns0:name>Fluvastatin</ns0:name>
      <ns0:description>The metabolism of Fluvastatin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00238</ns0:drugbank-id>
      <ns0:name>Nevirapine</ns0:name>
      <ns0:description>The metabolism of Nevirapine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00250</ns0:drugbank-id>
      <ns0:name>Dapsone</ns0:name>
      <ns0:description>The metabolism of Dapsone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00281</ns0:drugbank-id>
      <ns0:name>Lidocaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Lidocaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00321</ns0:drugbank-id>
      <ns0:name>Amitriptyline</ns0:name>
      <ns0:description>The metabolism of Amitriptyline can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00343</ns0:drugbank-id>
      <ns0:name>Diltiazem</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Diltiazem.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00401</ns0:drugbank-id>
      <ns0:name>Nisoldipine</ns0:name>
      <ns0:description>The metabolism of Nisoldipine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00490</ns0:drugbank-id>
      <ns0:name>Buspirone</ns0:name>
      <ns0:description>The metabolism of Buspirone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00497</ns0:drugbank-id>
      <ns0:name>Oxycodone</ns0:name>
      <ns0:description>The metabolism of Oxycodone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00499</ns0:drugbank-id>
      <ns0:name>Flutamide</ns0:name>
      <ns0:description>The metabolism of Flutamide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00514</ns0:drugbank-id>
      <ns0:name>Dextromethorphan</ns0:name>
      <ns0:description>The metabolism of Dextromethorphan can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00528</ns0:drugbank-id>
      <ns0:name>Lercanidipine</ns0:name>
      <ns0:description>The metabolism of Lercanidipine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00571</ns0:drugbank-id>
      <ns0:name>Propranolol</ns0:name>
      <ns0:description>The metabolism of Propranolol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00588</ns0:drugbank-id>
      <ns0:name>Fluticasone propionate</ns0:name>
      <ns0:description>The metabolism of Fluticasone propionate can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00608</ns0:drugbank-id>
      <ns0:name>Chloroquine</ns0:name>
      <ns0:description>The metabolism of Chloroquine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00620</ns0:drugbank-id>
      <ns0:name>Triamcinolone</ns0:name>
      <ns0:description>The metabolism of Triamcinolone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00656</ns0:drugbank-id>
      <ns0:name>Trazodone</ns0:name>
      <ns0:description>The metabolism of Trazodone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00673</ns0:drugbank-id>
      <ns0:name>Aprepitant</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Aprepitant.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00700</ns0:drugbank-id>
      <ns0:name>Eplerenone</ns0:name>
      <ns0:description>The metabolism of Eplerenone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00714</ns0:drugbank-id>
      <ns0:name>Apomorphine</ns0:name>
      <ns0:description>The metabolism of Apomorphine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00731</ns0:drugbank-id>
      <ns0:name>Nateglinide</ns0:name>
      <ns0:description>The metabolism of Nateglinide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00734</ns0:drugbank-id>
      <ns0:name>Risperidone</ns0:name>
      <ns0:description>The metabolism of Risperidone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00738</ns0:drugbank-id>
      <ns0:name>Pentamidine</ns0:name>
      <ns0:description>The metabolism of Pentamidine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00741</ns0:drugbank-id>
      <ns0:name>Hydrocortisone</ns0:name>
      <ns0:description>The metabolism of Hydrocortisone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00755</ns0:drugbank-id>
      <ns0:name>Tretinoin</ns0:name>
      <ns0:description>The metabolism of Tretinoin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00758</ns0:drugbank-id>
      <ns0:name>Clopidogrel</ns0:name>
      <ns0:description>The metabolism of Clopidogrel can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00802</ns0:drugbank-id>
      <ns0:name>Alfentanil</ns0:name>
      <ns0:description>The metabolism of Alfentanil can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00829</ns0:drugbank-id>
      <ns0:name>Diazepam</ns0:name>
      <ns0:description>The metabolism of Diazepam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00897</ns0:drugbank-id>
      <ns0:name>Triazolam</ns0:name>
      <ns0:description>The metabolism of Triazolam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00904</ns0:drugbank-id>
      <ns0:name>Ondansetron</ns0:name>
      <ns0:description>The metabolism of Ondansetron can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00916</ns0:drugbank-id>
      <ns0:name>Metronidazole</ns0:name>
      <ns0:description>The metabolism of Metronidazole can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00938</ns0:drugbank-id>
      <ns0:name>Salmeterol</ns0:name>
      <ns0:description>The metabolism of Salmeterol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00962</ns0:drugbank-id>
      <ns0:name>Zaleplon</ns0:name>
      <ns0:description>The metabolism of Zaleplon can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00972</ns0:drugbank-id>
      <ns0:name>Azelastine</ns0:name>
      <ns0:description>The metabolism of Azelastine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01058</ns0:drugbank-id>
      <ns0:name>Praziquantel</ns0:name>
      <ns0:description>The metabolism of Praziquantel can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01062</ns0:drugbank-id>
      <ns0:name>Oxybutynin</ns0:name>
      <ns0:description>The metabolism of Oxybutynin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01103</ns0:drugbank-id>
      <ns0:name>Quinacrine</ns0:name>
      <ns0:description>The metabolism of Quinacrine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01114</ns0:drugbank-id>
      <ns0:name>Chlorpheniramine</ns0:name>
      <ns0:description>The metabolism of Chlorpheniramine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01126</ns0:drugbank-id>
      <ns0:name>Dutasteride</ns0:name>
      <ns0:description>The metabolism of Dutasteride can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01184</ns0:drugbank-id>
      <ns0:name>Domperidone</ns0:name>
      <ns0:description>The metabolism of Domperidone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01216</ns0:drugbank-id>
      <ns0:name>Finasteride</ns0:name>
      <ns0:description>The metabolism of Finasteride can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01218</ns0:drugbank-id>
      <ns0:name>Halofantrine</ns0:name>
      <ns0:description>The metabolism of Halofantrine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01224</ns0:drugbank-id>
      <ns0:name>Quetiapine</ns0:name>
      <ns0:description>The metabolism of Quetiapine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04856</ns0:drugbank-id>
      <ns0:name>Dexloxiglumide</ns0:name>
      <ns0:description>The metabolism of Dexloxiglumide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04957</ns0:drugbank-id>
      <ns0:name>Azimilide</ns0:name>
      <ns0:description>The metabolism of Azimilide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06267</ns0:drugbank-id>
      <ns0:name>Udenafil</ns0:name>
      <ns0:description>The metabolism of Udenafil can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06335</ns0:drugbank-id>
      <ns0:name>Saxagliptin</ns0:name>
      <ns0:description>The metabolism of Saxagliptin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06652</ns0:drugbank-id>
      <ns0:name>Vicriviroc</ns0:name>
      <ns0:description>The metabolism of Vicriviroc can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06697</ns0:drugbank-id>
      <ns0:name>Artemether</ns0:name>
      <ns0:description>The metabolism of Artemether can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08906</ns0:drugbank-id>
      <ns0:name>Fluticasone furoate</ns0:name>
      <ns0:description>The serum concentration of Fluticasone furoate can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09068</ns0:drugbank-id>
      <ns0:name>Vortioxetine</ns0:name>
      <ns0:description>The metabolism of Vortioxetine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09231</ns0:drugbank-id>
      <ns0:name>Benidipine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Benidipine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11737</ns0:drugbank-id>
      <ns0:name>Icotinib</ns0:name>
      <ns0:description>The metabolism of Icotinib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11915</ns0:drugbank-id>
      <ns0:name>Valbenazine</ns0:name>
      <ns0:description>The metabolism of Valbenazine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12130</ns0:drugbank-id>
      <ns0:name>Lorlatinib</ns0:name>
      <ns0:description>The metabolism of Lorlatinib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12161</ns0:drugbank-id>
      <ns0:name>Deutetrabenazine</ns0:name>
      <ns0:description>The metabolism of Deutetrabenazine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12301</ns0:drugbank-id>
      <ns0:name>Doravirine</ns0:name>
      <ns0:description>The metabolism of Doravirine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13867</ns0:drugbank-id>
      <ns0:name>Fluticasone</ns0:name>
      <ns0:description>The metabolism of Fluticasone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14539</ns0:drugbank-id>
      <ns0:name>Hydrocortisone acetate</ns0:name>
      <ns0:description>The metabolism of Hydrocortisone acetate can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14540</ns0:drugbank-id>
      <ns0:name>Hydrocortisone butyrate</ns0:name>
      <ns0:description>The metabolism of Hydrocortisone butyrate can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14541</ns0:drugbank-id>
      <ns0:name>Hydrocortisone cypionate</ns0:name>
      <ns0:description>The metabolism of Hydrocortisone cypionate can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00619</ns0:drugbank-id>
      <ns0:name>Imatinib</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Imatinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14542</ns0:drugbank-id>
      <ns0:name>Hydrocortisone phosphate</ns0:name>
      <ns0:description>The metabolism of Hydrocortisone phosphate can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12016</ns0:drugbank-id>
      <ns0:name>Ponesimod</ns0:name>
      <ns0:description>The metabolism of Ponesimod can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09256</ns0:drugbank-id>
      <ns0:name>Tegafur</ns0:name>
      <ns0:description>The metabolism of Tegafur can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00214</ns0:drugbank-id>
      <ns0:name>Torasemide</ns0:name>
      <ns0:description>The metabolism of Torasemide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00347</ns0:drugbank-id>
      <ns0:name>Trimethadione</ns0:name>
      <ns0:description>The metabolism of Trimethadione can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00359</ns0:drugbank-id>
      <ns0:name>Sulfadiazine</ns0:name>
      <ns0:description>The metabolism of Sulfadiazine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00465</ns0:drugbank-id>
      <ns0:name>Ketorolac</ns0:name>
      <ns0:description>The metabolism of Ketorolac can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00471</ns0:drugbank-id>
      <ns0:name>Montelukast</ns0:name>
      <ns0:description>The metabolism of Montelukast can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00532</ns0:drugbank-id>
      <ns0:name>Mephenytoin</ns0:name>
      <ns0:description>The metabolism of Mephenytoin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00554</ns0:drugbank-id>
      <ns0:name>Piroxicam</ns0:name>
      <ns0:description>The metabolism of Piroxicam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00613</ns0:drugbank-id>
      <ns0:name>Amodiaquine</ns0:name>
      <ns0:description>The metabolism of Amodiaquine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00617</ns0:drugbank-id>
      <ns0:name>Paramethadione</ns0:name>
      <ns0:description>The metabolism of Paramethadione can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00799</ns0:drugbank-id>
      <ns0:name>Tazarotene</ns0:name>
      <ns0:description>The metabolism of Tazarotene can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00818</ns0:drugbank-id>
      <ns0:name>Propofol</ns0:name>
      <ns0:description>The metabolism of Propofol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00857</ns0:drugbank-id>
      <ns0:name>Terbinafine</ns0:name>
      <ns0:description>The metabolism of Terbinafine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00918</ns0:drugbank-id>
      <ns0:name>Almotriptan</ns0:name>
      <ns0:description>The metabolism of Almotriptan can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01029</ns0:drugbank-id>
      <ns0:name>Irbesartan</ns0:name>
      <ns0:description>The metabolism of Irbesartan can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01037</ns0:drugbank-id>
      <ns0:name>Selegiline</ns0:name>
      <ns0:description>The metabolism of Selegiline can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01050</ns0:drugbank-id>
      <ns0:name>Ibuprofen</ns0:name>
      <ns0:description>The metabolism of Ibuprofen can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01124</ns0:drugbank-id>
      <ns0:name>Tolbutamide</ns0:name>
      <ns0:description>The metabolism of Tolbutamide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01217</ns0:drugbank-id>
      <ns0:name>Anastrozole</ns0:name>
      <ns0:description>The metabolism of Anastrozole can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01221</ns0:drugbank-id>
      <ns0:name>Ketamine</ns0:name>
      <ns0:description>The metabolism of Ketamine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01424</ns0:drugbank-id>
      <ns0:name>Aminophenazone</ns0:name>
      <ns0:description>The metabolism of Aminophenazone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01435</ns0:drugbank-id>
      <ns0:name>Antipyrine</ns0:name>
      <ns0:description>The metabolism of Antipyrine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04725</ns0:drugbank-id>
      <ns0:name>Licofelone</ns0:name>
      <ns0:description>The metabolism of Licofelone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05229</ns0:drugbank-id>
      <ns0:name>Beraprost</ns0:name>
      <ns0:description>The metabolism of Beraprost can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06510</ns0:drugbank-id>
      <ns0:name>Muraglitazar</ns0:name>
      <ns0:description>The metabolism of Muraglitazar can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06738</ns0:drugbank-id>
      <ns0:name>Ketobemidone</ns0:name>
      <ns0:description>The metabolism of Ketobemidone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06739</ns0:drugbank-id>
      <ns0:name>Seratrodast</ns0:name>
      <ns0:description>The metabolism of Seratrodast can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06770</ns0:drugbank-id>
      <ns0:name>Benzyl alcohol</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Benzyl alcohol.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08502</ns0:drugbank-id>
      <ns0:name>Capravirine</ns0:name>
      <ns0:description>The metabolism of Capravirine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08922</ns0:drugbank-id>
      <ns0:name>Perospirone</ns0:name>
      <ns0:description>The metabolism of Perospirone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09080</ns0:drugbank-id>
      <ns0:name>Olodaterol</ns0:name>
      <ns0:description>The metabolism of Olodaterol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09198</ns0:drugbank-id>
      <ns0:name>Lobeglitazone</ns0:name>
      <ns0:description>The metabolism of Lobeglitazone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09199</ns0:drugbank-id>
      <ns0:name>Netoglitazone</ns0:name>
      <ns0:description>The metabolism of Netoglitazone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09200</ns0:drugbank-id>
      <ns0:name>Rivoglitazone</ns0:name>
      <ns0:description>The metabolism of Rivoglitazone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09201</ns0:drugbank-id>
      <ns0:name>Ciglitazone</ns0:name>
      <ns0:description>The metabolism of Ciglitazone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09213</ns0:drugbank-id>
      <ns0:name>Dexibuprofen</ns0:name>
      <ns0:description>The metabolism of Dexibuprofen can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09288</ns0:drugbank-id>
      <ns0:name>Propacetamol</ns0:name>
      <ns0:description>The metabolism of Propacetamol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12781</ns0:drugbank-id>
      <ns0:name>Balaglitazone</ns0:name>
      <ns0:description>The metabolism of Balaglitazone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01611</ns0:drugbank-id>
      <ns0:name>Hydroxychloroquine</ns0:name>
      <ns0:description>The metabolism of Hydroxychloroquine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00544</ns0:drugbank-id>
      <ns0:name>Fluorouracil</ns0:name>
      <ns0:description>The metabolism of Fluorouracil can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01035</ns0:drugbank-id>
      <ns0:name>Procainamide</ns0:name>
      <ns0:description>The excretion of Procainamide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00787</ns0:drugbank-id>
      <ns0:name>Acyclovir</ns0:name>
      <ns0:description>The excretion of Acyclovir can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01137</ns0:drugbank-id>
      <ns0:name>Levofloxacin</ns0:name>
      <ns0:description>The excretion of Levofloxacin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00331</ns0:drugbank-id>
      <ns0:name>Metformin</ns0:name>
      <ns0:description>The excretion of Metformin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00536</ns0:drugbank-id>
      <ns0:name>Guanidine</ns0:name>
      <ns0:description>The excretion of Guanidine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00537</ns0:drugbank-id>
      <ns0:name>Ciprofloxacin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ciprofloxacin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00879</ns0:drugbank-id>
      <ns0:name>Emtricitabine</ns0:name>
      <ns0:description>The excretion of Emtricitabine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01004</ns0:drugbank-id>
      <ns0:name>Ganciclovir</ns0:name>
      <ns0:description>The excretion of Ganciclovir can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01195</ns0:drugbank-id>
      <ns0:name>Flecainide</ns0:name>
      <ns0:description>The excretion of Flecainide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01203</ns0:drugbank-id>
      <ns0:name>Nadolol</ns0:name>
      <ns0:description>The excretion of Nadolol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01333</ns0:drugbank-id>
      <ns0:name>Cefradine</ns0:name>
      <ns0:description>The excretion of Cefradine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08840</ns0:drugbank-id>
      <ns0:name>N-methylnicotinamide</ns0:name>
      <ns0:description>The excretion of N-methylnicotinamide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12377</ns0:drugbank-id>
      <ns0:name>Relebactam</ns0:name>
      <ns0:description>The excretion of Relebactam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14754</ns0:drugbank-id>
      <ns0:name>Solriamfetol</ns0:name>
      <ns0:description>The excretion of Solriamfetol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00177</ns0:drugbank-id>
      <ns0:name>Valsartan</ns0:name>
      <ns0:description>The metabolism of Valsartan can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00285</ns0:drugbank-id>
      <ns0:name>Venlafaxine</ns0:name>
      <ns0:description>Venlafaxine may increase the excretion rate of Pralsetinib which could result in a lower serum level and potentially a reduction in efficacy.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00216</ns0:drugbank-id>
      <ns0:name>Eletriptan</ns0:name>
      <ns0:description>The metabolism of Eletriptan can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00307</ns0:drugbank-id>
      <ns0:name>Bexarotene</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Bexarotene.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00327</ns0:drugbank-id>
      <ns0:name>Hydromorphone</ns0:name>
      <ns0:description>The metabolism of Hydromorphone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00374</ns0:drugbank-id>
      <ns0:name>Treprostinil</ns0:name>
      <ns0:description>The metabolism of Treprostinil can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00414</ns0:drugbank-id>
      <ns0:name>Acetohexamide</ns0:name>
      <ns0:description>The metabolism of Acetohexamide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00420</ns0:drugbank-id>
      <ns0:name>Promazine</ns0:name>
      <ns0:description>The metabolism of Promazine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00440</ns0:drugbank-id>
      <ns0:name>Trimethoprim</ns0:name>
      <ns0:description>The metabolism of Trimethoprim can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00461</ns0:drugbank-id>
      <ns0:name>Nabumetone</ns0:name>
      <ns0:description>The metabolism of Nabumetone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00469</ns0:drugbank-id>
      <ns0:name>Tenoxicam</ns0:name>
      <ns0:description>The metabolism of Tenoxicam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00472</ns0:drugbank-id>
      <ns0:name>Fluoxetine</ns0:name>
      <ns0:description>The metabolism of Fluoxetine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00533</ns0:drugbank-id>
      <ns0:name>Rofecoxib</ns0:name>
      <ns0:description>The metabolism of Rofecoxib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00568</ns0:drugbank-id>
      <ns0:name>Cinnarizine</ns0:name>
      <ns0:description>The metabolism of Cinnarizine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00580</ns0:drugbank-id>
      <ns0:name>Valdecoxib</ns0:name>
      <ns0:description>The metabolism of Valdecoxib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00672</ns0:drugbank-id>
      <ns0:name>Chlorpropamide</ns0:name>
      <ns0:description>The metabolism of Chlorpropamide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00712</ns0:drugbank-id>
      <ns0:name>Flurbiprofen</ns0:name>
      <ns0:description>The metabolism of Flurbiprofen can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00744</ns0:drugbank-id>
      <ns0:name>Zileuton</ns0:name>
      <ns0:description>The metabolism of Zileuton can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00749</ns0:drugbank-id>
      <ns0:name>Etodolac</ns0:name>
      <ns0:description>The metabolism of Etodolac can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00784</ns0:drugbank-id>
      <ns0:name>Mefenamic acid</ns0:name>
      <ns0:description>The metabolism of Mefenamic acid can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00796</ns0:drugbank-id>
      <ns0:name>Candesartan cilexetil</ns0:name>
      <ns0:description>The metabolism of Candesartan cilexetil can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00812</ns0:drugbank-id>
      <ns0:name>Phenylbutazone</ns0:name>
      <ns0:description>The metabolism of Phenylbutazone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00814</ns0:drugbank-id>
      <ns0:name>Meloxicam</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Meloxicam.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00839</ns0:drugbank-id>
      <ns0:name>Tolazamide</ns0:name>
      <ns0:description>The metabolism of Tolazamide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00936</ns0:drugbank-id>
      <ns0:name>Salicylic acid</ns0:name>
      <ns0:description>The metabolism of Salicylic acid can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00945</ns0:drugbank-id>
      <ns0:name>Acetylsalicylic acid</ns0:name>
      <ns0:description>The metabolism of Acetylsalicylic acid can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00969</ns0:drugbank-id>
      <ns0:name>Alosetron</ns0:name>
      <ns0:description>The metabolism of Alosetron can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00980</ns0:drugbank-id>
      <ns0:name>Ramelteon</ns0:name>
      <ns0:description>The metabolism of Ramelteon can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00983</ns0:drugbank-id>
      <ns0:name>Formoterol</ns0:name>
      <ns0:description>The metabolism of Formoterol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01028</ns0:drugbank-id>
      <ns0:name>Methoxyflurane</ns0:name>
      <ns0:description>The metabolism of Methoxyflurane can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01036</ns0:drugbank-id>
      <ns0:name>Tolterodine</ns0:name>
      <ns0:description>The metabolism of Tolterodine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01041</ns0:drugbank-id>
      <ns0:name>Thalidomide</ns0:name>
      <ns0:description>The metabolism of Thalidomide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01075</ns0:drugbank-id>
      <ns0:name>Diphenhydramine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Diphenhydramine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01104</ns0:drugbank-id>
      <ns0:name>Sertraline</ns0:name>
      <ns0:description>The metabolism of Sertraline can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01120</ns0:drugbank-id>
      <ns0:name>Gliclazide</ns0:name>
      <ns0:description>The metabolism of Gliclazide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01131</ns0:drugbank-id>
      <ns0:name>Proguanil</ns0:name>
      <ns0:description>The metabolism of Proguanil can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01142</ns0:drugbank-id>
      <ns0:name>Doxepin</ns0:name>
      <ns0:description>The metabolism of Doxepin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01154</ns0:drugbank-id>
      <ns0:name>Thiamylal</ns0:name>
      <ns0:description>The metabolism of Thiamylal can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01156</ns0:drugbank-id>
      <ns0:name>Bupropion</ns0:name>
      <ns0:description>The metabolism of Bupropion can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01159</ns0:drugbank-id>
      <ns0:name>Halothane</ns0:name>
      <ns0:description>The metabolism of Halothane can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01177</ns0:drugbank-id>
      <ns0:name>Idarubicin</ns0:name>
      <ns0:description>The metabolism of Idarubicin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01251</ns0:drugbank-id>
      <ns0:name>Gliquidone</ns0:name>
      <ns0:description>The metabolism of Gliquidone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01274</ns0:drugbank-id>
      <ns0:name>Arformoterol</ns0:name>
      <ns0:description>The metabolism of Arformoterol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01283</ns0:drugbank-id>
      <ns0:name>Lumiracoxib</ns0:name>
      <ns0:description>The metabolism of Lumiracoxib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01289</ns0:drugbank-id>
      <ns0:name>Glisoxepide</ns0:name>
      <ns0:description>The metabolism of Glisoxepide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01355</ns0:drugbank-id>
      <ns0:name>Hexobarbital</ns0:name>
      <ns0:description>The metabolism of Hexobarbital can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01544</ns0:drugbank-id>
      <ns0:name>Flunitrazepam</ns0:name>
      <ns0:description>The metabolism of Flunitrazepam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01628</ns0:drugbank-id>
      <ns0:name>Etoricoxib</ns0:name>
      <ns0:description>The metabolism of Etoricoxib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB03756</ns0:drugbank-id>
      <ns0:name>Doconexent</ns0:name>
      <ns0:description>The metabolism of Doconexent can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB03783</ns0:drugbank-id>
      <ns0:name>Phenacetin</ns0:name>
      <ns0:description>The metabolism of Phenacetin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04557</ns0:drugbank-id>
      <ns0:name>Arachidonic Acid</ns0:name>
      <ns0:description>The metabolism of Arachidonic Acid can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04665</ns0:drugbank-id>
      <ns0:name>Coumarin</ns0:name>
      <ns0:description>The metabolism of Coumarin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04841</ns0:drugbank-id>
      <ns0:name>Flunarizine</ns0:name>
      <ns0:description>The metabolism of Flunarizine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04898</ns0:drugbank-id>
      <ns0:name>Ximelagatran</ns0:name>
      <ns0:description>The metabolism of Ximelagatran can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04938</ns0:drugbank-id>
      <ns0:name>Ospemifene</ns0:name>
      <ns0:description>The metabolism of Ospemifene can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05541</ns0:drugbank-id>
      <ns0:name>Brivaracetam</ns0:name>
      <ns0:description>The metabolism of Brivaracetam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06209</ns0:drugbank-id>
      <ns0:name>Prasugrel</ns0:name>
      <ns0:description>The metabolism of Prasugrel can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06268</ns0:drugbank-id>
      <ns0:name>Sitaxentan</ns0:name>
      <ns0:description>The metabolism of Sitaxentan can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06370</ns0:drugbank-id>
      <ns0:name>Indisulam</ns0:name>
      <ns0:description>The metabolism of Indisulam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06414</ns0:drugbank-id>
      <ns0:name>Etravirine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Etravirine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06725</ns0:drugbank-id>
      <ns0:name>Lornoxicam</ns0:name>
      <ns0:description>The metabolism of Lornoxicam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06737</ns0:drugbank-id>
      <ns0:name>Zaltoprofen</ns0:name>
      <ns0:description>The metabolism of Zaltoprofen can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06803</ns0:drugbank-id>
      <ns0:name>Niclosamide</ns0:name>
      <ns0:description>The metabolism of Niclosamide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB07615</ns0:drugbank-id>
      <ns0:name>Tranilast</ns0:name>
      <ns0:description>The metabolism of Tranilast can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08439</ns0:drugbank-id>
      <ns0:name>Parecoxib</ns0:name>
      <ns0:description>The metabolism of Parecoxib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08962</ns0:drugbank-id>
      <ns0:name>Glibornuride</ns0:name>
      <ns0:description>The metabolism of Glibornuride can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11560</ns0:drugbank-id>
      <ns0:name>Lesinurad</ns0:name>
      <ns0:description>The metabolism of Lesinurad can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11614</ns0:drugbank-id>
      <ns0:name>Rupatadine</ns0:name>
      <ns0:description>The metabolism of Rupatadine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11823</ns0:drugbank-id>
      <ns0:name>Esketamine</ns0:name>
      <ns0:description>The metabolism of Esketamine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12245</ns0:drugbank-id>
      <ns0:name>Triclabendazole</ns0:name>
      <ns0:description>The metabolism of Triclabendazole can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13406</ns0:drugbank-id>
      <ns0:name>Carbutamide</ns0:name>
      <ns0:description>The metabolism of Carbutamide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13675</ns0:drugbank-id>
      <ns0:name>Metahexamide</ns0:name>
      <ns0:description>The metabolism of Metahexamide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13919</ns0:drugbank-id>
      <ns0:name>Candesartan</ns0:name>
      <ns0:description>The metabolism of Candesartan can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13941</ns0:drugbank-id>
      <ns0:name>Piperaquine</ns0:name>
      <ns0:description>The metabolism of Piperaquine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15233</ns0:drugbank-id>
      <ns0:name>Avapritinib</ns0:name>
      <ns0:description>The metabolism of Avapritinib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00313</ns0:drugbank-id>
      <ns0:name>Valproic acid</ns0:name>
      <ns0:description>The metabolism of Valproic acid can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00363</ns0:drugbank-id>
      <ns0:name>Clozapine</ns0:name>
      <ns0:description>The serum concentration of Clozapine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00549</ns0:drugbank-id>
      <ns0:name>Zafirlukast</ns0:name>
      <ns0:description>The metabolism of Zafirlukast can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00333</ns0:drugbank-id>
      <ns0:name>Methadone</ns0:name>
      <ns0:description>The metabolism of Methadone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00476</ns0:drugbank-id>
      <ns0:name>Duloxetine</ns0:name>
      <ns0:description>The metabolism of Duloxetine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00266</ns0:drugbank-id>
      <ns0:name>Dicoumarol</ns0:name>
      <ns0:description>The metabolism of Dicoumarol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08875</ns0:drugbank-id>
      <ns0:name>Cabozantinib</ns0:name>
      <ns0:description>The metabolism of Cabozantinib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13136</ns0:drugbank-id>
      <ns0:name>Fluindione</ns0:name>
      <ns0:description>The metabolism of Fluindione can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01101</ns0:drugbank-id>
      <ns0:name>Capecitabine</ns0:name>
      <ns0:description>The metabolism of Capecitabine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09142</ns0:drugbank-id>
      <ns0:name>Sincalide</ns0:name>
      <ns0:description>The excretion of Sincalide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11936</ns0:drugbank-id>
      <ns0:name>Bempedoic acid</ns0:name>
      <ns0:description>The excretion of Bempedoic acid can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11855</ns0:drugbank-id>
      <ns0:name>Revefenacin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Revefenacin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00381</ns0:drugbank-id>
      <ns0:name>Amlodipine</ns0:name>
      <ns0:description>The metabolism of Amlodipine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01068</ns0:drugbank-id>
      <ns0:name>Clonazepam</ns0:name>
      <ns0:description>The metabolism of Clonazepam can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00425</ns0:drugbank-id>
      <ns0:name>Zolpidem</ns0:name>
      <ns0:description>The metabolism of Zolpidem can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12147</ns0:drugbank-id>
      <ns0:name>Erdafitinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Erdafitinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00390</ns0:drugbank-id>
      <ns0:name>Digoxin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Digoxin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13401</ns0:drugbank-id>
      <ns0:name>Metildigoxin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Metildigoxin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13691</ns0:drugbank-id>
      <ns0:name>Acetyldigoxin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12015</ns0:drugbank-id>
      <ns0:name>Alpelisib</ns0:name>
      <ns0:description>The serum concentration of Alpelisib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00402</ns0:drugbank-id>
      <ns0:name>Eszopiclone</ns0:name>
      <ns0:description>The serum concentration of Eszopiclone can be decreased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11986</ns0:drugbank-id>
      <ns0:name>Entrectinib</ns0:name>
      <ns0:description>The metabolism of Entrectinib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12825</ns0:drugbank-id>
      <ns0:name>Lefamulin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Lefamulin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11732</ns0:drugbank-id>
      <ns0:name>Lasmiditan</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Lasmiditan.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14975</ns0:drugbank-id>
      <ns0:name>Voxelotor</ns0:name>
      <ns0:description>The serum concentration of Voxelotor can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06119</ns0:drugbank-id>
      <ns0:name>Cenobamate</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Cenobamate.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09237</ns0:drugbank-id>
      <ns0:name>Levamlodipine</ns0:name>
      <ns0:description>The serum concentration of Levamlodipine can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12941</ns0:drugbank-id>
      <ns0:name>Darolutamide</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Darolutamide.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06077</ns0:drugbank-id>
      <ns0:name>Lumateperone</ns0:name>
      <ns0:description>The serum concentration of Lumateperone can be decreased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15328</ns0:drugbank-id>
      <ns0:name>Ubrogepant</ns0:name>
      <ns0:description>The serum concentration of Ubrogepant can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00243</ns0:drugbank-id>
      <ns0:name>Ranolazine</ns0:name>
      <ns0:description>The metabolism of Ranolazine can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11644</ns0:drugbank-id>
      <ns0:name>Tafamidis</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Tafamidis.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00193</ns0:drugbank-id>
      <ns0:name>Tramadol</ns0:name>
      <ns0:description>The metabolism of Tramadol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01132</ns0:drugbank-id>
      <ns0:name>Pioglitazone</ns0:name>
      <ns0:description>The metabolism of Pioglitazone can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01190</ns0:drugbank-id>
      <ns0:name>Clindamycin</ns0:name>
      <ns0:description>The metabolism of Clindamycin can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12457</ns0:drugbank-id>
      <ns0:name>Rimegepant</ns0:name>
      <ns0:description>The metabolism of Rimegepant can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00503</ns0:drugbank-id>
      <ns0:name>Ritonavir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ritonavir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12612</ns0:drugbank-id>
      <ns0:name>Ozanimod</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00502</ns0:drugbank-id>
      <ns0:name>Haloperidol</ns0:name>
      <ns0:description>The serum concentration of Haloperidol can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05990</ns0:drugbank-id>
      <ns0:name>Obeticholic acid</ns0:name>
      <ns0:description>The risk or severity of adverse effects can be increased when Pralsetinib is combined with Obeticholic acid.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11652</ns0:drugbank-id>
      <ns0:name>Tucatinib</ns0:name>
      <ns0:description>Tucatinib may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11791</ns0:drugbank-id>
      <ns0:name>Capmatinib</ns0:name>
      <ns0:description>The serum concentration of Capmatinib can be decreased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11932</ns0:drugbank-id>
      <ns0:name>Abametapir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Abametapir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14881</ns0:drugbank-id>
      <ns0:name>Oliceridine</ns0:name>
      <ns0:description>The serum concentration of Oliceridine can be decreased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15762</ns0:drugbank-id>
      <ns0:name>Satralizumab</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Satralizumab.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08916</ns0:drugbank-id>
      <ns0:name>Afatinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Afatinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00199</ns0:drugbank-id>
      <ns0:name>Erythromycin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Erythromycin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00641</ns0:drugbank-id>
      <ns0:name>Simvastatin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Simvastatin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00834</ns0:drugbank-id>
      <ns0:name>Mifepristone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Mifepristone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01590</ns0:drugbank-id>
      <ns0:name>Everolimus</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Everolimus.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09280</ns0:drugbank-id>
      <ns0:name>Lumacaftor</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Lumacaftor.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06636</ns0:drugbank-id>
      <ns0:name>Isavuconazonium</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Isavuconazonium.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11633</ns0:drugbank-id>
      <ns0:name>Isavuconazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Isavuconazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00091</ns0:drugbank-id>
      <ns0:name>Cyclosporine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Cyclosporine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00398</ns0:drugbank-id>
      <ns0:name>Sorafenib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Sorafenib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04881</ns0:drugbank-id>
      <ns0:name>Elacridar</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Elacridar.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05294</ns0:drugbank-id>
      <ns0:name>Vandetanib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Vandetanib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06290</ns0:drugbank-id>
      <ns0:name>Simeprevir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Simeprevir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08896</ns0:drugbank-id>
      <ns0:name>Regorafenib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Regorafenib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08901</ns0:drugbank-id>
      <ns0:name>Ponatinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ponatinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09073</ns0:drugbank-id>
      <ns0:name>Palbociclib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Palbociclib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09102</ns0:drugbank-id>
      <ns0:name>Daclatasvir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Daclatasvir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09291</ns0:drugbank-id>
      <ns0:name>Rolapitant</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Rolapitant.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11581</ns0:drugbank-id>
      <ns0:name>Venetoclax</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Venetoclax.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11613</ns0:drugbank-id>
      <ns0:name>Velpatasvir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Velpatasvir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11757</ns0:drugbank-id>
      <ns0:name>Istradefylline</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Istradefylline.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11963</ns0:drugbank-id>
      <ns0:name>Dacomitinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Dacomitinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11978</ns0:drugbank-id>
      <ns0:name>Glasdegib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Glasdegib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12026</ns0:drugbank-id>
      <ns0:name>Voxilaprevir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Voxilaprevir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12332</ns0:drugbank-id>
      <ns0:name>Rucaparib</ns0:name>
      <ns0:description>Rucaparib may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12500</ns0:drugbank-id>
      <ns0:name>Fedratinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Fedratinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13874</ns0:drugbank-id>
      <ns0:name>Enasidenib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Enasidenib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13878</ns0:drugbank-id>
      <ns0:name>Pibrentasvir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Pibrentasvir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13879</ns0:drugbank-id>
      <ns0:name>Glecaprevir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Glecaprevir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14840</ns0:drugbank-id>
      <ns0:name>Ripretinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ripretinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00675</ns0:drugbank-id>
      <ns0:name>Tamoxifen</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Tamoxifen.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00196</ns0:drugbank-id>
      <ns0:name>Fluconazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Fluconazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00203</ns0:drugbank-id>
      <ns0:name>Sildenafil</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Sildenafil.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00206</ns0:drugbank-id>
      <ns0:name>Reserpine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Reserpine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00408</ns0:drugbank-id>
      <ns0:name>Loxapine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Loxapine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00468</ns0:drugbank-id>
      <ns0:name>Quinine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Quinine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00539</ns0:drugbank-id>
      <ns0:name>Toremifene</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Toremifene.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00661</ns0:drugbank-id>
      <ns0:name>Verapamil</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Verapamil.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00908</ns0:drugbank-id>
      <ns0:name>Quinidine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Quinidine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00909</ns0:drugbank-id>
      <ns0:name>Zonisamide</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Zonisamide.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00957</ns0:drugbank-id>
      <ns0:name>Norgestimate</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Norgestimate.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01118</ns0:drugbank-id>
      <ns0:name>Amiodarone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Amiodarone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01136</ns0:drugbank-id>
      <ns0:name>Carvedilol</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Carvedilol.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01182</ns0:drugbank-id>
      <ns0:name>Propafenone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Propafenone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01259</ns0:drugbank-id>
      <ns0:name>Lapatinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Lapatinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01267</ns0:drugbank-id>
      <ns0:name>Paliperidone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Paliperidone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01388</ns0:drugbank-id>
      <ns0:name>Mibefradil</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Mibefradil.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04851</ns0:drugbank-id>
      <ns0:name>Biricodar</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Biricodar.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04855</ns0:drugbank-id>
      <ns0:name>Dronedarone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Dronedarone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04908</ns0:drugbank-id>
      <ns0:name>Flibanserin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Flibanserin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06191</ns0:drugbank-id>
      <ns0:name>Zosuquidar</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Zosuquidar.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06240</ns0:drugbank-id>
      <ns0:name>Tariquidar</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Tariquidar.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06287</ns0:drugbank-id>
      <ns0:name>Temsirolimus</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Temsirolimus.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB07348</ns0:drugbank-id>
      <ns0:name>Brefeldin A</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Brefeldin A.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08816</ns0:drugbank-id>
      <ns0:name>Ticagrelor</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ticagrelor.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08820</ns0:drugbank-id>
      <ns0:name>Ivacaftor</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ivacaftor.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08827</ns0:drugbank-id>
      <ns0:name>Lomitapide</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Lomitapide.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08865</ns0:drugbank-id>
      <ns0:name>Crizotinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Crizotinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08882</ns0:drugbank-id>
      <ns0:name>Linagliptin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Linagliptin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08889</ns0:drugbank-id>
      <ns0:name>Carfilzomib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Carfilzomib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08893</ns0:drugbank-id>
      <ns0:name>Mirabegron</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Mirabegron.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08899</ns0:drugbank-id>
      <ns0:name>Enzalutamide</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Enzalutamide.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08907</ns0:drugbank-id>
      <ns0:name>Canagliflozin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Canagliflozin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09030</ns0:drugbank-id>
      <ns0:name>Vorapaxar</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Vorapaxar.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09034</ns0:drugbank-id>
      <ns0:name>Suvorexant</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Suvorexant.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09048</ns0:drugbank-id>
      <ns0:name>Netupitant</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Netupitant.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09239</ns0:drugbank-id>
      <ns0:name>Niguldipine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Niguldipine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09241</ns0:drugbank-id>
      <ns0:name>Methylene blue</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Methylene blue.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11586</ns0:drugbank-id>
      <ns0:name>Asunaprevir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Asunaprevir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11828</ns0:drugbank-id>
      <ns0:name>Neratinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Neratinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11869</ns0:drugbank-id>
      <ns0:name>Valspodar</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Valspodar.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11979</ns0:drugbank-id>
      <ns0:name>Elagolix</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Elagolix.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12035</ns0:drugbank-id>
      <ns0:name>Sarecycline</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Sarecycline.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12466</ns0:drugbank-id>
      <ns0:name>Favipiravir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Favipiravir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12799</ns0:drugbank-id>
      <ns0:name>Laniquidar</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Laniquidar.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14068</ns0:drugbank-id>
      <ns0:name>Dexniguldipine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Dexniguldipine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14069</ns0:drugbank-id>
      <ns0:name>ONT-093</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with ONT-093.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14568</ns0:drugbank-id>
      <ns0:name>Ivosidenib</ns0:name>
      <ns0:description>The metabolism of Pralsetinib can be increased when combined with Ivosidenib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04845</ns0:drugbank-id>
      <ns0:name>Ixabepilone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ixabepilone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06419</ns0:drugbank-id>
      <ns0:name>Cethromycin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Cethromycin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12582</ns0:drugbank-id>
      <ns0:name>Piperine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Piperine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00845</ns0:drugbank-id>
      <ns0:name>Clofazimine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Clofazimine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01169</ns0:drugbank-id>
      <ns0:name>Arsenic trioxide</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Arsenic trioxide.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00358</ns0:drugbank-id>
      <ns0:name>Mefloquine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Mefloquine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11693</ns0:drugbank-id>
      <ns0:name>Voclosporin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Voclosporin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14989</ns0:drugbank-id>
      <ns0:name>Umbralisib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Umbralisib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08995</ns0:drugbank-id>
      <ns0:name>Diosmin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Diosmin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00360</ns0:drugbank-id>
      <ns0:name>Sapropterin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Sapropterin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05667</ns0:drugbank-id>
      <ns0:name>Levoketoconazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Levoketoconazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16703</ns0:drugbank-id>
      <ns0:name>Belumosudil</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Belumosudil.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15982</ns0:drugbank-id>
      <ns0:name>Berotralstat</ns0:name>
      <ns0:description>The serum concentration of Berotralstat can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11853</ns0:drugbank-id>
      <ns0:name>Relugolix</ns0:name>
      <ns0:description>The serum concentration of Relugolix can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15133</ns0:drugbank-id>
      <ns0:name>Tepotinib</ns0:name>
      <ns0:description>The serum concentration of Tepotinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04854</ns0:drugbank-id>
      <ns0:name>Febuxostat</ns0:name>
      <ns0:description>The excretion of Pralsetinib can be decreased when combined with Febuxostat.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11800</ns0:drugbank-id>
      <ns0:name>Tivozanib</ns0:name>
      <ns0:description>The metabolism of Tivozanib can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15569</ns0:drugbank-id>
      <ns0:name>Sotorasib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Sotorasib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12151</ns0:drugbank-id>
      <ns0:name>Brincidofovir</ns0:name>
      <ns0:description>The serum concentration of Brincidofovir can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16165</ns0:drugbank-id>
      <ns0:name>Finerenone</ns0:name>
      <ns0:description>The serum concentration of Finerenone can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00951</ns0:drugbank-id>
      <ns0:name>Isoniazid</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Isoniazid.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01087</ns0:drugbank-id>
      <ns0:name>Primaquine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Primaquine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01110</ns0:drugbank-id>
      <ns0:name>Miconazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Miconazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04832</ns0:drugbank-id>
      <ns0:name>Zimelidine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Zimelidine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06700</ns0:drugbank-id>
      <ns0:name>Desvenlafaxine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Desvenlafaxine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06712</ns0:drugbank-id>
      <ns0:name>Nilvadipine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Nilvadipine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06731</ns0:drugbank-id>
      <ns0:name>Seproxetine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Seproxetine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08953</ns0:drugbank-id>
      <ns0:name>Indalpine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Indalpine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09227</ns0:drugbank-id>
      <ns0:name>Barnidipine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Barnidipine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14019</ns0:drugbank-id>
      <ns0:name>Fosnetupitant</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Fosnetupitant.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00220</ns0:drugbank-id>
      <ns0:name>Nelfinavir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Nelfinavir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00224</ns0:drugbank-id>
      <ns0:name>Indinavir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Indinavir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00342</ns0:drugbank-id>
      <ns0:name>Terfenadine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Terfenadine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00625</ns0:drugbank-id>
      <ns0:name>Efavirenz</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Efavirenz.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00932</ns0:drugbank-id>
      <ns0:name>Tipranavir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Tipranavir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01026</ns0:drugbank-id>
      <ns0:name>Ketoconazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ketoconazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01072</ns0:drugbank-id>
      <ns0:name>Atazanavir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Atazanavir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01149</ns0:drugbank-id>
      <ns0:name>Nefazodone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Nefazodone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01211</ns0:drugbank-id>
      <ns0:name>Clarithromycin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Clarithromycin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01232</ns0:drugbank-id>
      <ns0:name>Saquinavir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Saquinavir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04868</ns0:drugbank-id>
      <ns0:name>Nilotinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Nilotinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09065</ns0:drugbank-id>
      <ns0:name>Cobicistat</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Cobicistat.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00872</ns0:drugbank-id>
      <ns0:name>Conivaptan</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Conivaptan.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01167</ns0:drugbank-id>
      <ns0:name>Itraconazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Itraconazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01601</ns0:drugbank-id>
      <ns0:name>Lopinavir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Lopinavir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05521</ns0:drugbank-id>
      <ns0:name>Telaprevir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Telaprevir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00836</ns0:drugbank-id>
      <ns0:name>Loperamide</ns0:name>
      <ns0:description>The excretion of Loperamide can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01263</ns0:drugbank-id>
      <ns0:name>Posaconazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Posaconazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11730</ns0:drugbank-id>
      <ns0:name>Ribociclib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ribociclib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06595</ns0:drugbank-id>
      <ns0:name>Midostaurin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Midostaurin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00701</ns0:drugbank-id>
      <ns0:name>Amprenavir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Amprenavir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00976</ns0:drugbank-id>
      <ns0:name>Telithromycin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Telithromycin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08873</ns0:drugbank-id>
      <ns0:name>Boceprevir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Boceprevir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00582</ns0:drugbank-id>
      <ns0:name>Voriconazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Voriconazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00696</ns0:drugbank-id>
      <ns0:name>Ergotamine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ergotamine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00705</ns0:drugbank-id>
      <ns0:name>Delavirdine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Delavirdine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00763</ns0:drugbank-id>
      <ns0:name>Methimazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Methimazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01127</ns0:drugbank-id>
      <ns0:name>Econazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Econazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01264</ns0:drugbank-id>
      <ns0:name>Darunavir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Darunavir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB02520</ns0:drugbank-id>
      <ns0:name>Ditiocarb</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ditiocarb.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09101</ns0:drugbank-id>
      <ns0:name>Elvitegravir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Elvitegravir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09118</ns0:drugbank-id>
      <ns0:name>Stiripentol</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Stiripentol.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11672</ns0:drugbank-id>
      <ns0:name>Curcumin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Curcumin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11779</ns0:drugbank-id>
      <ns0:name>Danoprevir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Danoprevir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13179</ns0:drugbank-id>
      <ns0:name>Troleandomycin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Troleandomycin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06448</ns0:drugbank-id>
      <ns0:name>Lonafarnib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Lonafarnib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01406</ns0:drugbank-id>
      <ns0:name>Danazol</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Danazol.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00012</ns0:drugbank-id>
      <ns0:name>Darbepoetin alfa</ns0:name>
      <ns0:description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00016</ns0:drugbank-id>
      <ns0:name>Erythropoietin</ns0:name>
      <ns0:description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08894</ns0:drugbank-id>
      <ns0:name>Peginesatide</ns0:name>
      <ns0:description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09107</ns0:drugbank-id>
      <ns0:name>Methoxy polyethylene glycol-epoetin beta</ns0:name>
      <ns0:description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11951</ns0:drugbank-id>
      <ns0:name>Lemborexant</ns0:name>
      <ns0:description>The serum concentration of Lemborexant can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00557</ns0:drugbank-id>
      <ns0:name>Hydroxyzine</ns0:name>
      <ns0:description>The metabolism of Hydroxyzine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15685</ns0:drugbank-id>
      <ns0:name>Selpercatinib</ns0:name>
      <ns0:description>The serum concentration of Selpercatinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01234</ns0:drugbank-id>
      <ns0:name>Dexamethasone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Dexamethasone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01045</ns0:drugbank-id>
      <ns0:name>Rifampin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Rifampicin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01320</ns0:drugbank-id>
      <ns0:name>Fosphenytoin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Fosphenytoin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01323</ns0:drugbank-id>
      <ns0:name>St. John's Wort</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with St. John's Wort.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00564</ns0:drugbank-id>
      <ns0:name>Carbamazepine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Carbamazepine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00252</ns0:drugbank-id>
      <ns0:name>Phenytoin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Phenytoin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00794</ns0:drugbank-id>
      <ns0:name>Primidone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Primidone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01174</ns0:drugbank-id>
      <ns0:name>Phenobarbital</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Phenobarbital.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00312</ns0:drugbank-id>
      <ns0:name>Pentobarbital</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Pentobarbital.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00648</ns0:drugbank-id>
      <ns0:name>Mitotane</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Mitotane.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00896</ns0:drugbank-id>
      <ns0:name>Rimexolone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Rimexolone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01201</ns0:drugbank-id>
      <ns0:name>Rifapentine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Rifapentine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12265</ns0:drugbank-id>
      <ns0:name>Fexinidazole</ns0:name>
      <ns0:description>The metabolism of Fexinidazole can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00745</ns0:drugbank-id>
      <ns0:name>Modafinil</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Modafinil.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16098</ns0:drugbank-id>
      <ns0:name>Atogepant</ns0:name>
      <ns0:description>The serum concentration of Atogepant can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16390</ns0:drugbank-id>
      <ns0:name>Mobocertinib</ns0:name>
      <ns0:description>The metabolism of Mobocertinib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12597</ns0:drugbank-id>
      <ns0:name>Asciminib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Asciminib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06234</ns0:drugbank-id>
      <ns0:name>Maribavir</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Maribavir.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14960</ns0:drugbank-id>
      <ns0:name>Somatrogon</ns0:name>
      <ns0:description>The metabolism of Pralsetinib can be increased when combined with Somatrogon.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12713</ns0:drugbank-id>
      <ns0:name>Sotagliflozin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Sotagliflozin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14973</ns0:drugbank-id>
      <ns0:name>Abrocitinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Abrocitinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04847</ns0:drugbank-id>
      <ns0:name>Roxadustat</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Roxadustat.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16236</ns0:drugbank-id>
      <ns0:name>Mitapivat</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Mitapivat.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00486</ns0:drugbank-id>
      <ns0:name>Nabilone</ns0:name>
      <ns0:description>The metabolism of Nabilone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14737</ns0:drugbank-id>
      <ns0:name>Cannabinol</ns0:name>
      <ns0:description>The metabolism of Cannabinol can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11697</ns0:drugbank-id>
      <ns0:name>Pacritinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Pacritinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13055</ns0:drugbank-id>
      <ns0:name>Oteseconazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Oteseconazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14921</ns0:drugbank-id>
      <ns0:name>Mavacamten</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Mavacamten.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09185</ns0:drugbank-id>
      <ns0:name>Viloxazine</ns0:name>
      <ns0:description>The metabolism of Pralsetinib can be decreased when combined with Viloxazine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB04951</ns0:drugbank-id>
      <ns0:name>Pirfenidone</ns0:name>
      <ns0:description>The metabolism of Pirfenidone can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12095</ns0:drugbank-id>
      <ns0:name>Telotristat ethyl</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Telotristat ethyl.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15149</ns0:drugbank-id>
      <ns0:name>Futibatinib</ns0:name>
      <ns0:description>The serum concentration of Futibatinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00296</ns0:drugbank-id>
      <ns0:name>Ropivacaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Ropivacaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00297</ns0:drugbank-id>
      <ns0:name>Bupivacaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Bupivacaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00527</ns0:drugbank-id>
      <ns0:name>Cinchocaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Cinchocaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00645</ns0:drugbank-id>
      <ns0:name>Dyclonine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Dyclonine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00721</ns0:drugbank-id>
      <ns0:name>Procaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Procaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00750</ns0:drugbank-id>
      <ns0:name>Prilocaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Prilocaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00807</ns0:drugbank-id>
      <ns0:name>Proparacaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Proparacaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00892</ns0:drugbank-id>
      <ns0:name>Oxybuprocaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Oxybuprocaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00907</ns0:drugbank-id>
      <ns0:name>Cocaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Cocaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00961</ns0:drugbank-id>
      <ns0:name>Mepivacaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Mepivacaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01002</ns0:drugbank-id>
      <ns0:name>Levobupivacaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Levobupivacaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01086</ns0:drugbank-id>
      <ns0:name>Benzocaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Benzocaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01161</ns0:drugbank-id>
      <ns0:name>Chloroprocaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Chloroprocaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB03255</ns0:drugbank-id>
      <ns0:name>Phenol</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Phenol.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05232</ns0:drugbank-id>
      <ns0:name>Tetrodotoxin</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Tetrodotoxin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06774</ns0:drugbank-id>
      <ns0:name>Capsaicin</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Capsaicin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08987</ns0:drugbank-id>
      <ns0:name>Etidocaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Etidocaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09009</ns0:drugbank-id>
      <ns0:name>Articaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Articaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09085</ns0:drugbank-id>
      <ns0:name>Tetracaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Tetracaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09342</ns0:drugbank-id>
      <ns0:name>Propoxycaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Propoxycaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09345</ns0:drugbank-id>
      <ns0:name>Pramocaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Pramocaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11148</ns0:drugbank-id>
      <ns0:name>Butamben</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Butamben.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11502</ns0:drugbank-id>
      <ns0:name>Butacaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Butacaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12532</ns0:drugbank-id>
      <ns0:name>Oxethazaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Oxetacaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13259</ns0:drugbank-id>
      <ns0:name>Ethyl chloride</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Ethyl chloride.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13328</ns0:drugbank-id>
      <ns0:name>Butanilicaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Butanilicaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13578</ns0:drugbank-id>
      <ns0:name>Metabutethamine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Metabutethamine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB13683</ns0:drugbank-id>
      <ns0:name>Quinisocaine</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Quinisocaine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11739</ns0:drugbank-id>
      <ns0:name>Vonoprazan</ns0:name>
      <ns0:description>The metabolism of Vonoprazan can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00244</ns0:drugbank-id>
      <ns0:name>Mesalazine</ns0:name>
      <ns0:description>The excretion of Mesalazine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06374</ns0:drugbank-id>
      <ns0:name>Elacestrant</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Elacestrant.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB17472</ns0:drugbank-id>
      <ns0:name>Pirtobrutinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Pirtobrutinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11682</ns0:drugbank-id>
      <ns0:name>Daprodustat</ns0:name>
      <ns0:description>The metabolism of Daprodustat can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15568</ns0:drugbank-id>
      <ns0:name>Adagrasib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Adagrasib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12548</ns0:drugbank-id>
      <ns0:name>Sparsentan</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Sparsentan.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12513</ns0:drugbank-id>
      <ns0:name>Omaveloxolone</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Omaveloxolone.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15688</ns0:drugbank-id>
      <ns0:name>Zavegepant</ns0:name>
      <ns0:description>The serum concentration of Zavegepant can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16217</ns0:drugbank-id>
      <ns0:name>Leniolisib</ns0:name>
      <ns0:description>The excretion of Pralsetinib can be decreased when combined with Leniolisib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06742</ns0:drugbank-id>
      <ns0:name>Ambroxol</ns0:name>
      <ns0:description>The risk or severity of methemoglobinemia can be increased when Pralsetinib is combined with Ambroxol.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16672</ns0:drugbank-id>
      <ns0:name>Epcoritamab</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Epcoritamab.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12255</ns0:drugbank-id>
      <ns0:name>Vadadustat</ns0:name>
      <ns0:description>The serum concentration of Vadadustat can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16371</ns0:drugbank-id>
      <ns0:name>Glofitamab</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Glofitamab.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14924</ns0:drugbank-id>
      <ns0:name>Ritlecitinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Ritlecitinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01007</ns0:drugbank-id>
      <ns0:name>Tioconazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Tioconazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB08933</ns0:drugbank-id>
      <ns0:name>Luliconazole</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Luliconazole.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00607</ns0:drugbank-id>
      <ns0:name>Nafcillin</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Nafcillin.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB06442</ns0:drugbank-id>
      <ns0:name>Avasimibe</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Avasimibe.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14240</ns0:drugbank-id>
      <ns0:name>Echinacea</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be decreased when it is combined with Echinacea.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15490</ns0:drugbank-id>
      <ns0:name>Zuranolone</ns0:name>
      <ns0:description>The serum concentration of Zuranolone can be decreased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11763</ns0:drugbank-id>
      <ns0:name>Momelotinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Momelotinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12184</ns0:drugbank-id>
      <ns0:name>Gepirone</ns0:name>
      <ns0:description>The serum concentration of Gepirone can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12874</ns0:drugbank-id>
      <ns0:name>Quizartinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Quizartinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14766</ns0:drugbank-id>
      <ns0:name>Etrasimod</ns0:name>
      <ns0:description>The risk or severity of immunosuppression can be increased when Pralsetinib is combined with Etrasimod.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11718</ns0:drugbank-id>
      <ns0:name>Encorafenib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Encorafenib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15673</ns0:drugbank-id>
      <ns0:name>Lenacapavir</ns0:name>
      <ns0:description>The serum concentration of Lenacapavir can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12218</ns0:drugbank-id>
      <ns0:name>Capivasertib</ns0:name>
      <ns0:description>Capivasertib may decrease the excretion rate of Pralsetinib which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16826</ns0:drugbank-id>
      <ns0:name>Repotrectinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Repotrectinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11679</ns0:drugbank-id>
      <ns0:name>Fruquintinib</ns0:name>
      <ns0:description>The metabolism of Fruquintinib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12005</ns0:drugbank-id>
      <ns0:name>Nirogacestat</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Nirogacestat.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16200</ns0:drugbank-id>
      <ns0:name>Iptacopan</ns0:name>
      <ns0:description>The serum concentration of Iptacopan can be decreased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB11995</ns0:drugbank-id>
      <ns0:name>Avatrombopag</ns0:name>
      <ns0:description>The metabolism of Avatrombopag can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB09324</ns0:drugbank-id>
      <ns0:name>Sulbactam</ns0:name>
      <ns0:description>The excretion of Sulbactam can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12914</ns0:drugbank-id>
      <ns0:name>Resmetirom</ns0:name>
      <ns0:description>The serum concentration of Resmetirom can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15401</ns0:drugbank-id>
      <ns0:name>Danicopan</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Danicopan.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15266</ns0:drugbank-id>
      <ns0:name>Tovorafenib</ns0:name>
      <ns0:description>The metabolism of Tovorafenib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB05501</ns0:drugbank-id>
      <ns0:name>Mavorixafor</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Mavorixafor.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00242</ns0:drugbank-id>
      <ns0:name>Cladribine</ns0:name>
      <ns0:description>The excretion of Cladribine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00659</ns0:drugbank-id>
      <ns0:name>Acamprosate</ns0:name>
      <ns0:description>The excretion of Acamprosate can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB18847</ns0:drugbank-id>
      <ns0:name>Deuruxolitinib</ns0:name>
      <ns0:description>The metabolism of Deuruxolitinib can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15775</ns0:drugbank-id>
      <ns0:name>Algestone acetophenide</ns0:name>
      <ns0:description>The metabolism of Algestone acetophenide can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15903</ns0:drugbank-id>
      <ns0:name>Chlormadinone acetate</ns0:name>
      <ns0:description>The metabolism of Chlormadinone acetate can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB17048</ns0:drugbank-id>
      <ns0:name>Plumbagin</ns0:name>
      <ns0:description>The metabolism of Plumbagin can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB18000</ns0:drugbank-id>
      <ns0:name>Algestone</ns0:name>
      <ns0:description>The metabolism of Algestone can be increased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12390</ns0:drugbank-id>
      <ns0:name>Seladelpar</ns0:name>
      <ns0:description>The metabolism of Seladelpar can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16216</ns0:drugbank-id>
      <ns0:name>Lazertinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Lazertinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16956</ns0:drugbank-id>
      <ns0:name>L-Acetylleucine</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with L-Acetylleucine.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB17520</ns0:drugbank-id>
      <ns0:name>Vimseltinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Vimseltinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15141</ns0:drugbank-id>
      <ns0:name>Deutivacaftor</ns0:name>
      <ns0:description>The serum concentration of Deutivacaftor can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB18373</ns0:drugbank-id>
      <ns0:name>Vanzacaftor</ns0:name>
      <ns0:description>The serum concentration of Vanzacaftor can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB14860</ns0:drugbank-id>
      <ns0:name>Ensartinib</ns0:name>
      <ns0:description>The serum concentration of Ensartinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB01708</ns0:drugbank-id>
      <ns0:name>Prasterone</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Prasterone which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB18711</ns0:drugbank-id>
      <ns0:name>Taletrectinib</ns0:name>
      <ns0:description>The serum concentration of Taletrectinib can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB18925</ns0:drugbank-id>
      <ns0:name>Sunvozertinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Sunvozertinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16326</ns0:drugbank-id>
      <ns0:name>Sepiapterin</ns0:name>
      <ns0:description>Pralsetinib may decrease the excretion rate of Sepiapterin which could result in a higher serum level.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB17709</ns0:drugbank-id>
      <ns0:name>Rilzabrutinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Rilzabrutinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB18968</ns0:drugbank-id>
      <ns0:name>Elinzanetant</ns0:name>
      <ns0:description>The serum concentration of Elinzanetant can be increased when it is combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB00905</ns0:drugbank-id>
      <ns0:name>Bimatoprost</ns0:name>
      <ns0:description>The metabolism of Bimatoprost can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB18762</ns0:drugbank-id>
      <ns0:name>Zongertinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Zongertinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB15104</ns0:drugbank-id>
      <ns0:name>Telisotuzumab vedotin</ns0:name>
      <ns0:description>The metabolism of Telisotuzumab vedotin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB19043</ns0:drugbank-id>
      <ns0:name>Imlunestrant</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Imlunestrant.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16852</ns0:drugbank-id>
      <ns0:name>Remibrutinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Remibrutinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB16277</ns0:drugbank-id>
      <ns0:name>Paltusotine</ns0:name>
      <ns0:description>The metabolism of Paltusotine can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB21667</ns0:drugbank-id>
      <ns0:name>Sevabertinib</ns0:name>
      <ns0:description>The serum concentration of Pralsetinib can be increased when it is combined with Sevabertinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB12817</ns0:drugbank-id>
      <ns0:name>Zoliflodacin</ns0:name>
      <ns0:description>The metabolism of Zoliflodacin can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
    <ns0:drug-interaction>
      <ns0:drugbank-id>DB18490</ns0:drugbank-id>
      <ns0:name>Aficamten</ns0:name>
      <ns0:description>The metabolism of Aficamten can be decreased when combined with Pralsetinib.</ns0:description>
    </ns0:drug-interaction>
  </ns0:drug-interactions>
  <ns0:calculated-properties>
    <ns0:property>
      <ns0:kind>logP</ns0:kind>
      <ns0:value>3.65</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>IUPAC Name</ns0:kind>
      <ns0:value>(1s,4s)-N-[(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Traditional IUPAC Name</ns0:kind>
      <ns0:value>(1s,4s)-N-[(1R)-1-[6-(4-fluoropyrazol-1-yl)pyridin-3-yl]ethyl]-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Molecular Weight</ns0:kind>
      <ns0:value>533.612</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Monoisotopic Weight</ns0:kind>
      <ns0:value>533.266299469</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>SMILES</ns0:kind>
      <ns0:value>CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Molecular Formula</ns0:kind>
      <ns0:value>C27H32FN9O2</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>InChI</ns0:kind>
      <ns0:value>InChI=1S/C27H32FN9O2/c1-16-11-22(33-23-12-17(2)35-36-23)34-25(31-16)19-7-9-27(39-4,10-8-19)26(38)32-18(3)20-5-6-24(29-13-20)37-15-21(28)14-30-37/h5-6,11-15,18-19H,7-10H2,1-4H3,(H,32,38)(H2,31,33,34,35,36)/t18-,19-,27+/m0/s1</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>InChIKey</ns0:kind>
      <ns0:value>GBLBJPZSROAGMF-RWYJCYHVSA-N</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Polar Surface Area (PSA)</ns0:kind>
      <ns0:value>135.53</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Refractivity</ns0:kind>
      <ns0:value>146.12</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Polarizability</ns0:kind>
      <ns0:value>56.66</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Rotatable Bond Count</ns0:kind>
      <ns0:value>8</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>H Bond Acceptor Count</ns0:kind>
      <ns0:value>8</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>H Bond Donor Count</ns0:kind>
      <ns0:value>3</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>pKa (strongest acidic)</ns0:kind>
      <ns0:value>12.45</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>pKa (strongest basic)</ns0:kind>
      <ns0:value>4.13</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Physiological Charge</ns0:kind>
      <ns0:value>0</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Number of Rings</ns0:kind>
      <ns0:value>5</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Bioavailability</ns0:kind>
      <ns0:value>1</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Rule of Five</ns0:kind>
      <ns0:value>0</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>Ghose Filter</ns0:kind>
      <ns0:value>0</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
    <ns0:property>
      <ns0:kind>MDDR-Like Rule</ns0:kind>
      <ns0:value>1</ns0:value>
      <ns0:source>ChemAxon</ns0:source>
    </ns0:property>
  </ns0:calculated-properties>
  <ns0:experimental-properties>
    <ns0:property>
      <ns0:kind>Water Solubility</ns0:kind>
      <ns0:value>&lt;0.1 mg/ml</ns0:value>
      <ns0:source>Pralsetinib product sheet</ns0:source>
    </ns0:property>
  </ns0:experimental-properties>
  <ns0:external-identifiers>
    <ns0:external-identifier>
      <ns0:resource>Drugs Product Database (DPD)</ns0:resource>
      <ns0:identifier>23611</ns0:identifier>
    </ns0:external-identifier>
    <ns0:external-identifier>
      <ns0:resource>ChemSpider</ns0:resource>
      <ns0:identifier>75533827</ns0:identifier>
    </ns0:external-identifier>
    <ns0:external-identifier>
      <ns0:resource>PDB</ns0:resource>
      <ns0:identifier>Q4J</ns0:identifier>
    </ns0:external-identifier>
    <ns0:external-identifier>
      <ns0:resource>Wikipedia</ns0:resource>
      <ns0:identifier>Pralsetinib</ns0:identifier>
    </ns0:external-identifier>
    <ns0:external-identifier>
      <ns0:resource>ChEMBL</ns0:resource>
      <ns0:identifier>CHEMBL4582651</ns0:identifier>
    </ns0:external-identifier>
    <ns0:external-identifier>
      <ns0:resource>RxCUI</ns0:resource>
      <ns0:identifier>2394936</ns0:identifier>
    </ns0:external-identifier>
  </ns0:external-identifiers>
  <ns0:external-links />
  <ns0:pathways />
  <ns0:reactions />
  <ns0:snp-effects />
  <ns0:snp-adverse-drug-reactions />
  <ns0:targets>
    <ns0:target position="1">
      <ns0:id>BE0002411</ns0:id>
      <ns0:name>Proto-oncogene tyrosine-protein kinase receptor Ret</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles>
          <ns0:article>
            <ns0:ref-id>A219751</ns0:ref-id>
            <ns0:pubmed-id>29657135</ns0:pubmed-id>
            <ns0:citation>Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK: Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15.</ns0:citation>
          </ns0:article>
          <ns0:article>
            <ns0:ref-id>A264250</ns0:ref-id>
            <ns0:pubmed-id>37713619</ns0:pubmed-id>
            <ns0:citation>Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.</ns0:citation>
          </ns0:article>
        </ns0:articles>
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>yes</ns0:known-action>
      <ns0:polypeptide id="P07949" source="Swiss-Prot">
        <ns0:name>Proto-oncogene tyrosine-protein kinase receptor Ret</ns0:name>
        <ns0:general-function>Receptor tyrosine-protein kinase involved in numerous cellular mechanisms including cell proliferation, neuronal navigation, cell migration, and cell differentiation in response to glia cell line-derived growth family factors (GDNF, NRTN, ARTN, PSPN and GDF15) (PubMed:20064382, PubMed:20616503, PubMed:20702524, PubMed:21357690, PubMed:21454698, PubMed:24560924, PubMed:28846097, PubMed:28846099, PubMed:28953886, PubMed:31118272). In contrast to most receptor tyrosine kinases, RET requires not only its cognate ligands but also coreceptors, for activation (PubMed:21994944, PubMed:23333276, PubMed:28846097, PubMed:28846099, PubMed:28953886). GDNF ligands (GDNF, NRTN, ARTN, PSPN and GDF15) first bind their corresponding GDNFR coreceptors (GFRA1, GFRA2, GFRA3, GFRA4 and GFRAL, respectively), triggering RET autophosphorylation and activation, leading to activation of downstream signaling pathways, including the MAPK- and AKT-signaling pathways (PubMed:21994944, PubMed:23333276, PubMed:24560924, PubMed:25242331, PubMed:28846097, PubMed:28846099, PubMed:28953886). Acts as a dependence receptor via the GDNF-GFRA1 signaling: in the presence of the ligand GDNF in somatotrophs within pituitary, promotes survival and down regulates growth hormone (GH) production, but triggers apoptosis in absence of GDNF (PubMed:20616503, PubMed:21994944). Required for the molecular mechanisms orchestration during intestine organogenesis via the ARTN-GFRA3 signaling: involved in the development of enteric nervous system and renal organogenesis during embryonic life, and promotes the formation of Peyer's patch-like structures, a major component of the gut-associated lymphoid tissue (By similarity). Mediates, through interaction with GDF15-receptor GFRAL, GDF15-induced cell-signaling in the brainstem which triggers an aversive response, characterized by nausea, vomiting, and/or loss of appetite in response to various stresses (PubMed:28846097, PubMed:28846099, PubMed:28953886). Modulates cell adhesion via its cleavage by caspase in sympathetic neurons and mediates cell migration in an integrin (e.g. ITGB1 and ITGB3)-dependent manner (PubMed:20702524, PubMed:21357690). Also active in the absence of ligand, triggering apoptosis through a mechanism that requires receptor intracellular caspase cleavage (PubMed:21357690). Triggers the differentiation of rapidly adapting (RA) mechanoreceptors (PubMed:20064382). Involved in the development of the neural crest (By similarity). Regulates nociceptor survival and size (By similarity). Phosphorylates PTK2/FAK1 (PubMed:21454698)</ns0:general-function>
        <ns0:specific-function>ATP binding</ns0:specific-function>
        <ns0:gene-name>RET</ns0:gene-name>
        <ns0:locus>10q11.21</ns0:locus>
        <ns0:cellular-location>Cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>636-657</ns0:transmembrane-regions>
        <ns0:signal-regions>1-28</ns0:signal-regions>
        <ns0:theoretical-pi>6.57</ns0:theoretical-pi>
        <ns0:molecular-weight>124317.465</ns0:molecular-weight>
        <ns0:chromosome-location>10</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:9967</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>RET</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>RET</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>X12949</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>2185</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P07949</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>RET_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>2.7.10.1</ns0:synonym>
          <ns0:synonym>Cadherin family member 12</ns0:synonym>
          <ns0:synonym>CDHF12</ns0:synonym>
          <ns0:synonym>CDHR16</ns0:synonym>
          <ns0:synonym>Proto-oncogene c-Ret</ns0:synonym>
          <ns0:synonym>PTC</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004735|Proto-oncogene tyrosine-protein kinase receptor Ret
MAKATSGAAGLRLLLLLLLPLLGKVALGLYFSRDAYWEKLYVDQAAGTPLLYVHALRDAP
EEVPSFRLGQHLYGTYRTRLHENNWICIQEDTGLLYLNRSLDHSSWEKLSVRNRGFPLLT
VYLKVFLSPTSLREGECQWPGCARVYFSFFNTSFPACSSLKPRELCFPETRPSFRIRENR
PPGTFHQFRLLPVQFLCPNISVAYRLLEGEGLPFRCAPDSLEVSTRWALDREQREKYELV
AVCTVHAGAREEVVMVPFPVTVYDEDDSAPTFPAGVDTASAVVEFKRKEDTVVATLRVFD
ADVVPASGELVRRYTSTLLPGDTWAQQTFRVEHWPNETSVQANGSFVRATVHDYRLVLNR
NLSISENRTMQLAVLVNDSDFQGPGAGVLLLHFNVSVLPVSLHLPSTYSLSVSRRARRFA
QIGKVCVENCQAFSGINVQYKLHSSGANCSTLGVVTSAEDTSGILFVNDTKALRRPKCAE
LHYMVVATDQQTSRQAQAQLLVTVEGSYVAEEAGCPLSCAVSKRRLECEECGGLGSPTGR
CEWRQGDGKGITRNFSTCSPSTKTCPDGHCDVVETQDINICPQDCLRGSIVGGHEPGEPR
GIKAGYGTCNCFPEEEKCFCEPEDIQDPLCDELCRTVIAAAVLFSFIVSVLLSAFCIHCY
HKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFP
RKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLK
QVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDH
PDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVY
EEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERL
FNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLDLAA
STPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPLTRA
DGTNTGFPRYPNDSVYANWMLSPSAAKLMDTFDS</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0021933|Proto-oncogene tyrosine-protein kinase receptor Ret (RET)
ATGGCGAAGGCGACGTCCGGTGCCGCGGGGCTGCGTCTGCTGTTGCTGCTGCTGCTGCCG
CTGCTAGGCAAAGTGGCATTGGGCCTCTACTTCTCGAGGGATGCTTACTGGGAGAAGCTG
TATGTGGACCAGGCGGCCGGCACGCCCTTGCTGTACGTCCATGCCCTGCGGGACGCCCCT
GAGGAGGTGCCCAGCTTCCGCCTGGGCCAGCATCTCTACGGCACGTACCGCACACGGCTG
CATGAGAACAACTGGATCTGCATCCAGGAGGACACCGGCCTCCTCTACCTTAACCGGAGC
CTGGACCATAGCTCCTGGGAGAAGCTCAGTGTCCGCAACCGCGGCTTTCCCCTGCTCACC
GTCTACCTCAAGGTCTTCCTGTCACCCACATCCCTTCGTGAGGGCGAGTGCCAGTGGCCA
GGCTGTGCCCGCGTATACTTCTCCTTCTTCAACACCTCCTTTCCAGCCTGCAGCTCCCTC
AAGCCCCGGGAGCTCTGCTTCCCAGAGACAAGGCCCTCCTTCCGCATTCGGGAGAACCGA
CCCCCAGGCACCTTCCACCAGTTCCGCCTGCTGCCTGTGCAGTTCTTGTGCCCCAACATC
AGCGTGGCCTACAGGCTCCTGGAGGGTGAGGGTCTGCCCTTCCGCTGCGCCCCGGACAGC
CTGGAGGTGAGCACGCGCTGGGCCCTGGACCGCGAGCAGCGGGAGAAGTACGAGCTGGTG
GCCGTGTGCACCGTGCACGCCGGCGCGCGCGAGGAGGTGGTGATGGTGCCCTTCCCGGTG
ACCGTGTACGACGAGGACGACTCGGCGCCCACCTTCCCCGCGGGCGTCGACACCGCCAGC
GCCGTGGTGGAGTTCAAGCGGAAGGAGGACACCGTGGTGGCCACGCTGCGTGTCTTCGAT
GCAGACGTGGTACCTGCATCAGGGGAGCTGGTGAGGCGGTACACAAGCACGCTGCTCCCC
GGGGACACCTGGGCCCAGCAGACCTTCCGGGTGGAACACTGGCCCAACGAGACCTCGGTC
CAGGCCAACGGCAGCTTCGTGCGGGCGACCGTACATGACTATAGGCTGGTTCTCAACCGG
AACCTCTCCATCTCGGAGAACCGCACCATGCAGCTGGCGGTGCTGGTCAATGACTCAGAC
TTCCAGGGCCCAGGAGCGGGCGTCCTCTTGCTCCACTTCAACGTGTCGGTGCTGCCGGTC
AGCCTGCACCTGCCCAGTACCTACTCCCTCTCCGTGAGCAGGAGGGCTCGCCGATTTGCC
CAGATCGGGAAAGTCTGTGTGGAAAACTGCCAGGCATTCAGTGGCATCAACGTCCAGTAC
AAGCTGCATTCCTCTGGTGCCAACTGCAGCACGCTAGGGGTGGTCACCTCAGCCGAGGAC
ACCTCGGGGATCCTGTTTGTGAATGACACCAAGGCCCTGCGGCGGCCCAAGTGTGCCGAA
CTTCACTACATGGTGGTGGCCACCGACCAGCAGACCTCTAGGCAGGCCCAGGCCCAGCTG
CTTGTAACAGTGGAGGGGTCATATGTGGCCGAGGAGGCGGGCTGCCCCCTGTCCTGTGCA
GTCAGCAAGAGACGGCTGGAGTGTGAGGAGTGTGGCGGCCTGGGCTCCCCAACAGGCAGG
TGTGAGTGGAGGCAAGGAGATGGCAAAGGGATCACCAGGAACTTCTCCACCTGCTCTCCC
AGCACCAAGACCTGCCCCGACGGCCACTGCGATGTTGTGGAGACCCAAGACATCAACATT
TGCCCTCAGGACTGCCTCCGGGGCAGCATTGTTGGGGGACACGAGCCTGGGGAGCCCCGG
GGGATTAAAGCTGGCTATGGCACCTGCAACTGCTTCCCTGAGGAGGAGAAGTGCTTCTGC
GAGCCCGAAGACATCCAGGATCCACTGTGCGACGAGCTGTGCCGCACGGTGATCGCAGCC
GCTGTCCTCTTCTCCTTCATCGTCTCGGTGCTGCTGTCTGCCTTCTGCATCCACTGCTAC
CACAAGTTTGCCCACAAGCCACCCATCTCCTCAGCTGAGATGACCTTCCGGAGGCCCGCC
CAGGCCTTCCCGGTCAGCTACTCCTCTTCCGGTGCCCGCCGGCCCTCGCTGGACTCCATG
GAGAACCAGGTCTCCGTGGATGCCTTCAAGATCCTGGAGGATCCAAAGTGGGAATTCCCT
CGGAAGAACTTGGTTCTTGGAAAAACTCTAGGAGAAGGCGAATTTGGAAAAGTGGTCAAG
GCAACGGCCTTCCATCTGAAAGGCAGAGCAGGGTACACCACGGTGGCCGTGAAGATGCTG
AAAGAGAACGCCTCCCCGAGTGAGCTTCGAGACCTGCTGTCAGAGTTCAACGTCCTGAAG
CAGGTCAACCACCCACATGTCATCAAATTGTATGGGGCCTGCAGCCAGGATGGCCCGCTC
CTCCTCATCGTGGAGTACGCCAAATACGGCTCCCTGCGGGGCTTCCTCCGCGAGAGCCGC
AAAGTGGGGCCTGGCTACCTGGGCAGTGGAGGCAGCCGCAACTCCAGCTCCCTGGACCAC
CCGGATGAGCGGGCCCTCACCATGGGCGACCTCATCTCATTTGCCTGGCAGATCTCACAG
GGGATGCAGTATCTGGCCGAGATGAAGCTCGTTCATCGGGACTTGGCAGCCAGAAACATC
CTGGTAGCTGAGGGGCGGAAGATGAAGATTTCGGATTTCGGCTTGTCCCGAGATGTTTAT
GAAGAGGATTCCTACGTGAAGAGGAGCCAGGGTCGGATTCCAGTTAAATGGATGGCAATT
GAATCCCTTTTTGATCATATCTACACCACGCAAAGTGATGTATGGTCTTTTGGTGTCCTG
CTGTGGGAGATCGTGACCCTAGGGGGAAACCCCTATCCTGGGATTCCTCCTGAGCGGCTC
TTCAACCTTCTGAAGACCGGCCACCGGATGGAGAGGCCAGACAACTGCAGCGAGGAGATG
TACCGCCTGATGCTGCAATGCTGGAAGCAGGAGCCGGACAAAAGGCCGGTGTTTGCGGAC
ATCAGCAAAGACCTGGAGAAGATGATGGTTAAGAGGAGAGACTACTTGGACCTTGCGGCG
TCCACTCCATCTGACTCCCTGATTTATGACGACGGCCTCTCAGAGGAGGAGACACCGCTG
GTGGACTGTAATAATGCCCCCCTCCCTCGAGCCCTCCCTTCCACATGGATTGAAAACAAA
CTCTATGGTAGAATTTCCCATGCATTTACTAGATTCTAG</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00028</ns0:identifier>
            <ns0:name>Cadherin</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF17756</ns0:identifier>
            <ns0:name>RET_CLD1</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF17812</ns0:identifier>
            <ns0:name>RET_CLD3</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF17813</ns0:identifier>
            <ns0:name>RET_CLD4</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF22540</ns0:identifier>
            <ns0:name>RET_CRD</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07714</ns0:identifier>
            <ns0:name>PK_Tyr_Ser-Thr</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>axon</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endosome membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>receptor complex</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>calcium ion binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>transmembrane receptor protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to retinoic acid</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>embryonic epithelial tube formation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>enteric nervous system development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>homophilic cell adhesion via plasma membrane adhesion molecules</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lymphocyte migration into lymphoid organs</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>MAPK cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>membrane protein proteolysis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>neural crest cell migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>neuron cell-cell adhesion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>neuron maturation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>Peyer's patch morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell adhesion mediated by integrin</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell size</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of extrinsic apoptotic signaling pathway in absence of ligand</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of metanephric glomerulus development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of neuron projection development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>posterior midgut development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of axonogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of cell adhesion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to pain</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>signal transduction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>ureter maturation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>ureteric bud development</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:target>
    <ns0:target position="2">
      <ns0:id>BE0001124</ns0:id>
      <ns0:name>Epithelial discoidin domain-containing receptor 1</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>unknown</ns0:known-action>
      <ns0:polypeptide id="Q08345" source="Swiss-Prot">
        <ns0:name>Epithelial discoidin domain-containing receptor 1</ns0:name>
        <ns0:general-function>Tyrosine kinase that functions as a cell surface receptor for fibrillar collagen and regulates cell attachment to the extracellular matrix, remodeling of the extracellular matrix, cell migration, differentiation, survival and cell proliferation. Collagen binding triggers a signaling pathway that involves SRC and leads to the activation of MAP kinases. Regulates remodeling of the extracellular matrix by up-regulation of the matrix metalloproteinases MMP2, MMP7 and MMP9, and thereby facilitates cell migration and wound healing. Required for normal blastocyst implantation during pregnancy, for normal mammary gland differentiation and normal lactation. Required for normal ear morphology and normal hearing (By similarity). Promotes smooth muscle cell migration, and thereby contributes to arterial wound healing. Also plays a role in tumor cell invasion. Phosphorylates PTPN11</ns0:general-function>
        <ns0:specific-function>ATP binding</ns0:specific-function>
        <ns0:gene-name>DDR1</ns0:gene-name>
        <ns0:locus>6p21.33</ns0:locus>
        <ns0:cellular-location>Cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>418-438</ns0:transmembrane-regions>
        <ns0:signal-regions>1-18</ns0:signal-regions>
        <ns0:theoretical-pi>6.81</ns0:theoretical-pi>
        <ns0:molecular-weight>101126.72</ns0:molecular-weight>
        <ns0:chromosome-location>6</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:2730</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>DDR1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>DDR1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>L20817</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>306475</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1843</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>Q08345</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>DDR1_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>2.7.10.1</ns0:synonym>
          <ns0:synonym>CAK</ns0:synonym>
          <ns0:synonym>CD167 antigen-like family member A</ns0:synonym>
          <ns0:synonym>Cell adhesion kinase</ns0:synonym>
          <ns0:synonym>Discoidin receptor tyrosine kinase</ns0:synonym>
          <ns0:synonym>EDDR1</ns0:synonym>
          <ns0:synonym>Epithelial discoidin domain receptor 1</ns0:synonym>
          <ns0:synonym>HGK2</ns0:synonym>
          <ns0:synonym>Mammary carcinoma kinase 10</ns0:synonym>
          <ns0:synonym>MCK-10</ns0:synonym>
          <ns0:synonym>NEP</ns0:synonym>
          <ns0:synonym>NTRK4</ns0:synonym>
          <ns0:synonym>Protein-tyrosine kinase 3A</ns0:synonym>
          <ns0:synonym>Protein-tyrosine kinase RTK-6</ns0:synonym>
          <ns0:synonym>PTK3A</ns0:synonym>
          <ns0:synonym>RTK6</ns0:synonym>
          <ns0:synonym>TRK E</ns0:synonym>
          <ns0:synonym>TRKE</ns0:synonym>
          <ns0:synonym>Tyrosine kinase DDR</ns0:synonym>
          <ns0:synonym>Tyrosine-protein kinase CAK</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002236|Epithelial discoidin domain-containing receptor 1
MGPEALSSLLLLLLVASGDADMKGHFDPAKCRYALGMQDRTIPDSDISASSSWSDSTAAR
HSRLESSDGDGAWCPAGSVFPKEEEYLQVDLQRLHLVALVGTQGRHAGGLGKEFSRSYRL
RYSRDGRRWMGWKDRWGQEVISGNEDPEGVVLKDLGPPMVARLVRFYPRADRVMSVCLRV
ELYGCLWRDGLLSYTAPVGQTMYLSEAVYLNDSTYDGHTVGGLQYGGLGQLADGVVGLDD
FRKSQELRVWPGYDYVGWSNHSFSSGYVEMEFEFDRLRAFQAMQVHCNNMHTLGARLPGG
VECRFRRGPAMAWEGEPMRHNLGGNLGDPRARAVSVPLGGRVARFLQCRFLFAGPWLLFS
EISFISDVVNNSSPALGGTFPPAPWWPPGPPPTNFSSLELEPRGQQPVAKAEGSPTAILI
GCLVAIILLLLLIIALMLWRLHWRRLLSKAERRVLEEELTVHLSVPGDTILINNRPGPRE
PPPYQEPRPRGNPPHSAPCVPNGSALLLSNPAYRLLLATYARPPRGPGPPTPAWAKPTNT
QAYSGDYMEPEKPGAPLLPPPPQNSVPHYAEADIVTLQGVTGGNTYAVPALPPGAVGDGP
PRVDFPRSRLRFKEKLGEGQFGEVHLCEVDSPQDLVSLDFPLNVRKGHPLLVAVKILRPD
ATKNARNDFLKEVKIMSRLKDPNIIRLLGVCVQDDPLCMITDYMENGDLNQFLSAHQLED
KAAEGAPGDGQAAQGPTISYPMLLHVAAQIASGMRYLATLNFVHRDLATRNCLVGENFTI
KIADFGMSRNLYAGDYYRVQGRAVLPIRWMAWECILMGKFTTASDVWAFGVTLWEVLMLC
RAQPFGQLTDEQVIENAGEFFRDQGRQVYLSRPPACPQGLYELMLRCWSRESEQRPPFSQ
LHRFLAEDALNTV</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0010785|Epithelial discoidin domain-containing receptor 1 (DDR1)
ATGGGACCAGAGGCCCTGTCATCTTTACTGCTGCTGCTCTTGGTGGCAAGTGGAGATGCT
GACATGAAGGGACATTTTGATCCTGCCAAGTGCCGCTATGCCCTGGGCATGCAGGACCGG
ACCATCCCAGACAGTGACATCTCTGCTTCCAGCTCCTGGTCAGATTCCACTGCCGCCCGC
CACAGCAGGTTGGAGAGCAGTGACGGGGATGGGGCCTGGTGCCCCGCAGGGTCGGTGTTT
CCCAAGGAGGAGGAGTACTTGCAGGTGGATCTACAACGACTGCACCTGGTGGCTCTGGTG
GGCACCCAGGGACGGCATGCCGGGGGCCTGGGCAAGGAGTTCTCCCGGAGCTACCGGCTG
CGTTACTCCCGGGATGGTCGCCGCTGGATGGGCTGGAAGGACCGCTGGGGTCAGGAGGTG
ATCTCAGGCAATGAGGACCCTGAGGGAGTGGTGCTGAAGGACCTTGGGCCCCCCATGGTT
GCCCGACTGGTTCGCTTCTACCCCCGGGCTGACCGGGTCATGAGCGTCTGTCTGCGGGTA
GAGCTCTATGGCTGCCTCTGGAGGGATGGACTCCTGTCTTACACCGCCCCTGTGGGGCAG
ACAATGTATTTATCTGAGGCCGTGTACCTCAACGACTCCACCTATGACGGACATACCGTG
GGCGGACTGCAGTATGGGGGTCTGGGCCAGCTGGCAGATGGTGTGGTGGGGCTGGATGAC
TTTAGGAAGAGTCAGGAGCTGCGGGTCTGGCCAGGCTATGACTATGTGGGATGGAGCAAC
CACAGCTTCTCCAGTGGCTATGTGGAGATGGAGTTTGAGTTTGACCGGCTGAGGGCCTTC
CAGGCTATGCAGGTCCACTGTAACAACATGCACACGCTGGGAGCCCGTCTGCCTGGCGGG
GTGGAATGTCGCTTCCGGCGTGGCCCTGCCATGGCCTGGGAGGGGGAGCCCATGCGCCAC
AACCTAGGGGGCAACCTGGGGGACCCCAGAGCCCGGGCTGTCTCAGTGCCCCTTGGCGGC
CGTGTGGCTCGCTTTCTGCAGTGCCGCTTCCTCTTTGCGGGGCCCTGGTTACTCTTCAGC
GAAATCTCCTTCATCTCTGATGTGGTGAACAATTCCTCTCCGGCACTGGGAGGCACCTTC
CCGCCAGCCCCCTGGTGGCCGCCTGGCCCACCTCCCACCAACTTCAGCAGCTTGGAGCTG
GAGCCCAGAGGCCAGCAGCCCGTGGCCAAGGCCGAGGGGAGCCCGACCGCCATCCTCATC
GGCTGCCTGGTGGCCATCATCCTGCTCCTGCTGCTCATCATTGCCCTCATGCTCTGGCGG
CTGCACTGGCGCAGGCTCCTCAGCAAGGCTGAACGGAGGGTGTTGGAAGAGGAGCTGACG
GTTCACCTCTCTGTCCCTGGGGACACTATCCTCATCAACAACCGCCCAGGTCCTAGAGAG
CCACCCCCGTACCAGGAGCCCCGGCCTCGTGGGAATCCGCCCCACTCCGCTCCCTGTGTC
CCCAATGGCTCTGGTGCACCTGTGTGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00754</ns0:identifier>
            <ns0:name>F5_F8_type_C</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF21114</ns0:identifier>
            <ns0:name>DDR1-2_DS-like</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07714</ns0:identifier>
            <ns0:name>PK_Tyr_Ser-Thr</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>extracellular exosome</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>extracellular space</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>receptor complex</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>collagen binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>metal ion binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein tyrosine kinase collagen receptor activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>transmembrane receptor protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell adhesion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>collagen-activated tyrosine kinase receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lactation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>peptidyl-tyrosine autophosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein autophosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of extracellular matrix disassembly</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>smooth muscle cell migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>smooth muscle cell-matrix adhesion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>wound healing, spreading of cells</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:target>
    <ns0:target position="3">
      <ns0:id>BE0009501</ns0:id>
      <ns0:name>NT-3 growth factor receptor</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>unknown</ns0:known-action>
      <ns0:polypeptide id="Q16288" source="Swiss-Prot">
        <ns0:name>NT-3 growth factor receptor</ns0:name>
        <ns0:general-function>Receptor tyrosine kinase involved in nervous system and probably heart development. Upon binding of its ligand NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the phosphatidylinositol 3-kinase/AKT and the MAPK pathways, that control cell survival and differentiation</ns0:general-function>
        <ns0:specific-function>ATP binding</ns0:specific-function>
        <ns0:gene-name>NTRK3</ns0:gene-name>
        <ns0:locus>15q25.3</ns0:locus>
        <ns0:cellular-location>Membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>430-453</ns0:transmembrane-regions>
        <ns0:signal-regions>1-31</ns0:signal-regions>
        <ns0:theoretical-pi />
        <ns0:molecular-weight>94427.47</ns0:molecular-weight>
        <ns0:chromosome-location>15</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:8033</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>NTRK3</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1819</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>Q16288</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>NTRK3_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>2.7.10.1</ns0:synonym>
          <ns0:synonym>GP145-TrkC</ns0:synonym>
          <ns0:synonym>Neurotrophic tyrosine kinase receptor type 3</ns0:synonym>
          <ns0:synonym>Trk-C</ns0:synonym>
          <ns0:synonym>TRKC</ns0:synonym>
          <ns0:synonym>TrkC tyrosine kinase</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051880|NT-3 growth factor receptor
MDVSLCPAKCSFWRIFLLGSVWLDYVGSVLACPANCVCSKTEINCRRPDDGNLFPLLEGQ
DSGNSNGNASINITDISRNITSIHIENWRSLHTLNAVDMELYTGLQKLTIKNSGLRSIQP
RAFAKNPHLRYINLSSNRLTTLSWQLFQTLSLRELQLEQNFFNCSCDIRWMQLWQEQGEA
KLNSQNLYCINADGSQLPLFRMNISQCDLPEISVSHVNLTVREGDNAVITCNGSGSPLPD
VDWIVTGLQSINTHQTNLNWTNVHAINLTLVNVTSEDNGFTLTCIAENVVGMSNASVALT
VYYPPRVVSLEEPELRLEHCIEFVVRGNPPPTLHWLHNGQPLRESKIIHVEYYQEGEISE
GCLLFNKPTHYNNGNYTLIAKNPLGTANQTINGHFLKEPFPESTDNFILFDEVSPTPPIT
VTHKPEEDTFGVSIAVGLAAFACVLLVVLFVMINKYGRRSKFGMKGPVAVISGEEDSASP
LHHINHGITTPSSLDAGPDTVVIGMTRIPVIENPQYFRQGHNCHKPDTYVQHIKRRDIVL
KRELGEGAFGKVFLAECYNLSPTKDKMLVAVKALKDPTLAARKDFQREAELLTNLQHEHI
VKFYGVCGDGDPLIMVFEYMKHGDLNKFLRAHGPDAMILVDGQPRQAKGELGLSQMLHIA
SQIASGMVYLASQHFVHRDLATRNCLVGANLLVKIGDFGMSRDVYSTDYYRLFNPSGNDF
CIWCEVGGHTMLPIRWMPPESIMYRKFTTESDVWSFGVILWEIFTYGKQPWFQLSNTEVI
ECITQGRVLERPRVCPKEVYDVMLGCWQREPQQRLNIKEIYKILHALGKATPIYLDILG</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0051881|NT-3 growth factor receptor (NTRK3)
ATGGATGTCTCTCTTTGCCCAGCCAAGTGTAGTTTCTGGCGGATTTTCTTGCTGGGAAGC
GTCTGGCTGGACTATGTGGGCTCCGTGCTGGCTTGCCCTGCAAATTGTGTCTGCAGCAAG
ACTGAGATCAATTGCCGGCGGCCGGACGATGGGAACCTCTTCCCCCTCCTGGAAGGGCAG
GATTCAGGGAACAGCAATGGGAACGCCAGTATCAACATCACGGACATCTCAAGGAATATC
ACTTCCATACACATAGAGAACTGGCGCAGTCTTCACACGCTCAACGCCGTGGACATGGAG
CTCTACACCGGACTTCAAAAGCTGACCATCAAGAACTCAGGACTTCGGAGCATTCAGCCC
AGAGCCTTTGCCAAGAACCCCCATTTGCGTTATATAAACCTGTCAAGTAACCGGCTCACC
ACACTCTCGTGGCAGCTCTTCCAGACGCTGAGTCTTCGGGAATTGCAGTTGGAGCAGAAC
TTTTTCAACTGCAGCTGTGACATCCGCTGGATGCAGCTCTGGCAGGAGCAGGGGGAGGCC
AAGCTCAACAGCCAGAACCTCTACTGCATCAACGCTGATGGCTCCCAGCTTCCTCTCTTC
CGCATGAACATCAGTCAGTGTGACCTTCCTGAGATCAGCGTGAGCCACGTCAACCTGACC
GTACGAGAGGGTGACAATGCTGTTATCACTTGCAATGGCTCTGGATCACCCCTTCCTGAT
GTGGACTGGATAGTCACTGGGCTGCAGTCCATCAACACTCACCAGACCAATCTGAACTGG
ACCAATGTTCATGCCATCAACTTGACGCTGGTGAATGTGACGAGTGAGGACAATGGCTTC
ACCCTGACGTGCATTGCAGAGAACGTGGTGGGCATGAGCAATGCCAGTGTTGCCCTCACT
GTCTACTATCCCCCACGTGTGGTGAGCCTGGAGGAGCCTGAGCTGCGCCTGGAGCACTGC
ATCGAGTTTGTGGTGCGTGGCAACCCCCCACCAACGCTGCACTGGCTGCACAATGGGCAG
CCTCTGCGGGAGTCCAAGATCATCCATGTGGAATACTACCAAGAGGGAGAGATTTCCGAG
GGCTGCCTGCTCTTCAACAAGCCCACCCACTACAACAATGGCAACTATACCCTCATTGCC
AAAAACCCACTGGGCACAGCCAACCAGACCATCAATGGCCACTTCCTCAAGGAGCCCTTT
CCAGAGAGCACGGATAACTTTATCTTGTTTGACGAAGTGAGTCCCACACCTCCTATCACT
GTGACCCACAAACCAGAAGAAGACACTTTTGGGGTATCCATAGCAGTTGGACTTGCTGCT
TTTGCCTGTGTCCTGTTGGTGGTTCTCTTCGTCATGATCAACAAATATGGTCGACGGTCC
AAATTTGGAATGAAGGGTCCCGTGGCTGTCATCAGTGGTGAGGAGGACTCAGCCAGCCCA
CTGCACCACATCAACCACGGCATCACCACGCCCTCGTCACTGGATGCCGGGCCCGACACT
GTGGTCATTGGCATGACTCGCATCCCTGTCATTGAGAACCCCCAGTACTTCCGTCAGGGA
CACAACTGCCACAAGCCGGACACGTATGTGCAGCACATTAAGAGGAGAGACATCGTGCTG
AAGCGAGAACTGGGTGAGGGAGCCTTTGGAAAGGTCTTCCTGGCCGAGTGCTACAACCTC
AGCCCGACCAAGGACAAGATGCTTGTGGCTGTGAAGGCCCTGAAGGATCCCACCCTGGCT
GCCCGGAAGGATTTCCAGAGGGAGGCCGAGCTGCTCACCAACCTGCAGCATGAGCACATT
GTCAAGTTCTATGGAGTGTGCGGCGATGGGGACCCCCTCATCATGGTCTTTGAATACATG
AAGCATGGAGACCTGAATAAGTTCCTCAGGGCCCATGGGCCAGATGCAATGATCCTTGTG
GATGGACAGCCACGCCAGGCCAAGGGTGAGCTGGGGCTCTCCCAAATGCTCCACATTGCC
AGTCAGATCGCCTCGGGTATGGTGTACCTGGCCTCCCAGCACTTTGTGCACCGAGACCTG
GCCACCAGGAACTGCCTGGTTGGAGCGAATCTGCTAGTGAAGATTGGGGACTTCGGCATG
TCCAGAGATGTCTACAGCACGGATTATTACAGGCTCTTTAATCCATCTGGAAATGATTTT
TGTATATGGTGTGAGGTGGGAGGACACACCATGCTCCCCATTCGCTGGATGCCTCCTGAA
AGCATCATGTACCGGAAGTTCACTACAGAGAGTGATGTATGGAGCTTCGGGGTGATCCTC
TGGGAGATCTTCACCTATGGAAAGCAGCCATGGTTCCAACTCTCAAACACGGAGGTCATT
GAGTGCATTACCCAAGGTCGTGTTTTGGAGCGGCCCCGAGTCTGCCCCAAAGAGGTGTAC
GATGTCATGCTGGGGTGCTGGCAGAGGGAACCACAGCAGCGGTTGAACATCAAGGAGATC
TACAAAATCCTCCATGCTTTGGGGAAGGCCACCCCAATCTACCTGGACATTCTTGGCTAG
</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF01462</ns0:identifier>
            <ns0:name>LRRNT</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF13855</ns0:identifier>
            <ns0:name>LRR_8</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07679</ns0:identifier>
            <ns0:name>I-set</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF16920</ns0:identifier>
            <ns0:name>LRRCT_2</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF00047</ns0:identifier>
            <ns0:name>ig</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07714</ns0:identifier>
            <ns0:name>PK_Tyr_Ser-Thr</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoplasm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>glutamatergic synapse</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>postsynaptic membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>receptor complex</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>neurotrophin binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>neurotrophin receptor activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>p53 binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>axon extension involved in regeneration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to retinoic acid</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>circadian rhythm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cochlea development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>heart development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lens fiber cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>mechanoreceptor differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>myelination in peripheral nervous system</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>negative regulation of astrocyte differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>neuron fate specification</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>neuron migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>neuronal action potential propagation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of apoptotic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of axon extension involved in regeneration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of gene expression</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of MAPK cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of positive chemotaxis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of synapse assembly</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>postsynaptic density assembly</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of neural precursor cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of presynapse assembly</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to corticosterone</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to ethanol</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:target>
    <ns0:target position="4">
      <ns0:id>BE0000147</ns0:id>
      <ns0:name>Receptor-type tyrosine-protein kinase FLT3</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>unknown</ns0:known-action>
      <ns0:polypeptide id="P36888" source="Swiss-Prot">
        <ns0:name>Receptor-type tyrosine-protein kinase FLT3</ns0:name>
        <ns0:general-function>Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways</ns0:general-function>
        <ns0:specific-function>ATP binding</ns0:specific-function>
        <ns0:gene-name>FLT3</ns0:gene-name>
        <ns0:locus>13q12.2</ns0:locus>
        <ns0:cellular-location>Membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>544-563</ns0:transmembrane-regions>
        <ns0:signal-regions>1-26</ns0:signal-regions>
        <ns0:theoretical-pi>5.5</ns0:theoretical-pi>
        <ns0:molecular-weight>112902.51</ns0:molecular-weight>
        <ns0:chromosome-location>13</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:3765</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>FLT3</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>FLT3</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>U02687</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>409573</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1807</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P36888</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>FLT3_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>2.7.10.1</ns0:synonym>
          <ns0:synonym>CD135</ns0:synonym>
          <ns0:synonym>Fetal liver kinase-2</ns0:synonym>
          <ns0:synonym>FL cytokine receptor</ns0:synonym>
          <ns0:synonym>FLK-2</ns0:synonym>
          <ns0:synonym>FLK2</ns0:synonym>
          <ns0:synonym>FLT-3</ns0:synonym>
          <ns0:synonym>Fms-like tyrosine kinase 3</ns0:synonym>
          <ns0:synonym>Stem cell tyrosine kinase 1</ns0:synonym>
          <ns0:synonym>STK-1</ns0:synonym>
          <ns0:synonym>STK1</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036960|Receptor-type tyrosine-protein kinase FLT3
MPALARDGGQLPLLVVFSAMIFGTITNQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESP
EDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGNISCLWVFKHSSLNCQPHFDL
QNRGVVSMVILKMTETQAGEYLLFIQSEATNYTILFTVSIRNTLLYTLRRPYFRKMENQD
ALVCISESVPEPIVEWVLCDSQGESCKEESPAVVKKEEKVLHELFGTDIRCCARNELGRE
CTRLFTIDLNQTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEM
STYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFINATNSSEDYE
IDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNGYSISKFCNHKHQPGEYIFHA
ENDDAQFTKMFTLNIRRKPQVLAEASASQASCFSDGYPLPSWTWKKCSDKSPNCTEEITE
GVWNRKANRKVFGQWVSSSTLNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQD
NISFYATIGVCLLFIVVLTLLICHKYKKQFRYESQLQMVQVTGSSDNEYFYVDFREYEYD
LKWEFPRENLEFGKVLGSGAFGKVMNATAYGISKTGVSIQVAVKMLKEKADSSEREALMS
ELKMMTQLGSHENIVNLLGACTLSGPIYLIFEYCCYGDLLNYLRSKREKFHRTWTEIFKE
HNFSFYPTFQSHPNSSMPGSREVQIHPDSDQISGLHGNSFHSEDEIEYENQKRLEEEEDL
NVLTFEDLLCFAYQVAKGMEFLEFKSCVHRDLAARNVLVTHGKVVKICDFGLARDIMSDS
NYVVRGNARLPVKWMAPESLFEGIYTIKSDVWSYGILLWEIFSLGVNPYPGIPVDANFYK
LIQNGFKMDQPFYATEEIYIIMQSCWAFDSRKRPSFPNLTSFLGCQLADAEEAMYQNVDG
RVSECPHTYQNRRPFSREMDLGLLSPQAQVEDS</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0018920|Receptor-type tyrosine-protein kinase FLT3 (FLT3)
ATGCCGGCGTTGGCGCGCGACGGCGGCCAGCTGCCGCTGCTCGTTGTTTTTTCTGCAATG
ATATTTGGGACTATTACAAATCAAGATCTGCCTGTGATCAAGTGTGTTTTAATCAATCAT
AAGAACAATGATTCATCAGTGGGGAAGTCATCATCATATCCCATGGTATCAGAATCCCCG
GAAGACCTCGGGTGTGCGTTGAGACCCCAGAGCTCAGGGACAGTGTACGAAGCTGCCGCT
GTGGAAGTGGATGTATCTGCTTCCATCACACTGCAAGTGCTGGTCGACGCCCCAGGGAAC
ATTTCCTGTCTCTGGGTCTTTAAGCACAGCTCCCTGAATTGCCAGCCACATTTTGATTTA
CAAAACAGAGGAGTTGTTTCCATGGTCATTTTGAAAATGACAGAAACCCAAGCTGGAGAA
TACCTACTTTTTATTCAGAGTGAAGCTACCAATTACACAATATTGTTTACAGTGAGTATA
AGAAATACCCTGCTTTACACATTAAGAAGACCTTACTTTAGAAAAATGGAAAACCAGGAC
GCCCTGGTCTGCATATCTGAGAGCGTTCCAGAGCCGATCGTGGAATGGGTGCTTTGCGAT
TCACAGGGGGAAAGCTGTAAAGAAGAAAGTCCAGCTGTTGTTAAAAAGGAGGAAAAAGTG
CTTCATGAATTATTTGGGACGGACATAAGGTGCTGTGCCAGAAATGAACTGGGCAGGGAA
TGCACCAGGCTGTTCACAATAGATCTAAATCAAACTCCTCAGACCACATTGCCACAATTA
TTTCTTAAAGTAGGGGAACCCTTATGGATAAGGTGCAAAGCTGTTCATGTGAACCATGGA
TTCGGGCTCACCTGGGAATTAGAAAACAAAGCACTCGAGGAGGGCAACTACTTTGAGATG
AGTACCTATTCAACAAACAGAACTATGATACGGATTCTGTTTGCTTTTGTATCATCAGTG
GCAAGAAACGACACCGGATACTACACTTGTTCCTCTTCAAAGCATCCCAGTCAATCAGCT
TTGGTTACCATCGTAGAAAAGGGATTTATAAATGCTACCAATTCAAGTGAAGATTATGAA
ATTGACCAATATGAAGAGTTTTGTTTTTCTGTCAGGTTTAAAGCCTACCCACAAATCAGA
TGTACGTGGACCTTCTCTCGAAAATCATTTCCTTGTGAGCAAAAGGGTCTTGATAACGGA
TACAGCATATCCAAGTTTTGCAATCATAAGCACCAGCCAGGAGAATATATATTCCATGCA
GAAAATGATGATGCCCAATTTACCAAAATGTTCACGCTGAATATAAGAAGGAAACCTCAA
GTGCTCGCAGAAGCATCGGCAAGTCAGGCGTCCTGTTTCTCGGATGGATACCCATTACCA
TCTTGGACCTGGAAGAAGTGTTCAGACAAGTCTCCCAACTGCACAGAAGAGATCACAGAA
GGAGTCTGGAATAGAAAGGCTAACAGAAAAGTGTTTGGACAGTGGGTGTCGAGCAGTACT
CTAAACATGAGTGAAGCCATAAAAGGGTTCCTGGTCAAGTGCTGTGCATACAATTCCCTT
GGCACATCTTGTGAGACGATCCTTTTAAACTCTCCAGGCCCCTTCCCTTTCATCCAAGAC
AACATCTCATTCTATGCAACAATTGGTGTTTGTCTCCTCTTCATTGTCGTTTTAACCCTG
CTAATTTGTCACAAGTACAAAAAGCAATTTAGGTATGAAAGCCAGCTACAGATGGTACAG
GTGACCGGCTCCTCAGATAATGAGTACTTCTACGTTGATTTCAGAGAATATGAATATGAT
CTCAAATGGGAGTTTCCAAGAGAAAATTTAGAGTTTGGGAAGGTACTAGGATCAGGTGCT
TTTGGAAAAGTGATGAACGCAACAGCTTATGGAATTAGCAAAACAGGAGTCTCAATCCAG
GTTGCCGTCAAAATGCTGAAAGAAAAAGCAGACAGCTCTGAAAGAGAGGCACTCATGTCA
GAACTCAAGATGATGACCCAGCTGGGAAGCCACGAGAATATTGTGAACCTGCTGGGGGCG
TGCACACTGTCAGGACCAATTTACTTGATTTTTGAATACTGTTGCTATGGTGATCTTCTC
AACTATCTAAGAAGTAAAAGAGAAAAATTTCACAGGACTTGGACAGAGATTTTCAAGGAA
CACAATTTCAGTTTTTACCCCACTTTCCAATCACATCCAAATTCCAGCATGCCTGGTTCA
AGAGAAGTTCAGATACACCCGGACTCGGATCAAATCTCAGGGCTTCATGGGAATTCATTT
CACTCTGAAGATGAAATTGAATATGAAAACCAAAAAAGGCTGGAAGAAGAGGAGGACTTG
AATGTGCTTACATTTGAAGATCTTCTTTGCTTTGCATATCAAGTTGCCAAAGGAATGGAA
TTTCTGGAATTTAAGTCGTGTGTTCACAGAGACCTGGCCGCCAGGAACGTGCTTGTCACC
CACGGGAAAGTGGTGAAGATATGTGACTTTGGATTGGCTCGAGATATCATGAGTGATTCC
AACTATGTTGTCAGGGGCAATGCCCGTCTGCCTGTAAAATGGATGGCCCCCGAAAGCCTG
TTTGAAGGCATCTACACCATTAAGAGTGATGTCTGGTCATATGGAATATTACTGTGGGAA
ATCTTCTCACTTGGTGTGAATCCTTACCCTGGCATTCCGGTTGATGCTAACTTCTACAAA
CTGATTCAAAATGGATTTAAAATGGATCAGCCATTTTATGCTACAGAAGAAATATACATT
ATAATGCAATCCTGCTGGGCTTTTGACTCAAGGAAACGGCCATCCTTCCCTAATTTGACT
TCGTTTTTAGGATGTCAGCTGGCAGATGCAGAAGAAGCGATGTATCAGAATGTGGATGGC
CGTGTTTCGGAATGTCCTCACACCTACCAAAACAGGCGACCTTTCAGCAGAGAGATGGAT
TTGGGGCTACTCTCTCCGCAGGCTCAGGTCGAAGATTCGTAG</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00047</ns0:identifier>
            <ns0:name>ig</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07714</ns0:identifier>
            <ns0:name>PK_Tyr_Ser-Thr</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endoplasmic reticulum lumen</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>cytokine receptor activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>transmembrane receptor protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>B cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to cytokine stimulus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>common myeloid progenitor cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cytokine-mediated signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>dendritic cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>hemopoiesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>leukocyte homeostasis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>liver regeneration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lymphocyte proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>myeloid progenitor cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>peptidyl-tyrosine phosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of MAP kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of MAPK cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of tyrosine phosphorylation of STAT protein</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>pro-B cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein autophosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of apoptotic process</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:target>
    <ns0:target position="5">
      <ns0:id>BE0004145</ns0:id>
      <ns0:name>Tyrosine-protein kinase JAK1</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>unknown</ns0:known-action>
      <ns0:polypeptide id="P23458" source="Swiss-Prot">
        <ns0:name>Tyrosine-protein kinase JAK1</ns0:name>
        <ns0:general-function>Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway (PubMed:16239216, PubMed:28111307, PubMed:32750333, PubMed:7615558, PubMed:8232552). Kinase partner for the interleukin (IL)-2 receptor (PubMed:11909529) as well as interleukin (IL)-10 receptor (PubMed:12133952). Kinase partner for the type I interferon receptor IFNAR2 (PubMed:16239216, PubMed:28111307, PubMed:32750333, PubMed:7615558, PubMed:8232552). In response to interferon-binding to IFNAR1-IFNAR2 heterodimer, phosphorylates and activates its binding partner IFNAR2, creating docking sites for STAT proteins (PubMed:7759950). Directly phosphorylates STAT proteins but also activates STAT signaling through the transactivation of other JAK kinases associated with signaling receptors (PubMed:16239216, PubMed:32750333, PubMed:8232552)</ns0:general-function>
        <ns0:specific-function>ATP binding</ns0:specific-function>
        <ns0:gene-name>JAK1</ns0:gene-name>
        <ns0:locus>1p31.3</ns0:locus>
        <ns0:cellular-location>Endomembrane system</ns0:cellular-location>
        <ns0:transmembrane-regions />
        <ns0:signal-regions />
        <ns0:theoretical-pi />
        <ns0:molecular-weight>133275.995</ns0:molecular-weight>
        <ns0:chromosome-location>1</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:6190</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>JAK1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>2047</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P23458</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>JAK1_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>2.7.10.2</ns0:synonym>
          <ns0:synonym>JAK-1</ns0:synonym>
          <ns0:synonym>JAK1A</ns0:synonym>
          <ns0:synonym>JAK1B</ns0:synonym>
          <ns0:synonym>Janus kinase 1</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009345|Tyrosine-protein kinase JAK1
MQYLNIKEDCNAMAFCAKMRSSKKTEVNLEAPEPGVEVIFYLSDREPLRLGSGEYTAEEL
CIRAAQACRISPLCHNLFALYDENTKLWYAPNRTITVDDKMSLRLHYRMRFYFTNWHGTN
DNEQSVWRHSPKKQKNGYEKKKIPDATPLLDASSLEYLFAQGQYDLVKCLAPIRDPKTEQ
DGHDIENECLGMAVLAISHYAMMKKMQLPELPKDISYKRYIPETLNKSIRQRNLLTRMRI
NNVFKDFLKEFNNKTICDSSVSTHDLKVKYLATLETLTKHYGAEIFETSMLLISSENEMN
WFHSNDGGNVLYYEVMVTGNLGIQWRHKPNVVSVEKEKNKLKRKKLENKHKKDEEKNKIR
EEWNNFSYFPEITHIVIKESVVSINKQDNKKMELKLSSHEEALSFVSLVDGYFRLTADAH
HYLCTDVAPPLIVHNIQNGCHGPICTEYAINKLRQEGSEEGMYVLRWSCTDFDNILMTVT
CFEKSEQVQGAQKQFKNFQIEVQKGRYSLHGSDRSFPSLGDLMSHLKKQILRTDNISFML
KRCCQPKPREISNLLVATKKAQEWQPVYPMSQLSFDRILKKDLVQGEHLGRGTRTHIYSG
TLMDYKDDEGTSEEKKIKVILKVLDPSHRDISLAFFEAASMMRQVSHKHIVYLYGVCVRD
VENIMVEEFVEGGPLDLFMHRKSDVLTTPWKFKVAKQLASALSYLEDKDLVHGNVCTKNL
LLAREGIDSECGPFIKLSDPGIPITVLSRQECIERIPWIAPECVEDSKNLSVAADKWSFG
TTLWEICYNGEIPLKDKTLIEKERFYESRCRPVTPSCKELADLMTRCMNYDPNQRPFFRA
IMRDINKLEEQNPDIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDN
TGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLP
SGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIG
DFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDS
DSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRT
SFQNLIEGFEALLK</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0021380|Tyrosine-protein kinase JAK1 (JAK1)
ATGCAGTATCTAAATATAAAAGAGGACTGCAATGCCATGGCTTTCTGTGCTAAAATGAGG
AGCTCCAAGAAGACTGAGGTGAACCTGGAGGCCCCTGAGCCAGGGGTGGAAGTGATCTTC
TATCTGTCGGACAGGGAGCCCCTCCGGCTGGGCAGTGGAGAGTACACAGCAGAGGAACTG
TGCATCAGGGCTGCACAGGCATGCCGTATCTCTCCTCTTTGTCACAACCTCTTTGCCCTG
TATGACGAGAACACCAAGCTCTGGTATGCTCCAAATCGCACCATCACCGTTGATGACAAG
ATGTCCCTCCGGCTCCACTACCGGATGAGGTTCTATTTCACCAATTGGCATGGAACCAAC
GACAATGAGCAGTCAGTGTGGCGTCATTCTCCAAAGAAGCAGAAAAATGGCTACGAGAAA
AAAAAGATTCCAGATGCAACCCCTCTCCTTGATGCCAGCTCACTGGAGTATCTGTTTGCT
CAGGGACAGTATGATTTGGTGAAATGCCTGGCTCCTATTCGAGACCCCAAGACCGAGCAG
GATGGACATGATATTGAGAACGAGTGTCTAGGGATGGCTGTCCTGGCCATCTCACACTAT
GCCATGATGAAGAAGATGCAGTTGCCAGAACTGCCCAAGGACATCAGCTACAAGCGATAT
ATTCCAGAAACATTGAATAAGTCCATCAGACAGAGGAACCTTCTCACCAGGATGCGGATA
AATAATGTTTTCAAGGATTTCCTAAAGGAATTTAACAACAAGACCATTTGTGACAGCAGC
GTGTCCACGCATGACCTGAAGGTGAAATACTTGGCTACCTTGGAAACTTTGACAAAACAT
TACGGTGCTGAAATATTTGAGACTTCCATGTTACTGATTTCATCAGAAAATGAGATGAAT
TGGTTTCATTCGAATGACGGTGGAAACGTTCTCTACTACGAAGTGATGGTGACTGGGAAT
CTTGGAATCCAGTGGAGGCATAAACCAAATGTTGTTTCTGTTGAAAAGGAAAAAAATAAA
CTGAAGCGGAAAAAACTGGAAAATAAACACAAGAAGGATGAGGAGAAAAACAAGATCCGG
GAAGAGTGGAACAATTTTTCTTACTTCCCTGAAATCACTCACATTGTAATAAAGGAGTCT
GTGGTCAGCATTAACAAGCAGGACAACAAGAAAATGGAACTGAAGCTCTCTTCCCACGAG
GAGGCCTTGTCCTTTGTGTCCCTGGTAGATGGCTACTTCCGGCTCACAGCAGATGCCCAT
CATTACCTCTGCACCGACGTGGCCCCCCCGTTGATCGTCCACAACATACAGAATGGCTGT
CATGGTCCAATCTGTACAGAATACGCCATCAATAAATTGCGGCAAGAAGGAAGCGAGGAG
GGGATGTACGTGCTGAGGTGGAGCTGCACCGACTTTGACAACATCCTCATGACCGTCACC
TGCTTTGAGAAGTCTGAGCAGGTGCAGGGTGCCCAGAAGCAGTTCAAGAACTTTCAGATC
GAGGTGCAGAAGGGCCGCTACAGTCTGCACGGTTCGGACCGCAGCTTCCCCAGCTTGGGA
GACCTCATGAGCCACCTCAAGAAGCAGATCCTGCGCACGGATAACATCAGCTTCATGCTA
AAACGCTGCTGCCAGCCCAAGCCCCGAGAAATCTCCAACCTGCTGGTGGCTACTAAGAAA
GCCCAGGAGTGGCAGCCCGTCTACCCCATGAGCCAGCTGAGTTTCGATCGGATCCTCAAG
AAGGATCTGGTGCAGGGCGAGCACCTTGGGAGAGGCACGAGAACACACATCTATTCTGGG
ACCCTGATGGATTACAAGGATGACGAAGGAACTTCTGAAGAGAAGAAGATAAAAGTGATC
CTCAAAGTCTTAGACCCCAGCCACAGGGATATTTCCCTGGCCTTCTTCGAGGCAGCCAGC
ATGATGAGACAGGTCTCCCACAAACACATCGTGTACCTCTATGGCGTCTGTGTCCGCGAC
GTGGAGAATATCATGGTGGAAGAGTTTGTGGAAGGGGGTCCTCTGGATCTCTTCATGCAC
CGGAAAAGCGATGTCCTTACCACACCATGGAAATTCAAAGTTGCCAAACAGCTGGCCAGT
GCCCTGAGCTACTTGGAGGATAAAGACCTGGTCCATGGAAATGTGTGTACTAAAAACCTC
CTCCTGGCCCGTGAGGGCATCGACAGTGAGTGTGGCCCATTCATCAAGCTCAGTGACCCC
GGCATCCCCATTACGGTGCTGTCTAGGCAAGAATGCATTGAACGAATCCCATGGATTGCT
CCTGAGTGTGTTGAGGACTCCAAGAACCTGAGTGTGGCTGCTGACAAGTGGAGCTTTGGA
ACCACGCTCTGGGAAATCTGCTACAATGGCGAGATCCCCTTGAAAGACAAGACGCTGATT
GAGAAAGAGAGATTCTATGAAAGCCGGTGCAGGCCAGTGACACCATCATGTAAGGAGCTG
GCTGACCTCATGACCCGCTGCATGAACTATGACCCCAATCAGAGGCCTTTCTTCCGAGCC
ATCATGAGAGACATTAATAAGCTTGAAGAGCAGAATCCAGATATTGTTTCAGAAAAAAAA
CCAGCAACTGAAGTGGACCCCACACATTTTGAAAAGCGCTTCCTAAAGAGGATCCGTGAC
TTGGGAGAGGGCCACTTTGGGAAGGTTGAGCTCTGCAGGTATGACCCCGAAGGGGACAAT
ACAGGGGAGCAGGTGGCTGTTAAATCTCTGAAGCCTGAGAGTGGAGGTAACCACATAGCT
GATCTGAAAAAGGAAATCGAGATCTTAAGGAACCTCTATCATGAGAACATTGTGAAGTAC
AAAGGAATCTGCACAGAAGACGGAGGAAATGGTATTAAGCTCATCATGGAATTTCTGCCT
TCGGGAAGCCTTAAGGAATATCTTCCAAAGAATAAGAACAAAATAAACCTCAAACAGCAG
CTAAAATATGCCGTTCAGATTTGTAAGGGGATGGACTATTTGGGTTCTCGGCAATACGTT
CACCGGGACTTGGCAGCAAGAAATGTCCTTGTTGAGAGTGAACACCAAGTGAAAATTGGA
GACTTCGGTTTAACCAAAGCAATTGAAACCGATAAGGAGTATTACACCGTCAAGGATGAC
CGGGACAGCCCTGTGTTTTGGTATGCTCCAGAATGTTTAATGCAATCTAAATTTTATATT
GCCTCTGACGTCTGGTCTTTTGGAGTCACTCTGCATGAGCTGCTGACTTACTGTGATTCA
GATTCTAGTCCCATGGCTTTGTTCCTGAAAATGATAGGCCCAACCCATGGCCAGATGACA
GTCACAAGACTTGTGAATACGTTAAAAGAAGGAAAACGCCTGCCGTGCCCACCTAACTGT
CCAGATGAGGTTTATCAACTTATGAGGAAATGCTGGGAATTCCAACCATCCAATCGGACA
AGCTTTCAGAACCTTATTGAAGGATTTGAAGCACTTTTAAAATAA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF18379</ns0:identifier>
            <ns0:name>FERM_F1</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF18377</ns0:identifier>
            <ns0:name>FERM_F2</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF17887</ns0:identifier>
            <ns0:name>Jak1_Phl</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF21990</ns0:identifier>
            <ns0:name>SH2_1</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07714</ns0:identifier>
            <ns0:name>PK_Tyr_Ser-Thr</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoplasm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoskeleton</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytosol</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>extrinsic component of cytoplasmic side of plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>focal adhesion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>nucleus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>receptor complex</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>growth hormone receptor binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>non-membrane spanning protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein phosphatase binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ubiquitin protein ligase binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cytokine-mediated signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>interleukin-2-mediated signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>intracellular signal transduction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein phosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to antibiotic</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:target>
    <ns0:target position="6">
      <ns0:id>BE0002408</ns0:id>
      <ns0:name>Tyrosine-protein kinase JAK2</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>unknown</ns0:known-action>
      <ns0:polypeptide id="O60674" source="Swiss-Prot">
        <ns0:name>Tyrosine-protein kinase JAK2</ns0:name>
        <ns0:general-function>Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications. Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin receptor (MPL/TPOR); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins (PubMed:15690087, PubMed:7615558, PubMed:9657743, PubMed:15899890). Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins (PubMed:15690087, PubMed:9618263). Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain (PubMed:9657743). Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that leads to the activation of STAT5 (STAT5A or STAT5B) (PubMed:21368206). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation (PubMed:20098430). Plays a role in cell cycle by phosphorylating CDKN1B (PubMed:21423214). Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin (PubMed:19783980). Up-regulates the potassium voltage-gated channel activity of KCNA3 (PubMed:25644777)</ns0:general-function>
        <ns0:specific-function>acetylcholine receptor binding</ns0:specific-function>
        <ns0:gene-name>JAK2</ns0:gene-name>
        <ns0:locus>9p24.1</ns0:locus>
        <ns0:cellular-location>Endomembrane system</ns0:cellular-location>
        <ns0:transmembrane-regions />
        <ns0:signal-regions />
        <ns0:theoretical-pi>7.21</ns0:theoretical-pi>
        <ns0:molecular-weight>130672.475</ns0:molecular-weight>
        <ns0:chromosome-location>9</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:6192</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>JAK2</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>JAK2</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>AF058925</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>2048</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>O60674</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>JAK2_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>2.7.10.2</ns0:synonym>
          <ns0:synonym>JAK-2</ns0:synonym>
          <ns0:synonym>Janus kinase 2</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021326|Tyrosine-protein kinase JAK2
MGMACLTMTEMEGTSTSSIYQNGDISGNANSMKQIDPVLQVYLYHSLGKSEADYLTFPSG
EYVAEEICIAASKACGITPVYHNMFALMSETERIWYPPNHVFHIDESTRHNVLYRIRFYF
PRWYCSGSNRAYRHGISRGAEAPLLDDFVMSYLFAQWRHDFVHGWIKVPVTHETQEECLG
MAVLDMMRIAKENDQTPLAIYNSISYKTFLPKCIRAKIQDYHILTRKRIRYRFRRFIQQF
SQCKATARNLKLKYLINLETLQSAFYTEKFEVKEPGSGPSGEEIFATIIITGNGGIQWSR
GKHKESETLTEQDLQLYCDFPNIIDVSIKQANQEGSNESRVVTIHKQDGKNLEIELSSLR
EALSFVSLIDGYYRLTADAHHYLCKEVAPPAVLENIQSNCHGPISMDFAISKLKKAGNQT
GLYVLRCSPKDFNKYFLTFAVERENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNC
YQMETVRSDNIIFQFTKCCPPKPKDKSNLLVFRTNGVSDVPTSPTLQRPTHMNQMVFHKI
RNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHRNYSESFFEAASM
MSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWA
MHFLEENTLIHGNVCAKNILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVP
PECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYEDRHQLPAPKWAEL
ANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIGALGFSGAFEDRD
PTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIE
ILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQI
CKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFW
YAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIE
LLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0021327|Tyrosine-protein kinase JAK2 (JAK2)
ATGGGAATGGCCTGCCTTACGATGACAGAAATGGAGGGAACATCCACCTCTTCTATATAT
CAGAATGGTGATATTTCTGGAAATGCCAATTCTATGAAGCAAATAGATCCAGTTCTTCAG
GTGTATCTTTACCATTCCCTTGGGAAATCTGAGGCAGATTATCTGACCTTTCCATCTGGG
GAGTATGTTGCAGAAGAAATCTGTATTGCTGCTTCTAAAGCTTGTGGTATCACACCTGTG
TATCATAATATGTTTGCTTTAATGAGTGAAACAGAAAGGATCTGGTATCCACCCAACCAT
GTCTTCCATATAGATGAGTCAACCAGGCATAATGTACTCTACAGAATAAGATTTTACTTT
CCTCGTTGGTATTGCAGTGGCAGCAACAGAGCCTATCGGCATGGAATATCTCGAGGTGCT
GAAGCTCCTCTTCTTGATGACTTTGTCATGTCTTACCTCTTTGCTCAGTGGCGGCATGAT
TTTGTGCACGGATGGATAAAAGTACCTGTGACTCATGAAACACAGGAAGAATGTCTTGGG
ATGGCAGTGTTAGATATGATGAGAATAGCCAAAGAAAACGATCAAACCCCACTGGCCATC
TATAACTCTATCAGCTACAAGACATTCTTACCAAAATGTATTCGAGCAAAGATCCAAGAC
TATCATATTTTGACAAGGAAGCGAATAAGGTACAGATTTCGCAGATTTATTCAGCAATTC
AGCCAATGCAAAGCCACTGCCAGAAACTTGAAACTTAAGTATCTTATAAATCTGGAAACT
CTGCAGTCTGCCTTCTACACAGAGAAATTTGAAGTAAAAGAACCTGGAAGTGGTCCTTCA
GGTGAGGAGATTTTTGCAACCATTATAATAACTGGAAACGGTGGAATTCAGTGGTCAAGA
GGGAAACATAAAGAAAGTGAGACACTGACAGAACAGGATTTACAGTTATATTGCGATTTT
CCTAATATTATTGATGTCAGTATTAAGCAAGCAAACCAAGAGGGTTCAAATGAAAGCCGA
GTTGTAACTATCCATAAGCAAGATGGTAAAAATCTGGAAATTGAACTTAGCTCATTAAGG
GAAGCTTTGTCTTTCGTGTCATTAATTGATGGATATTATAGATTAACTGCAGATGCACAT
CATTACCTCTGTAAAGAAGTAGCACCTCCAGCCGTGCTTGAAAATATACAAAGCAACTGT
CATGGCCCAATTTCGATGGATTTTGCCATTAGTAAACTGAAGAAAGCAGGTAATCAGACT
GGACTGTATGTACTTCGATGCAGTCCTAAGGACTTTAATAAATATTTTTTGACTTTTGCT
GTCGAGCGAGAAAATGTCATTGAATATAAACACTGTTTGATTACAAAAAATGAGAATGAA
GAGTACAACCTCAGTGGGACAAAGAAGAACTTCAGCAGTCTTAAAGATCTTTTGAATTGT
TACCAGATGGAAACTGTTCGCTCAGACAATATAATTTTCCAGTTTACTAAATGCTGTCCC
CCAAAGCCAAAAGATAAATCAAACCTTCTAGTCTTCAGAACGAATGGTGTTTCTGATGTA
CCAACCTCACCAACATTACAGAGGCCTACTCATATGAACCAAATGGTGTTTCACAAAATC
AGAAATGAAGATTTGATATTTAATGAAAGCCTTGGCCAAGGCACTTTTACAAAGATTTTT
AAAGGCGTACGAAGAGAAGTAGGAGACTACGGTCAACTGCATGAAACAGAAGTTCTTTTA
AAAGTTCTGGATAAAGCACACAGAAACTATTCAGAGTCTTTCTTTGAAGCAGCAAGTATG
ATGAGCAAGCTTTCTCACAAGCATTTGGTTTTAAATTATGGAGTATGTGTCTGTGGAGAC
GAGAATATTCTGGTTCAGGAGTTTGTAAAATTTGGATCACTAGATACATATCTGAAAAAG
AATAAAAATTGTATAAATATATTATGGAAACTTGAAGTTGCTAAACAGTTGGCATGGGCC
ATGCATTTTCTAGAAGAAAACACCCTTATTCATGGGAATGTATGTGCCAAAAATATTCTG
CTTATCAGAGAAGAAGACAGGAAGACAGGAAATCCTCCTTTCATCAAACTTAGTGATCCT
GGCATTAGTATTACAGTTTTGCCAAAGGACATTCTTCAGGAGAGAATACCATGGGTACCA
CCTGAATGCATTGAAAATCCTAAAAATTTAAATTTGGCAACAGACAAATGGAGTTTTGGT
ACCACTTTGTGGGAAATCTGCAGTGGAGGAGATAAACCTCTAAGTGCTCTGGATTCTCAA
AGAAAGCTACAATTTTATGAAGATAGGCATCAGCTTCCTGCACCAAAGTGGGCAGAATTA
GCAAACCTTATAAATAATTGTATGGATTATGAACCAGATTTCAGGCCTTCTTTCAGAGCC
ATCATACGAGATCTTAACAGTTTGTTTACTCCAGATTATGAACTATTAACAGAAAATGAC
ATGTTACCAAATATGAGGATAGGTGCCCTGGGGTTTTCTGGTGCCTTTGAAGACCGGGAT
CCTACACAGTTTGAAGAGAGACATTTGAAATTTCTACAGCAACTTGGCAAGGGTAATTTT
GGGAGTGTGGAGATGTGCCGGTATGACCCTCTACAGGACAACACTGGGGAGGTGGTCGCT
GTAAAAAAGCTTCAGCATAGTACTGAAGAGCACCTAAGAGACTTTGAAAGGGAAATTGAA
ATCCTGAAATCCCTACAGCATGACAACATTGTAAAGTACAAGGGAGTGTGCTACAGTGCT
GGTCGGCGTAATCTAAAATTAATTATGGAATATTTACCATATGGAAGTTTACGAGACTAT
CTTCAAAAACATAAAGAACGGATAGATCACATAAAACTTCTGCAGTACACATCTCAGATA
TGCAAGGGTATGGAGTATCTTGGTACAAAAAGGTATATCCACAGGGATCTGGCAACGAGA
AATATATTGGTGGAGAACGAGAACAGAGTTAAAATTGGAGATTTTGGGTTAACCAAAGTC
TTGCCACAAGACAAAGAATACTATAAAGTAAAAGAACCTGGTGAAAGTCCCATATTCTGG
TATGCTCCAGAATCACTGACAGAGAGCAAGTTTTCTGTGGCCTCAGATGTTTGGAGCTTT
GGAGTGGTTCTGTATGAACTTTTCACATACATTGAGAAGAGTAAAAGTCCACCAGCGGAA
TTTATGCGTATGATTGGCAATGACAAACAAGGACAGATGATCGTGTTCCATTTGATAGAA
CTTTTGAAGAATAATGGAAGATTACCAAGACCAGATGGATGCCCAGATGAGATCTATATG
ATCATGACAGAATGCTGGAACAATAATGTAAATCAACGCCCCTCCTTTAGGGATCTAGCT
CTTCGAGTGGATCAAATAAGGGATAACATGGCTGGATGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF18379</ns0:identifier>
            <ns0:name>FERM_F1</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF18377</ns0:identifier>
            <ns0:name>FERM_F2</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF17887</ns0:identifier>
            <ns0:name>Jak1_Phl</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF21990</ns0:identifier>
            <ns0:name>SH2_1</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07714</ns0:identifier>
            <ns0:name>PK_Tyr_Ser-Thr</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>caveola</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoplasm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoskeleton</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytosol</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endosome lumen</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>extrinsic component of cytoplasmic side of plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>membrane raft</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>nucleoplasm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>nucleus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>growth hormone receptor binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>heme binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>histone binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>interleukin-12 receptor binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>non-membrane spanning protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein kinase binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>SH2 domain binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>actin filament polymerization</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>adaptive immune response</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>apoptotic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>axon regeneration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to dexamethasone stimulus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cytokine-mediated signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>erythrocyte differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>extrinsic apoptotic signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>growth hormone receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>interleukin-12-mediated signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>intracellular signal transduction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>intrinsic apoptotic signaling pathway in response to oxidative stress</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>mammary gland epithelium development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>mesoderm development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>negative regulation of cardiac muscle cell apoptotic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>negative regulation of cell-cell adhesion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>negative regulation of cytokine production involved in inflammatory response</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>negative regulation of neuron apoptotic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>platelet-derived growth factor receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell-substrate adhesion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cytosolic calcium ion concentration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of growth hormone receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of insulin secretion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of interleukin-1 beta production</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of nitric oxide biosynthetic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of tumor necrosis factor production</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein autophosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of apoptotic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of inflammatory response</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to antibiotic</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to hydroperoxide</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to interleukin-12</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to tumor necrosis factor</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>signal transduction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>tumor necrosis factor-mediated signaling pathway</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:target>
    <ns0:target position="7">
      <ns0:id>BE0001039</ns0:id>
      <ns0:name>High affinity nerve growth factor receptor</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>unknown</ns0:known-action>
      <ns0:polypeptide id="P04629" source="Swiss-Prot">
        <ns0:name>High affinity nerve growth factor receptor</ns0:name>
        <ns0:general-function>Receptor tyrosine kinase involved in the development and the maturation of the central and peripheral nervous systems through regulation of proliferation, differentiation and survival of sympathetic and nervous neurons. High affinity receptor for NGF which is its primary ligand (PubMed:1281417, PubMed:15488758, PubMed:17196528, PubMed:1849459, PubMed:1850821, PubMed:22649032, PubMed:27445338, PubMed:8325889). Can also bind and be activated by NTF3/neurotrophin-3. However, NTF3 only supports axonal extension through NTRK1 but has no effect on neuron survival (By similarity). Upon dimeric NGF ligand-binding, undergoes homodimerization, autophosphorylation and activation (PubMed:1281417). Recruits, phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation. Through SHC1 and FRS2 activates a GRB2-Ras-MAPK cascade that regulates cell differentiation and survival. Through PLCG1 controls NF-Kappa-B activation and the transcription of genes involved in cell survival. Through SHC1 and SH2B1 controls a Ras-PI3 kinase-AKT1 signaling cascade that is also regulating survival. In absence of ligand and activation, may promote cell death, making the survival of neurons dependent on trophic factors</ns0:general-function>
        <ns0:specific-function>ATP binding</ns0:specific-function>
        <ns0:gene-name>NTRK1</ns0:gene-name>
        <ns0:locus>1q23.1</ns0:locus>
        <ns0:cellular-location>Cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>424-439</ns0:transmembrane-regions>
        <ns0:signal-regions>1-32</ns0:signal-regions>
        <ns0:theoretical-pi>6.62</ns0:theoretical-pi>
        <ns0:molecular-weight>87496.465</ns0:molecular-weight>
        <ns0:chromosome-location>1</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:8031</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>NTRK1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>NTRK1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>M23102</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>339918</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1817</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P04629</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>NTRK1_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>2.7.10.1</ns0:synonym>
          <ns0:synonym>gp140trk</ns0:synonym>
          <ns0:synonym>MTC</ns0:synonym>
          <ns0:synonym>Neurotrophic tyrosine kinase receptor type 1</ns0:synonym>
          <ns0:synonym>p140-TrkA</ns0:synonym>
          <ns0:synonym>TRK</ns0:synonym>
          <ns0:synonym>Trk-A</ns0:synonym>
          <ns0:synonym>TRK1-transforming tyrosine kinase protein</ns0:synonym>
          <ns0:synonym>TRKA</ns0:synonym>
          <ns0:synonym>Tropomyosin-related kinase A</ns0:synonym>
          <ns0:synonym>Tyrosine kinase receptor</ns0:synonym>
          <ns0:synonym>Tyrosine kinase receptor A</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002069|High affinity nerve growth factor receptor
MLRGGRRGQLGWHSWAAGPGSLLAWLILASAGAAPCPDACCPHGSSGLRCTRDGALDSLH
HLPGAENLTELYIENQQHLQHLELRDLRGLGELRNLTIVKSGLRFVAPDAFHFTPRLSRL
NLSFNALESLSWKTVQGLSLQELVLSGNPLHCSCALRWLQRWEEEGLGGVPEQKLQCHGQ
GPLAHMPNASCGVPTLKVQVPNASVDVGDDVLLRCQVEGRGLEQAGWILTELEQSATVMK
SGGLPSLGLTLANVTSDLNRKNVTCWAENDVGRAEVSVQVNVSFPASVQLHTAVEMHHWC
IPFSVDGQPAPSLRWLFNGSVLNETSFIFTEFLEPAANETVRHGCLRLNQPTHVNNGNYT
LLAANPFGQASASIMAAFMDNPFEFNPEDPIPVSFSPVDTNSTSGDPVEKKDETPFGVSV
AVGLAVFACLFLSTLLLVLNKCGRRNKFGINRPAVLAPEDGLAMSLHFMTLGGSSLSPTE
GKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKML
VAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRF
LRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQ
GLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEI
FTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHAR
LQALAQAPPVYLDVLG</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0010727|High affinity nerve growth factor receptor (NTRK1)
ATGAAGGAGGCCGCCCTCATCTGCCTGGCACCCTCTGTACCCCCGATCTTGACGGTGAAG
TCCTGGGACACCATGCAGTTGCGGGCTGCTAGATCTCGGTGCACAAACTTGTTGGCAGCA
AGCTACATCGAGAACCAGCAGCATCTGCAGCATCTGGAGCTCCGTGATCTGAGGGGCCTG
GGGGAGCTGAGAAACCTCACCATCGTGAAGAGTGGTCTCCGTTTCGTGGCGCCAGATGCC
TTCCATTTCACTCCTCGGCTCAGTCGCCTGAATCTCTCCTTCAACGCTCTGGAGTCTCTC
TCCTGGAAAACTGTGCAGGGCCTCTCCTTACAGGAACTGGTCCTGTCGGGGAACCCTCTG
CACTGTTCTTGTGCCCTGCGCTGGCTACAGCGCTGGGAGGAGGAGGGACTGGGCGGAGTG
CCTGAACAGAAGCTGCAGTGTCATGGGCAAGGGCCCCTGGCCCACATGCCCAATGCCAGC
TGTGGTGTGCCCACGCTGAAGGTCCAGGTGCCCAATGCCTCGGTGGATGTGGGGGACGAC
GTGCTGCTGCGGTGCCAGGTGGAGGGGCGGGGCCTGGAGCAGGCCGGCTGGATCCTCACA
GAGCTGGAGCAGTCAGCCACGGTGATGAAATCTGGGGGTCTGCCATCCCTGGGGCTGACC
CTGGCCAATGTCACCAGTGACCTCAACAGGAAGAACGTGACGTGCTGGGCAGAGAACGAT
GTGGGCCGGGCAGAGGTCTCTGTTCAGGTCAACGTCTCCTTCCCGGCCAGTGTGCAGCTG
CACACGGCGGTGGAGATGCACCACTGGTGCATCCCCTTCTCTGTGGATGGGCAGCCGGCA
CCGTCTCTGCGCTGGCTCTTCAATGGCTCCGTGCTCAATGAGACCAGCTTCATCTTCACT
GAGTTCCTGGAGCCGGCAGCCAATGAGACCGTGCGGCACGGGTGTCTGCGCCTCAACCAG
CCCACCCACGTCAACAACGGCAACTACACGCTGCTGGCTGCCAACCCCTTCGGCCAGGCC
TCCGCCTCCATCATGGCTGCCTTCATGGACAACCCTTTCGAGTTCAACCCCGAGGACCCC
ATCCCTGACACTAACAGCACATCTGGAGACCCGGTGGAGAAGAAGGACGAAACACCTTTT
GGGGTCTCGGTGGCTGTGGGCCTGGCCGTCTTTGCCTGCCTCTTCCTTTCTACGCTGCTC
CTTGTGCTCAACAAATGTGGACGGAGAAACAAGTTTGGGATCAACCGCCCGGCTGTGCTG
GCTCCAGAGGATGGGCTGGCCATGTCCCTGCATTTCATGACATTGGGTGGCAGCTCCCTG
TCCCCCACCGAGGGCAAAGGCTCTGGGCTCCAAGGCCACATCATCGAGAACCCACAATAC
TTCAGTGATGCCTGTGTTCACCACATCAAGCGCCGGGACATCGTGCTCAAGTGGGAGCTG
GGGGAGGGCGCCTTTGGGAAGGTCTTCCTTGCTGAGTGCCACAACCTCCTGCCTGAGCAG
GACAAGATGCTGGTGGCTGTCAAGGCACTGAAGGAGGCGTCCGAGAGTGCTCGGCAGGAC
TTCCAGCGTGAGGCTGAGCTGCTCACCATGCTGCAGCACCAGCACATCGTGCGCTTCTTC
GGCGTCTGCACCGAGGGCCGCCCCCTGCTCATGGTCTTTGAGTATATGCGGCACGGGGAC
CTCAACCGCTTCCTCCGATCCCATGGACCTGATGCCAAGCTGCTGGCTGGTGGGGAGGAT
GTGGCTCCAGGCCCCCTGGGTCTGGGGCAGCTGCTGGCCGTGGCTAGCCAGGTCGCTGCG
GGGATGGTGTACCTGGCGGGTCTGCATTTTGTGCACCGGGACCTGGCCACACGCAACTGT
CTAGTGGGCCAGGGACTGGTGGTCAAGATTGGTGATTTTGGCATGAGCAGGGATATCTAC
AGCACCGACTATTACCGTGTGGGAGGCCGCACCATGCTGCCCATTCGCTGGATGCCGCCC
GAGAGCATCCTGTACCGTAAGTTCACCACCGAGAGCGACGTGTGGAGCTTCGGCGTGGTG
CTCTGGGAGATCTTCACCTACGGCAAGCAGCCCTGGTACCAGCTCTCCAACACGGAGGCA
ATCGACTGCATCACGCAGGGACGTGAGTTGGAGCGGCCACGTGCCTGCCCACCAGAGGTC
TACGCCATCATGCGGGGCTGCTGGCAGCGGGAGCCCCAGCAACGCCACAGCATCAAGGAT
GTGCACGCCCGGCTGCAAGCCCTGGCCCAGGCACCTCCTGTCTACCTGGATGTCCTGGGC
TAG</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF13855</ns0:identifier>
            <ns0:name>LRR_8</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF18613</ns0:identifier>
            <ns0:name>TrkA_TMD</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF16920</ns0:identifier>
            <ns0:name>LRRCT_2</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07714</ns0:identifier>
            <ns0:name>PK_Tyr_Ser-Thr</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>axon</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cell surface</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>dendrite</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>early endosome</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>early endosome membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>late endosome</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>late endosome membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>neuronal cell body</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>receptor complex</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>nerve growth factor binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>nerve growth factor receptor activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>neurotrophin binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein homodimerization activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>transmembrane receptor protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>axon guidance</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>axonogenesis involved in innervation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>B cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>behavioral response to formalin induced pain</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to nerve growth factor stimulus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to nicotine</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>circadian rhythm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>detection of mechanical stimulus involved in sensory perception of pain</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>detection of temperature stimulus involved in sensory perception of pain</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>learning or memory</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>mechanoreceptor differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>negative regulation of neuron apoptotic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>neurotrophin TRK receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>olfactory nerve development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>peptidyl-tyrosine phosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of angiogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of ERK1 and ERK2 cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of GTPase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of neuron projection development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of NF-kappaB transcription factor activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of programmed cell death</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of Ras protein signal transduction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of synapse assembly</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of synaptic transmission, glutamatergic</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein autophosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein phosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to axon injury</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to electrical stimulus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to hydrostatic pressure</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to nutrient levels</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>Sertoli cell development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>sympathetic nervous system development</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:target>
    <ns0:target position="8">
      <ns0:id>BE0000369</ns0:id>
      <ns0:name>Vascular endothelial growth factor receptor 2</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>unknown</ns0:known-action>
      <ns0:polypeptide id="P35968" source="Swiss-Prot">
        <ns0:name>Vascular endothelial growth factor receptor 2</ns0:name>
        <ns0:general-function>Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC</ns0:general-function>
        <ns0:specific-function>ATP binding</ns0:specific-function>
        <ns0:gene-name>KDR</ns0:gene-name>
        <ns0:locus>4q12</ns0:locus>
        <ns0:cellular-location>Cell junction</ns0:cellular-location>
        <ns0:transmembrane-regions>765-785</ns0:transmembrane-regions>
        <ns0:signal-regions>1-19</ns0:signal-regions>
        <ns0:theoretical-pi>5.64</ns0:theoretical-pi>
        <ns0:molecular-weight>151525.555</ns0:molecular-weight>
        <ns0:chromosome-location>4</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:6307</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>KDR</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>KDR</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>AF035121</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>2655412</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1813</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P35968</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>VGFR2_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>2.7.10.1</ns0:synonym>
          <ns0:synonym>Fetal liver kinase 1</ns0:synonym>
          <ns0:synonym>FLK-1</ns0:synonym>
          <ns0:synonym>FLK1</ns0:synonym>
          <ns0:synonym>KDR</ns0:synonym>
          <ns0:synonym>Kinase insert domain receptor</ns0:synonym>
          <ns0:synonym>Protein-tyrosine kinase receptor flk-1</ns0:synonym>
          <ns0:synonym>VEGFR-2</ns0:synonym>
          <ns0:synonym>VEGFR2</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000735|Vascular endothelial growth factor receptor 2
MQSKVLLAVALWLCVETRAASVGLPSVSLDLPRLSIQKDILTIKANTTLQITCRGQRDLD
WLWPNNQSGSEQRVEVTECSDGLFCKTLTIPKVIGNDTGAYKCFYRETDLASVIYVYVQD
YRSPFIASVSDQHGVVYITENKNKTVVIPCLGSISNLNVSLCARYPEKRFVPDGNRISWD
SKKGFTIPSYMISYAGMVFCEAKINDESYQSIMYIVVVVGYRIYDVVLSPSHGIELSVGE
KLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRS
DQGLYTCAASSGLMTKKNSTFVRVHEKPFVAFGSGMESLVEATVGERVRIPAKYLGYPPP
EIKWYKNGIPLESNHTIKAGHVLTIMEVSERDTGNYTVILTNPISKEKQSHVVSLVVYVP
PQIGEKSLISPVDSYQYGTTQTLTCTVYAIPPPHHIHWYWQLEEECANEPSQAVSVTNPY
PCEEWRSVEDFQGGNKIEVNKNQFALIEGKNKTVSTLVIQAANVSALYKCEAVNKVGRGE
RVISFHVTRGPEITLQPDMQPTEQESVSLWCTADRSTFENLTWYKLGPQPLPIHVGELPT
PVCKNLDTLWKLNATMFSNSTNDILIMELKNASLQDQGDYVCLAQDRKTKKRHCVVRQLT
VLERVAPTITGNLENQTTSIGESIEVSCTASGNPPPQIMWFKDNETLVEDSGIVLKDGNR
NLTIRRVRKEDEGLYTCQACSVLGCAKVEAFFIIEGAQEKTNLEIIILVGTAVIAMFFWL
LLVIILRTVKRANGGELKTGYLSIVMDPDELPLDEHCERLPYDASKWEFPRDRLKLGKPL
GRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVN
LLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVPYKTKGARFRQGKDYVGAIPVDLK
RRLDSITSSQSSASSGFVEEKSLSDVEEEEAPEDLYKDFLTLEHLICYSFQVAKGMEFLA
SRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDR
VYTIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTML
DCWHGEPSQRPTFSELVEHLGNLLQANAQQDGKDYIVLPISETLSMEEDSGLSLPTSPVS
CMEEEEVCDPKFHYDNTAGISQYLQNSKRKSRPVSVKTFEDIPLEEPEVKVIPDDNQTDS
GMVLASEELKTLEDRTKLSPSFGGMVPSKSRESVASEGSNQTSGYQSGYHSDDTDTTVYS
SEEAELLKLIEIGVQTGSTAQILQPDSGTTLSSPPV</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0020462|Vascular endothelial growth factor receptor 2 (KDR)
ATGCAGAGCAAGGTGCTGCTGGCCGTCGCCCTGTGGCTCTGCGTGGAGACCCGGGCCGCC
TCTGTGGGTTTGCCTAGTGTTTCTCTTGATCTGCCCAGGCTCAGCATACAAAAAGACATA
CTTACAATTAAGGCTAATACAACTCTTCAAATTACTTGCAGGGGACAGAGGGACTTGGAC
TGGCTTTGGCCCAATAATCAGAGTGGCAGTGAGCAAAGGGTGGAGGTGACTGAGTGCAGC
GATGGCCTCTTCTGTAAGACACTCACAATTCCAAAAGTGATCGGAAATGACACTGGAGCC
TACAAGTGCTTCTACCGGGAAACTGACTTGGCCTCGGTCATTTATGTCTATGTTCAAGAT
TACAGATCTCCATTTATTGCTTCTGTTAGTGACCAACATGGAGTCGTGTACATTACTGAG
AACAAAAACAAAACTGTGGTGATTCCATGTCTCGGGTCCATTTCAAATCTCAACGTGTCA
CTTTGTGCAAGATACCCAGAAAAGAGATTTGTTCCTGATGGTAACAGAATTTCCTGGGAC
AGCAAGAAGGGCTTTACTATTCCCAGCTACATGATCAGCTATGCTGGCATGGTCTTCTGT
GAAGCAAAAATTAATGATGAAAGTTACCAGTCTATTATGTACATAGTTGTCGTTGTAGGG
TATAGGATTTATGATGTGGTTCTGAGTCCGTCTCATGGAATTGAACTATCTGTTGGAGAA
AAGCTTGTCTTAAATTGTACAGCAAGAACTGAACTAAATGTGGGGATTGACTTCAACTGG
GAATACCCTTCTTCGAAGCATCAGCATAAGAAACTTGTAAACCGAGACCTAAAAACCCAG
TCTGGGAGTGAGATGAAGAAATTTTTGAGCACCTTAACTATAGATGGTGTAACCCGGAGT
GACCAAGGATTGTACACCTGTGCAGCATCCAGTGGGCTGATGACCAAGAAGAACAGCACA
TTTGTCAGGGTCCATGAAAAACCTTTTGTTGCTTTTGGAAGTGGCATGGAATCTCTGGTG
GAAGCCACGGTGGGGGAGCGTGTCAGAATCCCTGCGAAGTACCTTGGTTACCCACCCCCA
GAAATAAAATGGTATAAAAATGGAATACCCCTTGAGTCCAATCACACAATTAAAGCGGGG
CATGTACTGACGATTATGGAAGTGAGTGAAAGAGACACAGGAAATTACACTGTCATCCTT
ACCAATCCCATTTCAAAGGAGAAGCAGAGCCATGTGGTCTCTCTGGTTGTGTATGTCCCA
CCCCAGATTGGTGAGAAATCTCTAATCTCTCCTGTGGATTCCTACCAGTACGGCACCACT
CAAACGCTGACATGTACGGTCTATGCCATTCCTCCCCCGCATCACATCCACTGGTATTGG
CAGTTGGAGGAAGAGTGCGCCAACGAGCCCAGCCAAGCTGTCTCAGTGACAAACCCATAC
CCTTGTGAAGAATGGAGAAGTGTGGAGGACTTCCAGGGAGGAAATAAAATTGAAGTTAAT
AAAAATCAATTTGCTCTAATTGAAGGAAAAAACAAAACTGTAAGTACCCTTGTTATCCAA
GCGGCAAATGTGTCAGCTTTGTACAAATGTGAAGCGGTCAACAAAGTCGGGAGAGGAGAG
AGGGTGATCTCCTTCCACGTGACCAGGGGTCCTGAAATTACTTTGCAACCTGACATGCAG
CCCACTGAGCAGGAGAGCGTGTCTTTGTGGTGCACTGCAGACAGATCTACGTTTGAGAAC
CTCACATGGTACAAGCTTGGCCCACAGCCTCTGCCAATCCATGTGGGAGAGTTGCCCACA
CCTGTTTGCAAGAACTTGGATACTCTTTGGAAATTGAATGCCACCATGTTCTCTAATAGC
ACAAATGACATTTTGATCATGGAGCTTAAGAATGCATCCTTGCAGGACCAAGGAGACTAT
GTCTGCCTTGCTCAAGACAGGAAGACCAAGAAAAGACATTGCGTGGTCAGGCAGCTCACA
GTCCTAGAGCGTGTGGCACCCACGATCACAGGAAACCTGGAGAATCAGACGACAAGTATT
GGGGAAAGCATCGAAGTCTCATGCACGGCATCTGGGAATCCCCCTCCACAGATCATGTGG
TTTAAAGATAATGAGACCCTTGTAGAAGACTCAGGCATTGTATTGAAGGATGGGAACCGG
AACCTCACTATCCGCAGAGTGAGGAAGGAGGACGAAGGCCTCTACACCTGCCAGGCATGC
AGTGTTCTTGGCTGTGCAAAAGTGGAGGCATTTTTCATAATAGAAGGTGCCCAGGAAAAG
ACGAACTTGGAAATCATTATTCTAGTAGGCACGGCGGTGATTGCCATGTTCTTCTGGCTA
CTTCTTGTCATCATCCTACGGACCGTTAAGCGGGCCAATGGAGGGGAACTGAAGACAGGC
TACTTGTCCATCGTCATGGATCCAGATGAACTCCCATTGGATGAACATTGTGAACGACTG
CCTTATGATGCCAGCAAATGGGAATTCCCCAGAGACCGGCTGAAGCTAGGTAAGCCTCTT
GGCCGTGGTGCCTTTGGCCAAGTGATTGAAGCAGATGCCTTTGGAATTGACAAGACAGCA
ACTTGCAGGACAGTAGCAGTCAAAATGTTGAAAGAAGGAGCAACACACAGTGAGCATCGA
GCTCTCATGTCTGAACTCAAGATCCTCATTCATATTGGTCACCATCTCAATGTGGTCAAC
CTTCTAGGTGCCTGTACCAAGCCAGGAGGGCCACTCATGGTGATTGTGGAATTCTGCAAA
TTTGGAAACCTGTCCACTTACCTGAGGAGCAAGAGAAATGAATTTGTCCCCTACAAGACC
AAAGGGGCACGATTCCGTCAAGGGAAAGACTACGTTGGAGCAATCCCTGTGGATCTGAAA
CGGCGCTTGGACAGCATCACCAGTAGCCAGAGCTCAGCCAGCTCTGGATTTGTGGAGGAG
AAGTCCCTCAGTGATGTAGAAGAAGAGGAAGCTCCTGAAGATCTGTATAAGGACTTCCTG
ACCTTGGAGCATCTCATCTGTTACAGCTTCCAAGTGGCTAAGGGCATGGAGTTCTTGGCA
TCGCGAAAGTGTATCCACAGGGACCTGGCGGCACGAAATATCCTCTTATCGGAGAAGAAC
GTGGTTAAAATCTGTGACTTTGGCTTGGCCCGGGATATTTATAAAGATCCAGATTATGTC
AGAAAAGGAGATGCTCGCCTCCCTTTGAAATGGATGGCCCCAGAAACAATTTTTGACAGA
GTGTACACAATCCAGAGTGACGTCTGGTCTTTTGGTGTTTTGCTGTGGGAAATATTTTCC
TTAGGTGCTTCTCCATATCCTGGGGTAAAGATTGATGAAGAATTTTGTAGGCGATTGAAA
GAAGGAACTAGAATGAGGGCCCCTGATTATACTACACCAGAAATGTACCAGACCATGCTG
GACTGCTGGCACGGGGAGCCCAGTCAGAGACCCACGTTTTCAGAGTTGGTGGAACATTTG
GGAAATCTCTTGCAAGCTAATGCTCAGCAGGATGGCAAAGACTACATTGTTCTTCCGATA
TCAGAGACTTTGAGCATGGAAGAGGATTCTGGACTCTCTCTGCCTACCTCACCTGTTTCC
TGTATGGAGGAGGAGGAAGTATGTGACCCCAAATTCCATTATGACAACACAGCAGGAATC
AGTCAGTATCTGCAGAACAGTAAGCGAAAGAGCCGGCCTGTGAGTGTAAAAACATTTGAA
GATATCCCGTTAGAAGAACCAGAAGTAAAAGTAATCCCAGATGACAACCAGACGGACAGT
GGTATGGTTCTTGCCTCAGAAGAGCTGAAAACTTTGGAAGACAGAACCAAATTATCTCCA
TCTTTTGGTGGAATGGTGCCCAGCAAAAGCAGGGAGTCTGTGGCATCTGAAGGCTCAAAC
CAGACAAGCGGCTACCAGTCCGGATATCACTCCGATGACACAGACACCACCGTGTACTCC
AGTGAGGAAGCAGAACTTTTAAAGCTGATAGAGATTGGAGTGCAAACCGGTAGCACAGCC
CAGATTCTCCAGCCTGACTCGGGGACCACACTGAGCTCTCCTCCTGTTTAA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF17988</ns0:identifier>
            <ns0:name>VEGFR-2_TMD</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07679</ns0:identifier>
            <ns0:name>I-set</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF21339</ns0:identifier>
            <ns0:name>VEGFR-1-like_Ig-like</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF13895</ns0:identifier>
            <ns0:name>Ig_2</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF22854</ns0:identifier>
            <ns0:name>VEGFR1-3_N_Ig-like</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF00047</ns0:identifier>
            <ns0:name>ig</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07714</ns0:identifier>
            <ns0:name>PK_Tyr_Ser-Thr</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cell junction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>early endosome</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endoplasmic reticulum</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endosome</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>external side of plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>extracellular region</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>Golgi apparatus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>membrane raft</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>nucleus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>sorting endosome</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>growth factor binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>Hsp90 protein binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>integrin binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>transmembrane receptor protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>vascular endothelial growth factor binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>angiogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>calcium ion homeostasis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell fate commitment</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell migration involved in sprouting angiogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to vascular endothelial growth factor stimulus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>embryonic hemopoiesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>endothelial cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>endothelium development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lung alveolus development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lymph vessel development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>negative regulation of endothelial cell apoptotic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>ovarian follicle development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>peptidyl-tyrosine phosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of angiogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of endothelial cell migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of endothelial cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of ERK1 and ERK2 cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of focal adhesion assembly</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of MAPK cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of mesenchymal cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of nitric oxide-cGMP mediated signal transduction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of positive chemotaxis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of protein phosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of vasculogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein autophosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of cell shape</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of hematopoietic progenitor cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>surfactant homeostasis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>vascular endothelial growth factor receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>vascular endothelial growth factor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>vasculogenesis</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:target>
    <ns0:target position="9">
      <ns0:id>BE0000205</ns0:id>
      <ns0:name>Platelet-derived growth factor receptor beta</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>unknown</ns0:known-action>
      <ns0:polypeptide id="P09619" source="Swiss-Prot">
        <ns0:name>Platelet-derived growth factor receptor beta</ns0:name>
        <ns0:general-function>Tyrosine-protein kinase that acts as a cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of pericytes and smooth muscle cells to endothelial cells. Plays a role in the migration of vascular smooth muscle cells and the formation of neointima at vascular injury sites. Required for normal development of the cardiovascular system. Required for normal recruitment of pericytes (mesangial cells) in the kidney glomerulus, and for normal formation of a branched network of capillaries in kidney glomeruli. Promotes rearrangement of the actin cytoskeleton and the formation of membrane ruffles. Binding of its cognate ligands - homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFD -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PLCG1, PIK3R1, PTPN11, RASA1/GAP, CBL, SHC1 and NCK1. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leads to the activation of the AKT1 signaling pathway. Phosphorylation of SHC1, or of the C-terminus of PTPN11, creates a binding site for GRB2, resulting in the activation of HRAS, RAF1 and down-stream MAP kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation and activation of SRC family kinases. Promotes phosphorylation of PDCD6IP/ALIX and STAM. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor</ns0:general-function>
        <ns0:specific-function>ATP binding</ns0:specific-function>
        <ns0:gene-name>PDGFRB</ns0:gene-name>
        <ns0:locus>5q32</ns0:locus>
        <ns0:cellular-location>Cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>533-553</ns0:transmembrane-regions>
        <ns0:signal-regions>1-32</ns0:signal-regions>
        <ns0:theoretical-pi>4.62</ns0:theoretical-pi>
        <ns0:molecular-weight>123966.895</ns0:molecular-weight>
        <ns0:chromosome-location>5</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:8804</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>PDGFRB</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>PDGFRB</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>J03278</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>189732</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1804</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P09619</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>PGFRB_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>2.7.10.1</ns0:synonym>
          <ns0:synonym>Beta platelet-derived growth factor receptor</ns0:synonym>
          <ns0:synonym>Beta-type platelet-derived growth factor receptor</ns0:synonym>
          <ns0:synonym>CD140 antigen-like family member B</ns0:synonym>
          <ns0:synonym>PDGF-R-beta</ns0:synonym>
          <ns0:synonym>PDGFR</ns0:synonym>
          <ns0:synonym>PDGFR-1</ns0:synonym>
          <ns0:synonym>PDGFR-beta</ns0:synonym>
          <ns0:synonym>PDGFR1</ns0:synonym>
          <ns0:synonym>Platelet-derived growth factor receptor 1</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000409|Platelet-derived growth factor receptor beta
MRLPGAMPALALKGELLLLSLLLLLEPQISQGLVVTPPGPELVLNVSSTFVLTCSGSAPV
VWERMSQEPPQEMAKAQDGTFSSVLTLTNLTGLDTGEYFCTHNDSRGLETDERKRLYIFV
PDPTVGFLPNDAEELFIFLTEITEITIPCRVTDPQLVVTLHEKKGDVALPVPYDHQRGFS
GIFEDRSYICKTTIGDREVDSDAYYVYRLQVSSINVSVNAVQTVVRQGENITLMCIVIGN
EVVNFEWTYPRKESGRLVEPVTDFLLDMPYHIRSILHIPSAELEDSGTYTCNVTESVNDH
QDEKAINITVVESGYVRLLGEVGTLQFAELHRSRTLQVVFEAYPPPTVLWFKDNRTLGDS
SAGEIALSTRNVSETRYVSELTLVRVKVAEAGHYTMRAFHEDAEVQLSFQLQINVPVRVL
ELSESHPDSGEQTVRCRGRGMPQPNIIWSACRDLKRCPRELPPTLLGNSSEEESQLETNV
TYWEEEQEFEVVSTLRLQHVDRPLSVRCTLRNAVGQDTQEVIVVPHSLPFKVVVISAILA
LVVLTIISLIILIMLWQKKPRYEIRWKVIESVSSDGHEYIYVDPMQLPYDSTWELPRDQL
VLGRTLGSGAFGQVVEATAHGLSHSQATMKVAVKMLKSTARSSEKQALMSELKIMSHLGP
HLNVVNLLGACTKGGPIYIITEYCRYGDLVDYLHRNKHTFLQHHSDKRRPPSAELYSNAL
PVGLPLPSHVSLTGESDGGYMDMSKDESVDYVPMLDMKGDVKYADIESSNYMAPYDNYVP
SAPERTCRATLINESPVLSYMDLVGFSYQVANGMEFLASKNCVHRDLAARNVLICEGKLV
KICDFGLARDIMRDSNYISKGSTFLPLKWMAPESIFNSLYTTLSDVWSFGILLWEIFTLG
GTPYPELPMNEQFYNAIKRGYRMAQPAHASDEIYEIMQKCWEEKFEIRPPFSQLVLLLER
LLGEGYKKKYQQVDEEFLRSDHPAILRSQARLPGFHGLRSPLDTSSVLYTAVQPNEGDND
YIIPLPDPKPEVADEGPLEGSPSLASSTLNEVNTSSTISCDSPLEPQDEPEPEPQLELQV
EPEPELEQLPDSGCPAPRAEAEDSFL</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0021922|Platelet-derived growth factor receptor beta (PDGFRB)
ATGCGGCTTCCGGGTGCGATGCCAGCTCTGGCCCTCAAAGGCGAGCTGCTGTTGCTGTCT
CTCCTGTTACTTCTGGAACCACAGATCTCTCAGGGCCTGGTCGTCACACCCCCGGGGCCA
GAGCTTGTCCTCAATGTCTCCAGCACCTTCGTTCTGACCTGCTCGGGTTCAGCTCCGGTG
GTGTGGGAACGGATGTCCCAGGAGCCCCCACAGGAAATGGCCAAGGCCCAGGATGGCACC
TTCTCCAGCGTGCTCACACTGACCAACCTCACTGGGCTAGACACGGGAGAATACTTTTGC
ACCCACAATGACTCCCGTGGACTGGAGACCGATGAGCGGAAACGGCTCTACATCTTTGTG
CCAGATCCCACCGTGGGCTTCCTCCCTAATGATGCCGAGGAACTATTCATCTTTCTCACG
GAAATAACTGAGATCACCATTCCATGCCGAGTAACAGACCCACAGCTGGTGGTGACACTG
CACGAGAAGAAAGGGGACGTTGCACTGCCTGTCCCCTATGATCACCAACGTGGCTTTTCT
GGTATCTTTGAGGACAGAAGCTACATCTGCAAAACCACCATTGGGGACAGGGAGGTGGAT
TCTGATGCCTACTATGTCTACAGACTCCAGGTGTCATCCATCAACGTCTCTGTGAACGCA
GTGCAGACTGTGGTCCGCCAGGGTGAGAACATCACCCTCATGTGCATTGTGATCGGGAAT
GAGGTGGTCAACTTCGAGTGGACATACCCCCGCAAAGAAAGTGGGCGGCTGGTGGAGCCG
GTGACTGACTTCCTCTTGGATATGCCTTACCACATCCGCTCCATCCTGCACATCCCCAGT
GCCGAGTTAGAAGACTCGGGGACCTACACCTGCAATGTGACGGAGAGTGTGAATGACCAT
CAGGATGAAAAGGCCATCAACATCACCGTGGTTGAGAGCGGCTACGTGCGGCTCCTGGGA
GAGGTGGGCACACTACAATTTGCTGAGCTGCATCGGAGCCGGACACTGCAGGTAGTGTTC
GAGGCCTACCCACCGCCCACTGTCCTGTGGTTCAAAGACAACCGCACCCTGGGCGACTCC
AGCGCTGGCGAAATCGCCCTGTCCACGCGCAACGTGTCGGAGACCCGGTATGTGTCAGAG
CTGACACTGGTTCGCGTGAAGGTGGCAGAGGCTGGCCACTACACCATGCGGGCCTTCCAT
GAGGATGCTGAGGTCCAGCTCTCCTTCCAGCTACAGATCAATGTCCCTGTCCGAGTGCTG
GAGCTAAGTGAGAGCCACCCTGACAGTGGGGAACAGACAGTCCGCTGTCGTGGCCGGGGC
ATGCCCCAGCCGAACATCATCTGGTCTGCCTGCAGAGACCTCAAAAGGTGTCCACGTGAG
CTGCCGCCCACGCTGCTGGGGAACAGTTCCGAAGAGGAGAGCCAGCTGGAGACTAACGTG
ACGTACTGGGAGGAGGAGCAGGAGTTTGAGGTGGTGAGCACACTGCGTCTGCAGCACGTG
GATCGGCCACTGTCGGTGCGCTGCACGCTGCGCAACGCTGTGGGCCAGGACACGCAGGAG
GTCATCGTGGTGCCACACTCCTTGCCCTTTAAGGTGGTGGTGATCTCAGCCATCCTGGCC
CTGGTGGTGCTCACCATCATCTCCCTTATCATCCTCATCATGCTTTGGCAGAAGAAGCCA
CGTTACGAGATCCGATGGAAGGTGATTGAGTCTGTGAGCTCTGACGGCCATGAGTACATC
TACGTGGACCCCATGCAGCTGCCCTATGACTCCACGTGGGAGCTGCCGCGGGACCAGCTT
GTGCTGGGACGCACCCTCGGCTCTGGGGCCTTTGGGCAGGTGGTGGAGGCCACGGCTCAT
GGCCTGAGCCATTCTCAGGCCACGATGAAAGTGGCCGTCAAGATGCTTAAATCCACAGCC
CGCAGCAGTGAGAAGCAAGCCCTTATGTCGGAGCTGAAGATCATGAGTCACCTTGGGCCC
CACCTGAACGTGGTCAACCTGTTGGGGGCCTGCACCAAAGGAGGACCCATCTATATCATC
ACTGAGTACTGCCGCTACGGAGACCTGGTGGACTACCTGCACCGCAACAAACACACCTTC
CTGCAGCACCACTCCGACAAGCGCCGCCCGCCCAGCGCGGAGCTCTACAGCAATGCTCTG
CCCGTTGGGCTCCCCCTGCCCAGCCATGTGTCCTTGACCGGGGAGAGCGACGGTGGCTAC
ATGGACATGAGCAAGGACGAGTCGGTGGACTATGTGCCCATGCTGGACATGAAAGGAGAC
GTCAAATATGCAGACATCGAGTCCTCCAACTACATGGCCCCTTACGATAACTACGTTCCC
TCTGCCCCTGAGAGGACCTGCCGAGCAACTTTGATCAACGAGTCTCCAGTGCTAAGCTAC
ATGGACCTCGTGGGCTTCAGCTACCAGGTGGCCAATGGCATGGAGTTTCTGGCCTCCAAG
AACTGCGTCCACAGAGACCTGGCGGCTAGGAACGTGCTCATCTGTGAAGGCAAGCTGGTC
AAGATCTGTGACTTTGGCCTGGCTCGAGACATCATGCGGGACTCGAATTACATCTCCAAA
GGCAGCACCTTTTTGCCTTTAAAGTGGATGGCTCCGGAGAGCATCTTCAACAGCCTCTAC
ACCACCCTGAGCGACGTGTGGTCCTTCGGGATCCTGCTCTGGGAGATCTTCACCTTGGGT
GGCACCCCTTACCCAGAGCTGCCCATGAACGAGCAGTTCTACAATGCCATCAAACGGGGT
TACCGCATGGCCCAGCCTGCCCATGCCTCCGACGAGATCTATGAGATCATGCAGAAGTGC
TGGGAAGAGAAGTTTGAGATTCGGCCCCCCTTCTCCCAGCTGGTGCTGCTTCTCGAGAGA
CTGTTGGGCGAAGGTTACAAAAAGAAGTACCAGCAGGTGGATGAGGAGTTTCTGAGGAGT
GACCACCCAGCCATCCTTCGGTCCCAGGCCCGCTTGCCTGGGTTCCATGGCCTCCGATCT
CCCCTGGACACCAGCTCCGTCCTCTATACTGCCGTGCAGCCCAATGAGGGTGACAACGAC
TATATCATCCCCCTGCCTGACCCCAAACCCGAGGTTGCTGACGAGGGCCCACTGGAGGGT
TCCCCCAGCCTAGCCAGCTCCACCCTGAATGAAGTCAACACCTCCTCAACCATCTCCTGT
GACAGCCCCCTGGAGCCCCAGGACGAACCAGAGCCAGAGCCCCAGCTTGAGCTCCAGGTG
GAGCCGGAGCCAGAGCTGGAACAGTTGCCGGATTCGGGGTGCCCTGCGCCTCGGGCGGAA
GCAGAGGATAGCTTCCTGTAG</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00047</ns0:identifier>
            <ns0:name>ig</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF13927</ns0:identifier>
            <ns0:name>Ig_3</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07714</ns0:identifier>
            <ns0:name>PK_Tyr_Ser-Thr</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>apical plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoplasm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>focal adhesion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>lysosomal lumen</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>nucleus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>platelet activating factor receptor activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>platelet-derived growth factor beta-receptor activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>platelet-derived growth factor binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>platelet-derived growth factor receptor binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein kinase binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>vascular endothelial growth factor binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>angiogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>aorta morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cardiac myofibril assembly</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell chemotaxis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell migration involved in coronary angiogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell migration involved in vasculogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>metanephric glomerular capillary formation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>metanephric glomerular mesangial cell proliferation involved in metanephros development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>peptidyl-tyrosine phosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>platelet-derived growth factor receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>platelet-derived growth factor receptor-beta signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of calcium ion import</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of chemotaxis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of DNA biosynthetic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of ERK1 and ERK2 cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of MAP kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of metanephric mesenchymal cell migration by platelet-derived growth factor receptor-beta signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of mitotic nuclear division</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of reactive oxygen species metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of smooth muscle cell migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of smooth muscle cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein autophosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of actin cytoskeleton organization</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>retina vasculature development in camera-type eye</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>signal transduction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>smooth muscle adaptation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>smooth muscle cell chemotaxis</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:target>
    <ns0:target position="10">
      <ns0:id>BE0002131</ns0:id>
      <ns0:name>Fibroblast growth factor receptor 1</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>unknown</ns0:known-action>
      <ns0:polypeptide id="P11362" source="Swiss-Prot">
        <ns0:name>Fibroblast growth factor receptor 1</ns0:name>
        <ns0:general-function>Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration. Required for normal mesoderm patterning and correct axial organization during embryonic development, normal skeletogenesis and normal development of the gonadotropin-releasing hormone (GnRH) neuronal system. Phosphorylates PLCG1, FRS2, GAB1 and SHB. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes phosphorylation of SHC1, STAT1 and PTPN11/SHP2. In the nucleus, enhances RPS6KA1 and CREB1 activity and contributes to the regulation of transcription. FGFR1 signaling is down-regulated by IL17RD/SEF, and by FGFR1 ubiquitination, internalization and degradation</ns0:general-function>
        <ns0:specific-function>ATP binding</ns0:specific-function>
        <ns0:gene-name>FGFR1</ns0:gene-name>
        <ns0:locus>8p11.23</ns0:locus>
        <ns0:cellular-location>Cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>377-397</ns0:transmembrane-regions>
        <ns0:signal-regions>1-21</ns0:signal-regions>
        <ns0:theoretical-pi>6.14</ns0:theoretical-pi>
        <ns0:molecular-weight>91866.935</ns0:molecular-weight>
        <ns0:chromosome-location>8</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:3688</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>FGFR1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>FGFR1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>X51803</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>31368</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1808</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P11362</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>FGFR1_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>2.7.10.1</ns0:synonym>
          <ns0:synonym>Basic fibroblast growth factor receptor 1</ns0:synonym>
          <ns0:synonym>bFGF-R-1</ns0:synonym>
          <ns0:synonym>BFGFR</ns0:synonym>
          <ns0:synonym>CEK</ns0:synonym>
          <ns0:synonym>FGFBR</ns0:synonym>
          <ns0:synonym>FGFR-1</ns0:synonym>
          <ns0:synonym>FLG</ns0:synonym>
          <ns0:synonym>FLT-2</ns0:synonym>
          <ns0:synonym>FLT2</ns0:synonym>
          <ns0:synonym>Fms-like tyrosine kinase 2</ns0:synonym>
          <ns0:synonym>HBGFR</ns0:synonym>
          <ns0:synonym>N-sam</ns0:synonym>
          <ns0:synonym>Proto-oncogene c-Fgr</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004180|Fibroblast growth factor receptor 1
MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDD
VQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSD
ALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPS
SGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSIN
HTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKI
GPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLE
ALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKS
IPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVL
GKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGK
HKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDL
VSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNG
RLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMD
KPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSF
PDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0021960|Fibroblast growth factor receptor 1 (FGFR1)
ATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTCTGCACC
GCTAGGCCGTCCCCGACCTTGCCTGAACAAGCCCAGCCCTGGGGAGCCCCTGTGGAAGTG
GAGTCCTTCCTGGTCCACCCCGGTGACCTGCTGCAGCTTCGCTGTCGGCTGCGGGACGAT
GTGCAGAGCATCAACTGGCTGCGGGACGGGGTGCAGCTGGCGGAAAGCAACCGCACCCGC
ATCACAGGGGAGGAGGTGGAGGTGCAGGACTCCGTGCCCGCAGACTCCGGCCTCTATGCT
TGCGTAACCAGCAGCCCCTCGGGCAGTGACACCACCTACTTCTCCGTCAATGTTTCAGAT
GCTCTCCCCTCCTCGGAGGATGATGATGATGATGATGACTCCTCTTCAGAGGAGAAAGAA
ACAGATAACACCAAACCAAACCGTATGCCCGTAGCTCCATATTGGACATCCCCAGAAAAG
ATGGAAAAGAAATTGCATGCAGTGCCGGCTGCCAAGACAGTGAAGTTCAAATGCCCTTCC
AGTGGGACCCCAAACCCCACACTGCGCTGGTTGAAAAATGGCAAAGAATTCAAACCTGAC
CACAGAATTGGAGGCTACAAGGTCCGTTATGCCACCTGGAGCATCATAATGGACTCTGTG
GTGCCCTCTGACAAGGGCAACTACACCTGCATTGTGGAGAATGAGTACGGCAGCATCAAC
CACACATACCAGCTGGATGTCGTGGAGCGGTCCCCTCACCGGCCCATCCTGCAAGCAGGG
TTGCCCGCCAACAAAACAGTGGCCCTGGGTAGCAACGTGGAGTTCATGTGTAAGGTGTAC
AGTGACCCGCAGCCGCACATCCAGTGGCTAAAGCACATCGAGGTGAATGGGAGCAAGATT
GGCCCAGACAACCTGCCTTATGTCCAGATCTTGAAGACTGCTGGAGTTAATACCACCGAC
AAAGAGATGGAGGTGCTTCACTTAAGAAATGTCTCCTTTGAGGACGCAGGGGAGTATACG
TGCTTGGCGGGTAACTCTATCGGACTCTCCCATCACTCTGCATGGTTGACCGTTCTGGAA
GCCCTGGAAGAGAGGCCGGCAGTGATGACCTCGCCCCTGTACCTGGAGATCATCATCTAT
TGCACAGGGGCCTTCCTCATCTCCTGCATGGTGGGGTCGGTCATCGTCTACAAGATGAAG
AGTGGTACCAAGAAGAGTGACTTCCACAGCCAGATGGCTGTGCACAAGCTGGCCAAGAGC
ATCCCTCTGCGCAGACAGGTGTCTGCTGACTCCAGTGCATCCATGAACTCTGGGGTTCTT
CTGGTTCGGCCATCACGGCTCTCCTCCAGTGGGACTCCCATGCTAGCAGGGGTCTCTGAG
TATGAGCTTCCCGAAGACCCTCGCTGGGAGCTGCCTCGGGACAGACTGGTCTTAGGCAAA
CCCCTGGGAGAGGGCTGCTTTGGGCAGGTGGTGTTGGCAGAGGCTATCGGGCTGGACAAG
GACAAACCCAACCGTGTGACCAAAGTGGCTGTGAAGATGTTGAAGTCGGACGCAACAGAG
AAAGACTTGTCAGACCTGATCTCAGAAATGGAGATGATGAAGATGATCGGGAAGCATAAG
AATATCATCAACCTGCTGGGGGCCTGCACGCAGGATGGTCCCTTGTATGTCATCGTGGAG
TATGCCTCCAAGGGCAACCTGCGGGAGTACCTGCAGGCCCGGAGGCCCCCAGGGCTGGAA
TACTGCTACAACCCCAGCCACAACCCAGAGGAGCAGCTCTCCTCCAAGGACCTGGTGTCC
TGCGCCTACCAGGTGGCCCGAGGCATGGAGTATCTGGCCTCCAAGAAGTGCATACACCGA
GACCTGGCAGCCAGGAATGTCCTGGTGACAGAGGACAATGTGATGAAGATAGCAGACTTT
GGCCTCGCACGGGACATTCACCACATCGACTACTATAAAAAGACAACCAACGGCCGACTG
CCTGTGAAGTGGATGGCACCCGAGGCATTATTTGACCGGATCTACACCCACCAGAGTGAT
GTGTGGTCTTTCGGGGTGCTCCTGTGGGAGATCTTCACTCTGGGCGGCTCCCCATACCCC
GGTGTGCCTGTGGAGGAACTTTTCAAGCTGCTGAAGGAGGGTCACCGCATGGACAAGCCC
AGTAACTGCACCAACGAGCTGTACATGATGATGCGGGACTGCTGGCATGCAGTGCCCTCA
CAGAGACCCACCTTCAAGCAGCTGGTGGAAGACCTGGACCGCATCGTGGCCTTGACCTCC
AACCAGGAGTACCTGGACCTGTCCATGCCCCTGGACCAGTACTCCCCCAGCTTTCCCGAC
ACCCGGAGCTCTACGTGCTCCTCAGGGGAGGATTCCGTCTTCTCTCATGAGCCGCTGCCC
GAGGAGCCCTGCCTGCCCCGACACCCAGCCCAGCTTGCCAATGGCGGACTCAAACGCCGC
TGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF07679</ns0:identifier>
            <ns0:name>I-set</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF00047</ns0:identifier>
            <ns0:name>ig</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF07714</ns0:identifier>
            <ns0:name>PK_Tyr_Ser-Thr</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytosol</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>extracellular region</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>nucleus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>receptor complex</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>fibroblast growth factor binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>heparin binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>identical protein binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein homodimerization activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>angiogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>auditory receptor cell development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>branching involved in salivary gland morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell maturation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>chondrocyte differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>chordate embryonic development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>embryonic limb morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>fibroblast growth factor receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>in utero embryonic development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>inner ear morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lung-associated mesenchyme development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>MAPK cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>midbrain development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>middle ear morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>neuron migration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>organ induction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>outer ear morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>paraxial mesoderm development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>peptidyl-tyrosine phosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>phosphatidylinositol-mediated signaling</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cardiac muscle cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of MAP kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of MAPK cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of mesenchymal cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of neuron differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of neuron projection development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of phospholipase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein autophosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein phosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of extrinsic apoptotic signaling pathway in absence of ligand</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of lateral mesodermal cell fate specification</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>sensory perception of sound</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>skeletal system development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>skeletal system morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>ureteric bud development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>ventricular zone neuroblast division</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:target>
    <ns0:target position="11">
      <ns0:id>BE0000748</ns0:id>
      <ns0:name>Fibroblast growth factor receptor 2</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>unknown</ns0:known-action>
      <ns0:polypeptide id="P21802" source="Swiss-Prot">
        <ns0:name>Fibroblast growth factor receptor 2</ns0:name>
        <ns0:general-function>Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.</ns0:general-function>
        <ns0:specific-function>ATP binding</ns0:specific-function>
        <ns0:gene-name>FGFR2</ns0:gene-name>
        <ns0:locus>10q26</ns0:locus>
        <ns0:cellular-location>Cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>378-398</ns0:transmembrane-regions>
        <ns0:signal-regions>1-21</ns0:signal-regions>
        <ns0:theoretical-pi>5.68</ns0:theoretical-pi>
        <ns0:molecular-weight>92024.29</ns0:molecular-weight>
        <ns0:chromosome-location>10</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:3689</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>FGFR2</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>X52832</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>31374</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1809</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P21802</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>FGFR2_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>2.7.10.1</ns0:synonym>
          <ns0:synonym>BEK</ns0:synonym>
          <ns0:synonym>FGFR-2</ns0:synonym>
          <ns0:synonym>K-sam</ns0:synonym>
          <ns0:synonym>Keratinocyte growth factor receptor</ns0:synonym>
          <ns0:synonym>KGFR</ns0:synonym>
          <ns0:synonym>KSAM</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001492|Fibroblast growth factor receptor 2
MVSWGRFICLVVVTMATLSLARPSFSLVEDTTLEPEEPPTKYQISQPEVYVAAPGESLEV
RCLLKDAAVISWTKDGVHLGPNNRTVLIGEYLQIKGATPRDSGLYACTASRTVDSETWYF
MVNVTDAISSGDDEDDTDGAEDFVSENSNNKRAPYWTNTEKMEKRLHAVPAANTVKFRCP
AGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSI
NHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSK
YGPDGLPYLKVLKAAGVNTTDKEIEVLYIRNVTFEDAGEYTCLAGNSIGISFHSAWLTVL
PAPGREKEITASPDYLEIAIYCIGVFLIACMVVTVILCRMKNTTKKPDFSSQPAVHKLTK
RIPLRRQVTVSAESSSSMNSNTPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFPRDK
LTLGKPLGEGCFGQVVMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEMMKM
IGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRARRPPGMEYSYDINRVPEEQMTF
KDLVSCTYQLARGMEYLASQKCIHRDLAARNVLVTENNVMKIADFGLARDINNIDYYKKT
TNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPVEELFKLLKEGH
RMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEYLDLSQPLEQYS
PSYPDTRSSCSSGDDSVFSPDPMPYEPCLPQYPHINGSVKT</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0010527|Fibroblast growth factor receptor 2 (FGFR2)
ATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCCTG
GCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCAACC
AAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGAGGTG
CGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACTTGGGG
CCCAACAATAGGACAGTGCTTATTGGGGAGTACTTGCAGATAAAGGGCGCCACGCCTAGA
GACTCCGGCCTCTATGCTTGTACTGCCAGTAGGACTGTAGACAGTGAAACTTGGTACTTC
ATGGTGAATGTCACAGATGCCATCTCATCCGGAGATGATGAGGATGACACCGATGGTGCG
GAAGATTTTGTCAGTGAGAACAGTAACAACAAGAGAGCACCATACTGGACCAACACAGAA
AAGATGGAAAAGCGGCTCCATGCTGTGCCTGCGGCCAACACTGTCAAGTTTCGCTGCCCA
GCCGGGGGGAACCCAATGCCAACCATGCGGTGGCTGAAAAACGGGAAGGAGTTTAAGCAG
GAGCATCGCATTGGAGGCTACAAGGTACGAAACCAGCACTGGAGCCTCATTATGGAAAGT
GTGGTCCCATCTGACAAGGGAAATTATACCTGTGTAGTGGAGAATGAATACGGGTCCATC
AATCACACGTACCACCTGGATGTTGTGGAGCGATCGCCTCACCGGCCCATCCTCCAAGCC
GGACTGCCGGCAAATGCCTCCACAGTGGTCGGAGGAGACGTAGAGTTTGTCTGCAAGGTT
TACAGTGATGCCCAGCCCCACATCCAGTGGATCAAGCACGTGGAAAAGAACGGCAGTAAA
TACGGGCCCGACGGGCTGCCCTACCTCAAGGTTCTCAAGGCCGCCGGTGTTAACACCACG
GACAAAGAGATTGAGGTTCTCTATATTCGGAATGTAACTTTTGAGGACGCTGGGGAATAT
ACGTGCTTGGCGGGTAATTCTATTGGGATATCCTTTCACTCTGCATGGTTGACAGTTCTG
CCAGCGCCTGGAAGAGAAAAGGAGATTACAGCTTCCCCAGACTACCTGGAGATAGCCATT
TACTGCATAGGGGTCTTCTTAATCGCCTGTATGGTGGTAACAGTCATCCTGTGCCGAATG
AAGAACACGACCAAGAAGCCAGACTTCAGCAGCCAGCCGGCTGTGCACAAGCTGACCAAA
CGTATCCCCCTGCGGAGACAGGTAACAGTTTCGGCTGAGTCCAGCTCCTCCATGAACTCC
AACACCCCGCTGGTGAGGATAACAACACGCCTCTCTTCAACGGCAGACACCCCCATGCTG
GCAGGGGTCTCCGAGTATGAACTTCCAGAGGACCCAAAATGGGAGTTTCCAAGAGATAAG
CTGACACTGGGCAAGCCCCTGGGAGAAGGTTGCTTTGGGCAAGTGGTCATGGCGGAAGCA
GTGGGAATTGACAAAGACAAGCCCAAGGAGGCGGTCACCGTGGCCGTGAAGATGTTGAAA
GATGATGCCACAGAGAAAGACCTTTCTGATCTGGTGTCAGAGATGGAGATGATGAAGATG
ATTGGGAAACACAAGAATATCATAAATCTTCTTGGAGCCTGCACACAGGATGGGCCTCTC
TATGTCATAGTTGAGTATGCCTCTAAAGGCAACCTCCGAGAATACCTCCGAGCCCGGAGG
CCACCCGGGATGGAGTACTCCTATGACATTAACCGTGTTCCTGAGGAGCAGATGACCTTC
AAGGACTTGGTGTCATGCACCTACCAGCTGGCCAGAGGCATGGAGTACTTGGCTTCCCAA
AAATGTATTCATCGAGATTTAGCAGCCAGAAATGTTTTGGTAACAGAAAACAATGTGATG
AAAATAGCAGACTTTGGACTCGCCAGAGATATCAACAATATAGACTATTACAAAAAGACC
ACCAATGGGCGGCTTCCAGTCAAGTGGATGGCTCCAGAAGCCCTGTTTGATAGAGTATAC
ACTCATCAGAGTGATGTCTGGTCCTTCGGGGTGTTAATGTGGGAGATCTTCACTTTAGGG
GGCTCGCCCTACCCAGGGATTCCCGTGGAGGAACTTTTTAAGCTGCTGAAGGAAGGACAC
AGAATGGATAAGCCAGCCAACTGCACCAACGAACTGTACATGATGATGAGGGACTGTTGG
CATGCAGTGCCCTCCCAGAGACCAACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATT
CTCACTCTCACAACCAATGAGGAATACTTGGACCTCAGCCAACCTCTCGAACAGTATTCA
CCTAGTTACCCTGACACAAGAAGTTCTTGTTCTTCAGGAGATGATTCTGTTTTTTCTCCA
GACCCCATGCCTTACGAACCATGCCTTCCTCAGTATCCACACATAAACGGCAGTGTTAAA
ACATGA</ns0:gene-sequence>
        <ns0:pfams />
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cell cortex</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cell surface</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoplasm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoplasmic membrane-bounded vesicle</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>excitatory synapse</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>extracellular region</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>Golgi apparatus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>integral component of membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>integral component of plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>intracellular membrane-bounded organelle</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>nucleoplasm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>nucleus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>fibroblast growth factor binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>fibroblast growth factor-activated receptor activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>heparin binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein homodimerization activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein tyrosine kinase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>activation of MAPKK activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>angiogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>apoptotic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>axon guidance</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>axonogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>bone development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>bone mineralization</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>bone morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>branch elongation involved in salivary gland morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>branching involved in labyrinthine layer morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>branching involved in prostate gland morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>branching involved in salivary gland morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>branching morphogenesis of a nerve</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>bud elongation involved in lung branching</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell fate commitment</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cell-cell signaling</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>coronal suture morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>digestive tract development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>embryonic cranial skeleton morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>embryonic digestive tract morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>embryonic organ development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>embryonic organ morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>embryonic pattern specification</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>endodermal digestive tract morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>epidermal growth factor receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>epidermis morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>epithelial cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>epithelial cell proliferation involved in salivary gland morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>epithelial to mesenchymal transition</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>Fc-epsilon receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>fibroblast growth factor receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>fibroblast growth factor receptor signaling pathway involved in hemopoiesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>fibroblast growth factor receptor signaling pathway involved in mammary gland specification</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>fibroblast growth factor receptor signaling pathway involved in negative regulation of apoptotic process in bone marrow</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>fibroblast growth factor receptor signaling pathway involved in positive regulation of cell proliferation in bone marrow</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>gland morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>hair follicle morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>in utero embryonic development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>innate immune response</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>inner ear morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>insulin receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lacrimal gland development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lateral sprouting from an epithelium</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lens fiber cell development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>limb bud formation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lung alveolus development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lung development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lung lobe morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lung-associated mesenchyme development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>mammary gland bud formation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>MAPK cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>membranous septum morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>mesenchymal cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>mesenchymal cell differentiation involved in lung development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>mesenchymal cell proliferation involved in lung development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>mesodermal cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>midbrain development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>morphogenesis of embryonic epithelium</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>multicellular organism growth</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>negative regulation of epithelial cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>negative regulation of mitotic nuclear division</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>negative regulation of transcription from RNA polymerase II promoter</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>neuromuscular junction development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>neurotrophin TRK receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>odontogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>orbitofrontal cortex development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>organ growth</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>organ morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>otic vesicle formation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>outflow tract septum morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>peptidyl-tyrosine phosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>phosphatidylinositol-mediated signaling</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of canonical Wnt signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cardiac muscle cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell cycle</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell division</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of epithelial cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of epithelial cell proliferation involved in lung morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of ERK1 and ERK2 cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of MAPK cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of mesenchymal cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of phospholipase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of smooth muscle cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of transcription from RNA polymerase II promoter</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of Wnt signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>post-embryonic development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>prostate epithelial cord elongation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>prostate gland morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein autophosphorylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>pyramidal neuron development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>Ras protein signal transduction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of branching involved in prostate gland morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of cell fate commitment</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of ERK1 and ERK2 cascade</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of fibroblast growth factor receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of morphogenesis of a branching structure</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of multicellular organism growth</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of osteoblast differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of osteoblast proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of smooth muscle cell differentiation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of smoothened signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>reproductive structure development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>skeletal system morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>small GTPase mediated signal transduction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>squamous basal epithelial stem cell differentiation involved in prostate gland acinus development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>synaptic vesicle transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>ureteric bud development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>vascular endothelial growth factor receptor signaling pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>ventricular cardiac muscle tissue morphogenesis</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>ventricular zone neuroblast division</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:target>
  </ns0:targets>
  <ns0:enzymes>
    <ns0:enzyme position="1">
      <ns0:id>BE0002638</ns0:id>
      <ns0:name>Cytochrome P450 3A4</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>substrate</ns0:action>
        <ns0:action>inhibitor</ns0:action>
        <ns0:action>inducer</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L162</ns0:ref-id>
            <ns0:title>Flockhart Table of Drug Interactions</ns0:title>
            <ns0:url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="P08684" source="Swiss-Prot">
        <ns0:name>Cytochrome P450 3A4</ns0:name>
        <ns0:general-function>A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981)</ns0:general-function>
        <ns0:specific-function>1,8-cineole 2-exo-monooxygenase activity</ns0:specific-function>
        <ns0:gene-name>CYP3A4</ns0:gene-name>
        <ns0:locus>7q22.1</ns0:locus>
        <ns0:cellular-location>Endoplasmic reticulum membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>2-22</ns0:transmembrane-regions>
        <ns0:signal-regions />
        <ns0:theoretical-pi>8.25</ns0:theoretical-pi>
        <ns0:molecular-weight>57342.67</ns0:molecular-weight>
        <ns0:chromosome-location>7</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:2637</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>CYP3A4</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>CYP3A4</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>M18907</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1337</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P08684</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>CP3A4_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>1,4-cineole 2-exo-monooxygenase</ns0:synonym>
          <ns0:synonym>1,8-cineole 2-exo-monooxygenase</ns0:synonym>
          <ns0:synonym>1.14.14.1</ns0:synonym>
          <ns0:synonym>Albendazole monooxygenase (sulfoxide-forming)</ns0:synonym>
          <ns0:synonym>Albendazole sulfoxidase</ns0:synonym>
          <ns0:synonym>Cholesterol 25-hydroxylase</ns0:synonym>
          <ns0:synonym>CYP3A3</ns0:synonym>
          <ns0:synonym>CYPIIIA3</ns0:synonym>
          <ns0:synonym>CYPIIIA4</ns0:synonym>
          <ns0:synonym>Cytochrome P450 3A3</ns0:synonym>
          <ns0:synonym>Cytochrome P450 HLp</ns0:synonym>
          <ns0:synonym>Cytochrome P450 NF-25</ns0:synonym>
          <ns0:synonym>Cytochrome P450-PCN1</ns0:synonym>
          <ns0:synonym>Nifedipine oxidase</ns0:synonym>
          <ns0:synonym>Quinine 3-monooxygenase</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00067</ns0:identifier>
            <ns0:name>p450</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoplasm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endoplasmic reticulum membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>intracellular membrane-bounded organelle</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>caffeine oxidase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>enzyme binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>heme binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>iron ion binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>monooxygenase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>oxidoreductase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>oxygen binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>quinine 3-monooxygenase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>steroid binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>steroid hydroxylase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>testosterone 6-beta-hydroxylase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>vitamin D 24-hydroxylase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>vitamin D3 25-hydroxylase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>alkaloid catabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>androgen metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lipid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>monoterpenoid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>oxidative demethylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>steroid catabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>steroid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>vitamin D metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>xenobiotic metabolic process</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
      <ns0:inhibition-strength>unknown</ns0:inhibition-strength>
      <ns0:induction-strength>unknown</ns0:induction-strength>
    </ns0:enzyme>
    <ns0:enzyme position="2">
      <ns0:id>BE0002362</ns0:id>
      <ns0:name>Cytochrome P450 3A5</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
        <ns0:action>inducer</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L162</ns0:ref-id>
            <ns0:title>Flockhart Table of Drug Interactions</ns0:title>
            <ns0:url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="P20815" source="Swiss-Prot">
        <ns0:name>Cytochrome P450 3A5</ns0:name>
        <ns0:general-function>A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Exhibits high catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes 6beta-hydroxylation of the steroid hormones testosterone, progesterone, and androstenedione (PubMed:2732228). Catalyzes the oxidative conversion of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Also involved in the oxidative metabolism of xenobiotics, including calcium channel blocking drug nifedipine and immunosuppressive drug cyclosporine (PubMed:2732228)</ns0:general-function>
        <ns0:specific-function>estrogen 16-alpha-hydroxylase activity</ns0:specific-function>
        <ns0:gene-name>CYP3A5</ns0:gene-name>
        <ns0:locus>7q22.1</ns0:locus>
        <ns0:cellular-location>Endoplasmic reticulum membrane</ns0:cellular-location>
        <ns0:transmembrane-regions />
        <ns0:signal-regions />
        <ns0:theoretical-pi>9.09</ns0:theoretical-pi>
        <ns0:molecular-weight>57108.065</ns0:molecular-weight>
        <ns0:chromosome-location>7</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:2638</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>CYP3A5</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>CYP3A5</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>J04813</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>181346</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1338</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P20815</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>CP3A5_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>1.14.14.1</ns0:synonym>
          <ns0:synonym>CYPIIIA5</ns0:synonym>
          <ns0:synonym>Cytochrome P450-PCN3</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004639|Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0016766|Cytochrome P450 3A5 (CYP3A5)
ATGGACCTCATCCCAAATTTGGCGGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGGACCCGTACACATGGACTTTTTAAGAGACTGGGAATTCCAGGG
CCCACACCTCTGCCTTTGTTGGGAAATGTTTTGTCCTATCGTCAGGGTCTCTGGAAATTT
GACACAGAGTGCTATAAAAAGTATGGAAAAATGTGGGGAACGTATGAAGGTCAACTCCCT
GTGCTGGCCATCACAGATCCCGACGTGATCAGAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAATCGAAGGTCTTTAGGCCCAGTGGGATTTATGAAAAGTGCCATCTCTTTA
GCTGAGGATGAAGAATGGAAGAGAATACGGTCATTGCTGTCTCCAACCTTCACCAGCGGA
AAACTCAAGGAGATGTTCCCCATCATTGCCCAGTATGGAGATGTATTGGTGAGAAACTTG
AGGCGGGAAGCAGAGAAAGGCAAGCCTGTCACCTTGAAAGACATCTTTGGGGCCTACAGC
ATGGATGTGATTACTGGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAGAGCACTAAGAAGTTCCTAAAATTTGGTTTCTTAGATCCATTATTT
CTCTCAATAATACTCTTTCCATTCCTTACCCCAGTTTTTGAAGCATTAAATGTCTCTCTG
TTTCCAAAAGATACCATAAATTTTTTAAGTAAATCTGTAAACAGAATGAAGAAAAGTCGC
CTCAACGACAAACAAAAGCACCGACTAGATTTCCTTCAGCTGATGATTGACTCCCAGAAT
TCGAAAGAAACTGAGTCCCACAAAGCTCTGTCTGATCTGGAGCTCGCAGCCCAGTCAATA
ATCTTCATTTTTGCTGGCTATGAAACCACCAGCAGTGTTCTTTCCTTCACTTTATATGAA
CTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAAAAGGAGATTGATGCAGTTTTGCCC
AATAAGGCACCACCTACCTATGATGCCGTGGTACAGATGGAGTACCTTGACATGGTGGTG
AATGAAACACTCAGATTATTCCCAGTTGCTATTAGACTTGAGAGGACTTGCAAGAAAGAT
GTTGAAATCAATGGGGTATTCATTCCCAAAGGGTCAATGGTGGTGATTCCAACTTATGCT
CTTCACCATGACCCAAAGTACTGGACAGAGCCTGAGGAGTTCCGCCCTGAAAGGTTCAGT
AAGAAGAAGGACAGCATAGATCCTTACATATACACACCCTTTGGAACTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCTTGAAATTAGACACGCAAGGA
CTTCTTCAACCAGAAAAACCCATTGTTCTAAAGGTGGATTCAAGAGATGGAACCCTAAGT
GGAGAATGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00067</ns0:identifier>
            <ns0:name>p450</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endoplasmic reticulum membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>intracellular membrane-bounded organelle</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>estrogen 2-hydroxylase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>heme binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>iron ion binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>monooxygenase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>oxidoreductase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>oxygen binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>alkaloid catabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>oxidative demethylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>steroid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>xenobiotic metabolic process</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
      <ns0:inhibition-strength>unknown</ns0:inhibition-strength>
      <ns0:induction-strength>unknown</ns0:induction-strength>
    </ns0:enzyme>
    <ns0:enzyme position="3">
      <ns0:id>BE0002363</ns0:id>
      <ns0:name>Cytochrome P450 2D6</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>substrate</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L162</ns0:ref-id>
            <ns0:title>Flockhart Table of Drug Interactions</ns0:title>
            <ns0:url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="P10635" source="Swiss-Prot">
        <ns0:name>Cytochrome P450 2D6</ns0:name>
        <ns0:general-function>A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18698000, PubMed:19965576, PubMed:20972997, PubMed:21289075, PubMed:21576599). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:19965576, PubMed:20972997). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:18698000, PubMed:21289075). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid (PubMed:10681376). Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants</ns0:general-function>
        <ns0:specific-function>anandamide 11,12 epoxidase activity</ns0:specific-function>
        <ns0:gene-name>CYP2D6</ns0:gene-name>
        <ns0:locus>22q13.2</ns0:locus>
        <ns0:cellular-location>Endoplasmic reticulum membrane</ns0:cellular-location>
        <ns0:transmembrane-regions />
        <ns0:signal-regions />
        <ns0:theoretical-pi>7.26</ns0:theoretical-pi>
        <ns0:molecular-weight>55768.94</ns0:molecular-weight>
        <ns0:chromosome-location>22</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:2625</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>CYP2D6</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>CYP2D6</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>M20403</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>181350</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1329</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P10635</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>CP2D6_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>1.14.14.-</ns0:synonym>
          <ns0:synonym>Cholesterol 25-hydroxylase</ns0:synonym>
          <ns0:synonym>CYP2DL1</ns0:synonym>
          <ns0:synonym>CYPIID6</ns0:synonym>
          <ns0:synonym>Cytochrome P450-DB1</ns0:synonym>
          <ns0:synonym>Debrisoquine 4-hydroxylase</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004641|Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0019275|Cytochrome P450 2D6 (CYP2D6)
ATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTG
GACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTG
CCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAG
TTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTG
CTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGAC
CGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTC
CTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGC
AACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTT
TGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAA
GCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCT
CGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTG
CGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTC
CTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATG
ACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAG
AAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCT
GACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTC
ATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGG
CAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATT
CATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTGTGACCCATATGACATCCCGT
GACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCA
TCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTC
CTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGC
CGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTG
CTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTC
TTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAG</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00067</ns0:identifier>
            <ns0:name>p450</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoplasm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endoplasmic reticulum</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endoplasmic reticulum membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>mitochondrion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>heme binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>iron ion binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>monooxygenase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>oxidoreductase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>alkaloid catabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>alkaloid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>coumarin metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>isoquinoline alkaloid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>monoterpenoid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>oxidative demethylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>steroid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>xenobiotic metabolic process</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
      <ns0:inhibition-strength />
      <ns0:induction-strength />
    </ns0:enzyme>
    <ns0:enzyme position="4">
      <ns0:id>BE0002433</ns0:id>
      <ns0:name>Cytochrome P450 1A2</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>substrate</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L162</ns0:ref-id>
            <ns0:title>Flockhart Table of Drug Interactions</ns0:title>
            <ns0:url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="P05177" source="Swiss-Prot">
        <ns0:name>Cytochrome P450 1A2</ns0:name>
        <ns0:general-function>A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576, PubMed:9435160). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576, PubMed:9435160). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:11555828, PubMed:12865317). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2 (PubMed:11555828, PubMed:12865317). Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). May act as a major enzyme for all-trans retinoic acid biosynthesis in the liver. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid (PubMed:10681376). Primarily catalyzes stereoselective epoxidation of the last double bond of polyunsaturated fatty acids (PUFA), displaying a strong preference for the (R,S) stereoisomer (PubMed:19965576). Catalyzes bisallylic hydroxylation and omega-1 hydroxylation of PUFA (PubMed:9435160). May also participate in eicosanoids metabolism by converting hydroperoxide species into oxo metabolites (lipoxygenase-like reaction, NADPH-independent) (PubMed:21068195). Plays a role in the oxidative metabolism of xenobiotics. Catalyzes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin (PubMed:14725854). Metabolizes caffeine via N3-demethylation (Probable)</ns0:general-function>
        <ns0:specific-function>caffeine oxidase activity</ns0:specific-function>
        <ns0:gene-name>CYP1A2</ns0:gene-name>
        <ns0:locus>15q24.1</ns0:locus>
        <ns0:cellular-location>Endoplasmic reticulum membrane</ns0:cellular-location>
        <ns0:transmembrane-regions />
        <ns0:signal-regions />
        <ns0:theoretical-pi>9.43</ns0:theoretical-pi>
        <ns0:molecular-weight>58406.915</ns0:molecular-weight>
        <ns0:chromosome-location>15</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:2596</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>CYP1A2</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>CYP1A2</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>Z00036</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1319</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P05177</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>CP1A2_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>1.14.14.1</ns0:synonym>
          <ns0:synonym>Cholesterol 25-hydroxylase</ns0:synonym>
          <ns0:synonym>CYPIA2</ns0:synonym>
          <ns0:synonym>Cytochrome P(3)450</ns0:synonym>
          <ns0:synonym>Cytochrome P450 4</ns0:synonym>
          <ns0:synonym>Cytochrome P450-P3</ns0:synonym>
          <ns0:synonym>Hydroperoxy icosatetraenoate dehydratase</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0055669|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARLRFSIN</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00067</ns0:identifier>
            <ns0:name>p450</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endoplasmic reticulum membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>intracellular membrane-bounded organelle</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>caffeine oxidase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>demethylase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>enzyme binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>heme binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>iron ion binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>monooxygenase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>oxidoreductase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>alkaloid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular respiration</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to cadmium ion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>dibenzo-p-dioxin metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>epoxygenase P450 pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>hydrogen peroxide biosynthetic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lung development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>methylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>monocarboxylic acid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>monoterpenoid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>omega-hydroxylase P450 pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>oxidative demethylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>porphyrin-containing compound metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>post-embryonic development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of gene expression</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>steroid catabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>toxin biosynthetic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>xenobiotic metabolic process</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
      <ns0:inhibition-strength />
      <ns0:induction-strength />
    </ns0:enzyme>
    <ns0:enzyme position="5">
      <ns0:id>BE0002887</ns0:id>
      <ns0:name>Cytochrome P450 2C8</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
        <ns0:action>inducer</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L162</ns0:ref-id>
            <ns0:title>Flockhart Table of Drug Interactions</ns0:title>
            <ns0:url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="P10632" source="Swiss-Prot">
        <ns0:name>Cytochrome P450 2C8</ns0:name>
        <ns0:general-function>A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:11093772, PubMed:14559847, PubMed:15766564, PubMed:19965576, PubMed:7574697). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:11093772, PubMed:14559847, PubMed:15766564, PubMed:19965576, PubMed:7574697). Primarily catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) with a preference for the last double bond (PubMed:15766564, PubMed:19965576, PubMed:7574697). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes all trans-retinoic acid toward its 4-hydroxylated form (PubMed:11093772). Displays 16-alpha hydroxylase activity toward estrogen steroid hormones, 17beta-estradiol (E2) and estrone (E1) (PubMed:14559847). Plays a role in the oxidative metabolism of xenobiotics. It is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel (taxol) (PubMed:26427316)</ns0:general-function>
        <ns0:specific-function>arachidonate epoxygenase activity</ns0:specific-function>
        <ns0:gene-name>CYP2C8</ns0:gene-name>
        <ns0:locus>10q23.33</ns0:locus>
        <ns0:cellular-location>Endoplasmic reticulum membrane</ns0:cellular-location>
        <ns0:transmembrane-regions />
        <ns0:signal-regions />
        <ns0:theoretical-pi>8.62</ns0:theoretical-pi>
        <ns0:molecular-weight>55824.275</ns0:molecular-weight>
        <ns0:chromosome-location>10</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:2622</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>CYP2C8</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>CYP2C8</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>M17397</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1325</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P10632</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>CP2C8_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>1.14.14.1</ns0:synonym>
          <ns0:synonym>CYPIIC8</ns0:synonym>
          <ns0:synonym>Cytochrome P450 form 1</ns0:synonym>
          <ns0:synonym>Cytochrome P450 IIC2</ns0:synonym>
          <ns0:synonym>Cytochrome P450 MP-12</ns0:synonym>
          <ns0:synonym>Cytochrome P450 MP-20</ns0:synonym>
          <ns0:synonym>S-mephenytoin 4-hydroxylase</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005650|Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0021338|Cytochrome P450 2C8 (CYP2C8)
ATGGAACCTTTTGTGGTCCTGGTGCTGTGTCTCTCTTTTATGCTTCTCTTTTCACTCTGG
AGACAGAGCTGTAGGAGAAGGAAGCTCCCTCCTGGCCCCACTCCTCTTCCTATTATTGGA
AATATGCTACAGATAGATGTTAAGGACATCTGCAAATCTTTCACCAATTTCTCAAAAGTC
TATGGTCCTGTGTTCACCGTGTATTTTGGCATGAATCCCATAGTGGTGTTTCATGGATAT
GAGGCAGTGAAGGAAGCCCTGATTGATAATGGAGAGGAGTTTTCTGGAAGAGGCAATTCC
CCAATATCTCAAAGAATTACTAAAGGACTTGGAATCATTTCCAGCAATGGAAAGAGATGG
AAGGAGATCCGGCGTTTCTCCCTCACAACCTTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCTTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
GTTGTTTTCCAGAAACGATTTGATTATAAAGATCAGAATTTTCTCACCCTGATGAAAAGA
TTCAATGAAAACTTCAGGATTCTGAACTCCCCATGGATCCAGGTCTGCAATAATTTCCCT
CTACTCATTGATTGTTTCCCAGGAACTCACAACAAAGTGCTTAAAAATGTTGCTCTTACA
CGAAGTTACATTAGGGAGAAAGTAAAAGAACACCAAGCATCACTGGATGTTAACAATCCT
CGGGACTTTATCGATTGCTTCCTGATCAAAATGGAGCAGGAAAAGGACAACCAAAAGTCA
GAATTCAATATTGAAAACTTGGTTGGCACTGTAGCTGATCTATTTGTTGCTGGAACAGAG
ACAACAAGCACCACTCTGAGATATGGACTCCTGCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGATCATGTAATTGGCAGACACAGGAGCCCCTGCATGCAG
GATAGGAGCCACATGCCTTACACTGATGCTGTAGTGCACGAGATCCAGAGATACAGTGAC
CTTGTCCCCACCGGTGTGCCCCATGCAGTGACCACTGATACTAAGTTCAGAAACTACCTC
ATCCCCAAGGGCACAACCATAATGGCATTACTGACTTCCGTGCTACATGATGACAAAGAA
TTTCCTAATCCAAATATCTTTGACCCTGGCCACTTTCTAGATAAGAATGGCAACTTTAAG
AAAAGTGACTACTTCATGCCTTTCTCAGCAGGAAAACGAATTTGTGCAGGAGAAGGACTT
GCCCGCATGGAGCTATTTTTATTTCTAACCACAATTTTACAGAACTTTAACCTGAAATCT
GTTGATGATTTAAAGAACCTCAATACTACTGCAGTTACCAAAGGGATTGTTTCTCTGCCA
CCCTCATACCAGATCTGCTTCATCCCTGTCTGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00067</ns0:identifier>
            <ns0:name>p450</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoplasm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endoplasmic reticulum membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>intracellular membrane-bounded organelle</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>caffeine oxidase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>heme binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>iron ion binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>monooxygenase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>epoxygenase P450 pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>omega-hydroxylase P450 pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>organic acid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>oxidative demethylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>xenobiotic metabolic process</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
      <ns0:inhibition-strength>unknown</ns0:inhibition-strength>
      <ns0:induction-strength>unknown</ns0:induction-strength>
    </ns0:enzyme>
    <ns0:enzyme position="6">
      <ns0:id>BE0002793</ns0:id>
      <ns0:name>Cytochrome P450 2C9</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
        <ns0:action>inducer</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L162</ns0:ref-id>
            <ns0:title>Flockhart Table of Drug Interactions</ns0:title>
            <ns0:url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="P11712" source="Swiss-Prot">
        <ns0:name>Cytochrome P450 2C9</ns0:name>
        <ns0:general-function>A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and steroids (PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599, PubMed:7574697, PubMed:9435160, PubMed:9866708). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:12865317, PubMed:15766564, PubMed:19965576, PubMed:21576599, PubMed:7574697, PubMed:9435160, PubMed:9866708). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA) (PubMed:15766564, PubMed:19965576, PubMed:7574697, PubMed:9866708). Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). Exhibits low catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes bisallylic hydroxylation and hydroxylation with double-bond migration of polyunsaturated fatty acids (PUFA) (PubMed:9435160, PubMed:9866708). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan (PubMed:25994031)</ns0:general-function>
        <ns0:specific-function>(R)-limonene 6-monooxygenase activity</ns0:specific-function>
        <ns0:gene-name>CYP2C9</ns0:gene-name>
        <ns0:locus>10q23.33</ns0:locus>
        <ns0:cellular-location>Endoplasmic reticulum membrane</ns0:cellular-location>
        <ns0:transmembrane-regions />
        <ns0:signal-regions />
        <ns0:theoretical-pi>7.99</ns0:theoretical-pi>
        <ns0:molecular-weight>55627.365</ns0:molecular-weight>
        <ns0:chromosome-location>10</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:2623</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>CYP2C9</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>CYP2C9</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>AY341248</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1326</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P11712</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>CP2C9_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>(R)-limonene 6-monooxygenase</ns0:synonym>
          <ns0:synonym>(S)-limonene 6-monooxygenase</ns0:synonym>
          <ns0:synonym>(S)-limonene 7-monooxygenase</ns0:synonym>
          <ns0:synonym>1.14.14.1</ns0:synonym>
          <ns0:synonym>Cholesterol 25-hydroxylase</ns0:synonym>
          <ns0:synonym>CYP2C10</ns0:synonym>
          <ns0:synonym>CYPIIC9</ns0:synonym>
          <ns0:synonym>Cytochrome P-450MP</ns0:synonym>
          <ns0:synonym>Cytochrome P450 MP-4</ns0:synonym>
          <ns0:synonym>Cytochrome P450 MP-8</ns0:synonym>
          <ns0:synonym>Cytochrome P450 PB-1</ns0:synonym>
          <ns0:synonym>S-mephenytoin 4-hydroxylase</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005471|Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0016893|Cytochrome P450 2C9 (CYP2C9)
ATGGATTCTCTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCACTCTGG
AGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGA
AATATCCTACAGATAGGTATTAAGGACATCAGCAAATCCTTAACCAATCTCTCAAAGGTC
TATGGCCCTGTGTTCACTCTGTATTTTGGCCTGAAACCCATAGTGGTGCTGCATGGATAT
GAAGCAGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCATTTTC
CCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATTGTTTTCAGCAATGGAAAGAAATGG
AAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGC
ATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAG
GCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCC
ATTATTTTCCATAAACGTTTTGATTATAAAGATCAGCAATTTCTTAACTTAATGGAAAAG
TTGAATGAAAACATCAAGATTTTGAGCAGCCCCTGGATCCAGATCTGCAATAATTTTTCT
CCTATCATTGATTACTTCCCGGGAACTCACAACAAATTACTTAAAAACGTTGCTTTTATG
AAAAGTTATATTTTGGAAAAAGTAAAAGAACACCAAGAATCAATGGACATGAACAACCCT
CAGGACTTTATTGATTGCTTCCTGATGAAAATGGAGAAGGAAAAGCACAACCAACCATCT
GAATTTACTATTGAAAGCTTGGAAAACACTGCAGTTGACTTGTTTGGAGCTGGGACAGAG
ACGACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACA
GCTAAAGTCCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAA
GACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATTGAC
CTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTC
ATTCCCAAGGGCACAACCATATTAATTTCCCTGACTTCTGTGCTACATGACAACAAAGAA
TTTCCCAACCCAGAGATGTTTGACCCTCATCACTTTCTGGATGAAGGTGGCAATTTTAAG
AAAAGTAAATACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAAGCCCTG
GCCGGCATGGAGCTGTTTTTATTCCTGACCTCCATTTTACAGAACTTTAACCTGAAATCT
CTGGTTGACCCAAAGAACCTTGACACCACTCCAGTTGTCAATGGATTTGCCTCTGTGCCG
CCCTTCTACCAGCTGTGCTTCATTCCTGTCTGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00067</ns0:identifier>
            <ns0:name>p450</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cytoplasm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>endoplasmic reticulum membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>intracellular membrane-bounded organelle</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>(R)-limonene 6-monooxygenase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>(S)-limonene 6-monooxygenase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>(S)-limonene 7-monooxygenase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>caffeine oxidase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>estrogen 2-hydroxylase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>heme binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>iron ion binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>monooxygenase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>oxidoreductase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>steroid hydroxylase activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>epoxygenase P450 pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>monocarboxylic acid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>monoterpenoid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>omega-hydroxylase P450 pathway</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>organic acid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>organofluorine metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>oxidative demethylation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>steroid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>urea metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>xenobiotic metabolic process</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
      <ns0:inhibition-strength>unknown</ns0:inhibition-strength>
      <ns0:induction-strength>unknown</ns0:induction-strength>
    </ns0:enzyme>
  </ns0:enzymes>
  <ns0:carriers />
  <ns0:transporters>
    <ns0:transporter position="1">
      <ns0:id>BE0001032</ns0:id>
      <ns0:name>ATP-dependent translocase ABCB1</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>substrate</ns0:action>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="P08183" source="Swiss-Prot">
        <ns0:name>ATP-dependent translocase ABCB1</ns0:name>
        <ns0:general-function>Translocates drugs and phospholipids across the membrane (PubMed:2897240, PubMed:35970996, PubMed:8898203, PubMed:9038218, PubMed:35507548). Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins (PubMed:8898203). Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells (PubMed:2897240, PubMed:35970996, PubMed:9038218)</ns0:general-function>
        <ns0:specific-function>ABC-type xenobiotic transporter activity</ns0:specific-function>
        <ns0:gene-name>ABCB1</ns0:gene-name>
        <ns0:locus>7q21.12</ns0:locus>
        <ns0:cellular-location>Cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>45-67
117-137
187-208
216-236
293-316
331-352
712-732
757-777
833-853
855-874
935-957
974-995</ns0:transmembrane-regions>
        <ns0:signal-regions />
        <ns0:theoretical-pi>9.44</ns0:theoretical-pi>
        <ns0:molecular-weight>141477.255</ns0:molecular-weight>
        <ns0:chromosome-location>7</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:40</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>ABCB1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>ABCB1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>M14758</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>307180</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>768</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>P08183</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>MDR1_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>ATP-binding cassette sub-family B member 1</ns0:synonym>
          <ns0:synonym>MDR1</ns0:synonym>
          <ns0:synonym>Multidrug resistance protein 1</ns0:synonym>
          <ns0:synonym>P-glycoprotein 1</ns0:synonym>
          <ns0:synonym>PGY1</ns0:synonym>
          <ns0:synonym>Phospholipid transporter ABCB1</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037114|ATP-dependent translocase ABCB1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC
AAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00005</ns0:identifier>
            <ns0:name>ABC_tran</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF00664</ns0:identifier>
            <ns0:name>ABC_membrane</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>brush border membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>cell surface</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>extracellular exosome</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular hyperosmotic salinity response</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to alkaloid</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to antibiotic</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to borneol</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to dexamethasone stimulus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to estradiol stimulus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to external biotic stimulus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to L-glutamate</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to lipopolysaccharide</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to mycotoxin</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to nonylphenol</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>cellular response to tumor necrosis factor</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>circadian rhythm</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>daunorubicin transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>establishment of blood-brain barrier</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>establishment of blood-retinal barrier</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>female pregnancy</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>G2/M transition of mitotic cell cycle</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>hormone transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>intestinal absorption</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>lactation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>maintenance of blood-brain barrier</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>negative regulation of sensory perception of pain</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>placenta development</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of establishment of Sertoli cell barrier</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>positive regulation of response to drug</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>protein localization to bicellular tight junction</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>regulation of intestinal absorption</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to alcohol</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to antineoplastic agent</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to cadmium ion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to codeine</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to cyclosporin A</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to glucagon</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to glycoside</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to hypoxia</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to progesterone</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to quercetin</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to thyroxine</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to vitamin A</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>response to vitamin D</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>stem cell proliferation</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>transmembrane transport</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:transporter>
    <ns0:transporter position="2">
      <ns0:id>BE0001067</ns0:id>
      <ns0:name>Broad substrate specificity ATP-binding cassette transporter ABCG2</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>substrate</ns0:action>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="Q9UNQ0" source="Swiss-Prot">
        <ns0:name>Broad substrate specificity ATP-binding cassette transporter ABCG2</ns0:name>
        <ns0:general-function>Broad substrate specificity ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes a wide variety of physiological compounds, dietary toxins and xenobiotics from cells (PubMed:11306452, PubMed:12958161, PubMed:19506252, PubMed:20705604, PubMed:28554189, PubMed:30405239, PubMed:31003562). Involved in porphyrin homeostasis, mediating the export of protoporphyrin IX (PPIX) from both mitochondria to cytosol and cytosol to extracellular space, it also functions in the cellular export of heme (PubMed:20705604, PubMed:23189181). Also mediates the efflux of sphingosine-1-P from cells (PubMed:20110355). Acts as a urate exporter functioning in both renal and extrarenal urate excretion (PubMed:19506252, PubMed:20368174, PubMed:22132962, PubMed:31003562, PubMed:36749388). In kidney, it also functions as a physiological exporter of the uremic toxin indoxyl sulfate (By similarity). Also involved in the excretion of steroids like estrone 3-sulfate/E1S, 3beta-sulfooxy-androst-5-en-17-one/DHEAS, and other sulfate conjugates (PubMed:12682043, PubMed:28554189, PubMed:30405239). Mediates the secretion of the riboflavin and biotin vitamins into milk (By similarity). Extrudes pheophorbide a, a phototoxic porphyrin catabolite of chlorophyll, reducing its bioavailability (By similarity). Plays an important role in the exclusion of xenobiotics from the brain (Probable). It confers to cells a resistance to multiple drugs and other xenobiotics including mitoxantrone, pheophorbide, camptothecin, methotrexate, azidothymidine, and the anthracyclines daunorubicin and doxorubicin, through the control of their efflux (PubMed:11306452, PubMed:12477054, PubMed:15670731, PubMed:18056989, PubMed:31254042). In placenta, it limits the penetration of drugs from the maternal plasma into the fetus (By similarity). May play a role in early stem cell self-renewal by blocking differentiation (By similarity). In inflammatory macrophages, exports itaconate from the cytosol to the extracellular compartment and limits the activation of TFEB-dependent lysosome biogenesis involved in antibacterial innate immune response</ns0:general-function>
        <ns0:specific-function>ABC-type xenobiotic transporter activity</ns0:specific-function>
        <ns0:gene-name>ABCG2</ns0:gene-name>
        <ns0:locus>4q22.1</ns0:locus>
        <ns0:cellular-location>Cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>396-416
429-449
478-498
507-527
536-556
631-651</ns0:transmembrane-regions>
        <ns0:signal-regions />
        <ns0:theoretical-pi>8.9</ns0:theoretical-pi>
        <ns0:molecular-weight>72313.47</ns0:molecular-weight>
        <ns0:chromosome-location>4</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:74</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>ABCG2</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>ABCG2</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>AF103796</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>4185796</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>792</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>Q9UNQ0</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>ABCG2_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>7.6.2.2</ns0:synonym>
          <ns0:synonym>ABCP</ns0:synonym>
          <ns0:synonym>ATP-binding cassette sub-family G member 2</ns0:synonym>
          <ns0:synonym>BCRP</ns0:synonym>
          <ns0:synonym>BCRP1</ns0:synonym>
          <ns0:synonym>Breast cancer resistance protein</ns0:synonym>
          <ns0:synonym>CDw338</ns0:synonym>
          <ns0:synonym>Mitoxantrone resistance-associated protein</ns0:synonym>
          <ns0:synonym>MXR</ns0:synonym>
          <ns0:synonym>Placenta-specific ATP-binding cassette transporter</ns0:synonym>
          <ns0:synonym>Urate exporter</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002125|Broad substrate specificity ATP-binding cassette transporter ABCG2
MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKSGFLPCRKPVE
KEILSNINGIMKPGLNAILGPTGGGKSSLLDVLAARKDPSGLSGDVLINGAPRPANFKCN
SGYVVQDDVVMGTLTVRENLQFSAALRLATTMTNHEKNERINRVIQELGLDKVADSKVGT
QFIRGVSGGERKRTSIGMELITDPSILFLDEPTTGLDSSTANAVLLLLKRMSKQGRTIIF
SIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESAGYHCEAYNNPADFFLDIING
DSTAVALNREEDFKATEIIEPSKQDKPLIEKLAEIYVNSSFYKETKAELHQLSGGEKKKK
ITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQIIVTVVLGLVIGAIYFGLKNDS
TGIQNRAGVLFFLTTNQCFSSVSAVELFVVEKKLFIHEYISGYYRVSSYFLGKLLSDLLP
MRMLPSIIFTCIVYFMLGLKPKADAFFVMMFTLMMVAYSASSMALAIAAGQSVVSVATLL
MTICFVFMMIFSGLLVNLTTIASWLSWLQYFSIPRYGFTALQHNEFLGQNFCPGLNATGN
NPCNYATCTGEEYLVKQGIDLSPWGLWKNHVALACMIVIFLTIAYLKLLFLKKYS</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0016303|ATP-binding cassette sub-family G member 2 (ABCG2)
ATGTCTTCCAGTAATGTCGAAGTTTTTATCCCAGTGTCACAAGGAAACACCAATGGCTTC
CCCGCGACAGCTTCCAATGACCTGAAGGCATTTACTGAAGGAGCTGTGTTAAGTTTTCAT
AACATCTGCTATCGAGTAAAACTGAAGAGTGGCTTTCTACCTTGTCGAAAACCAGTTGAG
AAAGAAATATTATCGAATATCAATGGGATCATGAAACCTGGTCTCAACGCCATCCTGGGA
CCCACAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAAGT
GGATTATCTGGAGATGTTCTGATAAATGGAGCACCGCGACCTGCCAATTTCAAATGTAAT
TCAGGTTACGTGGTACAAGATGATGTTGTGATGGGCACTCTGACGGTGAGAGAAAACTTA
CAGTTCTCAGCAGCTCTTCGGCTTGCAACAACTATGACGAATCATGAAAAAAACGAACGG
ATTAACAGGGTCATTCAAGAGTTAGGTCTGGATAAAGTGGCAGACTCCAAGGTTGGAACT
CAGTTTATCCGTGGTGTGTCTGGAGGAGAAAGAAAAAGGACTAGTATAGGAATGGAGCTT
ATCACTGATCCTTCCATCTTGTTCTTGGATGAGCCTACAACTGGCTTAGACTCAAGCACA
GCAAATGCTGTCCTTTTGCTCCTGAAAAGGATGTCTAAGCAGGGACGAACAATCATCTTC
TCCATTCATCAGCCTCGATATTCCATCTTCAAGTTGTTTGATAGCCTCACCTTATTGGCC
TCAGGAAGACTTATGTTCCACGGGCCTGCTCAGGAGGCCTTGGGATACTTTGAATCAGCT
GGTTATCACTGTGAGGCCTATAATAACCCTGCAGACTTCTTCTTGGACATCATTAATGGA
GATTCCACTGCTGTGGCATTAAACAGAGAAGAAGACTTTAAAGCCACAGAGATCATAGAG
CCTTCCAAGCAGGATAAGCCACTCATAGAAAAATTAGCGGAGATTTATGTCAACTCCTCC
TTCTACAAAGAGACAAAAGCTGAATTACATCAACTTTCCGGGGGTGAGAAGAAGAAGAAG
ATCACAGTCTTCAAGGAGATCAGCTACACCACCTCCTTCTGTCATCAACTCAGATGGGTT
TCCAAGCGTTCATTCAAAAACTTGCTGGGTAATCCCCAGGCCTCTATAGCTCAGATCATT
GTCACAGTCGTACTGGGACTGGTTATAGGTGCCATTTACTTTGGGCTAAAAAATGATTCT
ACTGGAATCCAGAACAGAGCTGGGGTTCTCTTCTTCCTGACGACCAACCAGTGTTTCAGC
AGTGTTTCAGCCGTGGAACTCTTTGTGGTAGAGAAGAAGCTCTTCATACATGAATACATC
AGCGGATACTACAGAGTGTCATCTTATTTCCTTGGAAAACTGTTATCTGATTTATTACCC
ATGAGGATGTTACCAAGTATTATATTTACCTGTATAGTGTACTTCATGTTAGGATTGAAG
CCAAAGGCAGATGCCTTCTTCGTTATGATGTTTACCCTTATGATGGTGGCTTATTCAGCC
AGTTCCATGGCACTGGCCATAGCAGCAGGTCAGAGTGTGGTTTCTGTAGCAACACTTCTC
ATGACCATCTGTTTTGTGTTTATGATGGTCTGTTGGTCAATCTCACAACCATTGCATCTT
GGCTGTCATGGCTTCAGTACTTCAGCATTCCACGATATGGATTTACGGCTTTGCAGCATA
ATGAATTTTTGGGACAAAACTTCTGCCCAGGACTCAATGCAACAGGAAACAATCCTTGTA
ACTATGCAACATGTACTGGCGAAGAATATTTGGTAA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00005</ns0:identifier>
            <ns0:name>ABC_tran</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF01061</ns0:identifier>
            <ns0:name>ABC2_membrane</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF19055</ns0:identifier>
            <ns0:name>ABC2_membrane_7</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>mitochondrial membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>protein homodimerization activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>transmembrane transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>urate metabolic process</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:transporter>
    <ns0:transporter position="3">
      <ns0:id>BE0001004</ns0:id>
      <ns0:name>Solute carrier organic anion transporter family member 1B1</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="Q9Y6L6" source="Swiss-Prot">
        <ns0:name>Solute carrier organic anion transporter family member 1B1</ns0:name>
        <ns0:general-function>Mediates the Na(+)-independent uptake of organic anions (PubMed:10358072, PubMed:15159445, PubMed:17412826). Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (dehydroepiandrosterone 3-sulfate, 17-beta-glucuronosyl estradiol, and estrone 3-sulfate), as well as eicosanoids (prostaglandin E2, thromboxane B2, leukotriene C4, and leukotriene E4), and thyroid hormones (T4/L-thyroxine, and T3/3,3',5'-triiodo-L-thyronine) (PubMed:10358072, PubMed:10601278, PubMed:10873595, PubMed:11159893, PubMed:12196548, PubMed:12568656, PubMed:15159445, PubMed:15970799, PubMed:16627748, PubMed:17412826, PubMed:19129463, PubMed:26979622). Can take up bilirubin glucuronides from plasma into the liver, contributing to the detoxification-enhancing liver-blood shuttling loop (PubMed:22232210). Involved in the clearance of endogenous and exogenous substrates from the liver (PubMed:10358072, PubMed:10601278). Transports coproporphyrin I and III, by-products of heme synthesis, and may be involved in their hepatic disposition (PubMed:26383540). May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Can transport HMG-CoA reductase inhibitors (also known as statins), such as pravastatin and pitavastatin, a clinically important class of hypolipidemic drugs (PubMed:10601278, PubMed:15159445, PubMed:15970799). May play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutic drug methotrexate (PubMed:23243220). May also transport antihypertension agents, such as the angiotensin-converting enzyme (ACE) inhibitor prodrug enalapril, and the highly selective angiotensin II AT1-receptor antagonist valsartan, in the liver (PubMed:16624871, PubMed:16627748). Shows a pH-sensitive substrate specificity towards prostaglandin E2 and T4 which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment (PubMed:19129463). Hydrogencarbonate/HCO3(-) acts as the probable counteranion that exchanges for organic anions (PubMed:19129463)</ns0:general-function>
        <ns0:specific-function>bile acid transmembrane transporter activity</ns0:specific-function>
        <ns0:gene-name>SLCO1B1</ns0:gene-name>
        <ns0:locus>12p12.1</ns0:locus>
        <ns0:cellular-location>Basolateral cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>29-48
68-88
95-119
169-197
217-237
256-280
332-353
374-397
402-425
538-560
570-595
630-647</ns0:transmembrane-regions>
        <ns0:signal-regions />
        <ns0:theoretical-pi>8.68</ns0:theoretical-pi>
        <ns0:molecular-weight>76447.99</ns0:molecular-weight>
        <ns0:chromosome-location>12</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:10959</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>SLCO1B1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>SLCO1B1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>AF060500</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>5051630</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1220</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>Q9Y6L6</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>SO1B1_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>Liver-specific organic anion transporter 1</ns0:synonym>
          <ns0:synonym>LST-1</ns0:synonym>
          <ns0:synonym>LST1</ns0:synonym>
          <ns0:synonym>OATP-2</ns0:synonym>
          <ns0:synonym>OATP-C</ns0:synonym>
          <ns0:synonym>OATP1B1</ns0:synonym>
          <ns0:synonym>OATP2</ns0:synonym>
          <ns0:synonym>OATPC</ns0:synonym>
          <ns0:synonym>Organic anion transporter SLC21A6</ns0:synonym>
          <ns0:synonym>SLC21A6</ns0:synonym>
          <ns0:synonym>SLCO1B1</ns0:synonym>
          <ns0:synonym>Sodium-independent organic anion-transporting polypeptide 2</ns0:synonym>
          <ns0:synonym>Solute carrier family 21 member 6</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010701|Solute carrier organic anion transporter family member 1B1
MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKSSIIHIERRFE
ISSSLVGFIDGSFEIGNLLVIVFVSYFGSKLHRPKLIGIGCFIMGIGGVLTALPHFFMGY
YRYSKETNINSSENSTSTLSTCLINQILSLNRASPEIVGKGCLKESGSYMWIYVFMGNML
RGIGETPIVPLGLSYIDDFAKEGHSSLYLGILNAIAMIGPIIGFTLGSLFSKMYVDIGYV
DLSTIRITPTDSRWVGAWWLNFLVSGLFSIISSIPFFFLPQTPNKPQKERKASLSLHVLE
TNDEKDQTANLTNQGKNITKNVTGFFQSFKSILTNPLYVMFVLLTLLQVSSYIGAFTYVF
KYVEQQYGQPSSKANILLGVITIPIFASGMFLGGYIIKKFKLNTVGIAKFSCFTAVMSLS
FYLLYFFILCENKSVAGLTMTYDGNNPVTSHRDVPLSYCNSDCNCDESQWEPVCGNNGIT
YISPCLAGCKSSSGNKKPIVFYNCSCLEVTGLQNRNYSAHLGECPRDDACTRKFYFFVAI
QVLNLFFSALGGTSHVMLIVKIVQPELKSLALGFHSMVIRALGGILAPIYFGALIDTTCI
KWSTNNCGTRGSCRTYNSTSFSRVYLGLSSMLRVSSLVLYIILIYAMKKKYQEKDINASE
NGSVMDEANLESLNKNKHFVPSAGADSETHC</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0010702|Solute carrier organic anion transporter family member 1B1 (SLCO1B1)
ATGGACCAAAATCAACATTTGAATAAAACAGCAGAGGCACAACCTTCAGAGAATAAGAAA
ACAAGATACTGCAATGGATTGAAGATGTTCTTGGCAGCTCTGTCACTCAGCTTTATTGCT
AAGACACTAGGTGCAATTATTATGAAAAGTTCCATCATTCATATAGAACGGAGATTTGAG
ATATCCTCTTCTCTTGTTGGTTTTATTGACGGAAGCTTTGAAATTGGAAATTTGCTTGTG
ATTGTATTTGTGAGTTACTTTGGATCCAAACTACATAGACCAAAGTTAATTGGAATCGGT
TGTTTCATTATGGGAATTGGAGGTGTTTTGACTGCTTTGCCACATTTCTTCATGGGATAT
TACAGGTATTCTAAAGAAACTAATATCAATTCATCAGAAAATTCAACATCGACCTTATCC
ACTTGTTTAATTAATCAAATTTTATCACTCAATAGAGCATCACCTGAGATAGTGGGAAAA
GGTTGTTTAAAGGAATCTGGGTCATACATGTGGATATATGTGTTCATGGGTAATATGCTT
CGTGGAATAGGGGAGACTCCCATAGTACCATTGGGGCTTTCTTACATTGATGATTTCGCT
AAAGAAGGACATTCTTCTTTGTATTTAGGTATATTGAATGCAATAGCAATGATTGGTCCA
ATCATTGGCTTTACCCTGGGATCTCTGTTTTCTAAAATGTACGTGGATATTGGATATGTA
GATCTAAGCACTATCAGGATAACTCCTACTGATTCTCGATGGGTTGGAGCTTGGTGGCTT
AATTTCCTTGTGTCTGGACTATTCTCCATTATTTCTTCCATACCATTCTTTTTCTTGCCC
CAAACTCCAAATAAACCACAAAAAGAAAGAAAAGCTTCACTGTCTTTGCATGTGCTGGAA
ACAAATGATGAAAAGGATCAAACAGCTAATTTGACCAATCAAGGAAAAAATATTACCAAA
AATGTGACTGGTTTTTTCCAGTCTTTTAAAAGCATCCTTACTAATCCCCTGTATGTTATG
TTTGTGCTTTTGACGTTGTTACAAGTAAGCAGCTATATTGGTGCTTTTACTTATGTCTTC
AAATACGTAGAGCAACAGTATGGTCAGCCTTCATCTAAGGCTAACATCTTATTGGGAGTC
ATAACCATACCTATTTTTGCAAGTGGAATGTTTTTAGGAGGATATATCATTAAAAAATTC
AAACTGAACACCGTTGGAATTGCCAAATTCTCATGTTTTACTGCTGTGATGTCATTGTCC
TTTTACCTATTATATTTTTTCATACTCTGTGAAAACAAATCAGTTGCCGGACTAACCATG
ACCTATGATGGAAATAATCCAGTGACATCTCATAGAGATGTACCACTTTCTTATTGCAAC
TCAGACTGCAATTGTGATGAAAGTCAATGGGAACCAGTCTGTGGAAACAATGGAATAACT
TACATCTCACCCTGTCTAGCAGGTTGCAAATCTTCAAGTGGCAATAAAAAGCCTATAGTG
TTTTACAACTGCAGTTGTTTGGAAGTAACTGGTCTCCAGAACAGAAATTACTCAGCCCAT
TTGGGTGAATGCCCAAGAGATGATGCTTGTACAAGGAAATTTTACTTTTTTGTTGCAATA
CAAGTCTTGAATTTATTTTTCTCTGCACTTGGAGGCACCTCACATGTCATGCTGATTGTT
AAAATTGTTCAACCTGAATTGAAATCACTTGCACTGGGTTTCCACTCAATGGTTATACGA
GCACTAGGAGGAATTCTAGCTCCAATATATTTTGGGGCTCTGATTGATACAACGTGTATA
AAGTGGTCCACCAACAACTGTGGCACACGTGGGTCATGTAGGACATATAATTCCACATCA
TTTTCAAGGGTCTACTTGGGCTTGTCTTCAATGTTAAGAGTCTCATCACTTGTTTTATAT
ATTATATTAATTTATGCCATGAAGAAAAAATATCAAGAGAAAGATATCAATGCATCAGAA
AATGGAAGTGTCATGGATGAAGCAAACTTAGAATCCTTAAATAAAAATAAACATTTTGTC
CCTTCTGCTGGGGCAGATAGTGAAACACATTGTTAA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF07648</ns0:identifier>
            <ns0:name>Kazal_2</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF03137</ns0:identifier>
            <ns0:name>OATP</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>basolateral plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>bile acid transmembrane transporter activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>sodium-independent organic anion transmembrane transporter activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>bile acid and bile salt transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>organic anion transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>sodium-independent organic anion transport</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:transporter>
    <ns0:transporter position="4">
      <ns0:id>BE0003659</ns0:id>
      <ns0:name>Solute carrier organic anion transporter family member 1B3</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="Q9NPD5" source="Swiss-Prot">
        <ns0:name>Solute carrier organic anion transporter family member 1B3</ns0:name>
        <ns0:general-function>Mediates the Na(+)-independent uptake of organic anions (PubMed:10779507, PubMed:15159445, PubMed:17412826). Shows broad substrate specificity, can transport both organic anions such as bile acid taurocholate (cholyltaurine) and conjugated steroids (17-beta-glucuronosyl estradiol, dehydroepiandrosterone sulfate (DHEAS), and estrone 3-sulfate), as well as eicosanoid leukotriene C4, prostaglandin E2 and L-thyroxine (T4) (PubMed:10779507, PubMed:11159893, PubMed:12568656, PubMed:15159445, PubMed:17412826, PubMed:19129463). Hydrogencarbonate/HCO3(-) acts as the probable counteranion that exchanges for organic anions (PubMed:19129463). Shows a pH-sensitive substrate specificity towards sulfated steroids, taurocholate and T4 which may be ascribed to the protonation state of the binding site and leads to a stimulation of substrate transport in an acidic microenvironment (PubMed:19129463). Involved in the clearance of bile acids and organic anions from the liver (PubMed:22232210). Can take up bilirubin glucuronides from plasma into the liver, contributing to the detoxification-enhancing liver-blood shuttling loop (PubMed:22232210). Transports coproporphyrin I and III, by-products of heme synthesis, and may be involved in their hepatic disposition (PubMed:26383540). May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable). Can transport HMG-CoA reductase inhibitors (also known as statins) such as pitavastatin, a clinically important class of hypolipidemic drugs (PubMed:15159445). May play an important role in plasma and tissue distribution of the structurally diverse chemotherapeutic drugs methotrexate and paclitaxel (PubMed:23243220). May also transport antihypertension agents, such as the angiotensin-converting enzyme (ACE) inhibitor prodrug enalapril, and the highly selective angiotensin II AT1-receptor antagonist valsartan, in the liver (PubMed:16624871, PubMed:16627748)</ns0:general-function>
        <ns0:specific-function>bile acid transmembrane transporter activity</ns0:specific-function>
        <ns0:gene-name>SLCO1B3</ns0:gene-name>
        <ns0:locus>12p12.2</ns0:locus>
        <ns0:cellular-location>Basolateral cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>29-48
68-88
95-119
169-197
217-237
256-280
332-353
374-397
402-425
538-560
570-595
630-647</ns0:transmembrane-regions>
        <ns0:signal-regions />
        <ns0:theoretical-pi>8.95</ns0:theoretical-pi>
        <ns0:molecular-weight>77402.175</ns0:molecular-weight>
        <ns0:chromosome-location>12</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:10961</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>SLCO1B3</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>AJ251506</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>9187497</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1221</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>Q9NPD5</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>SO1B3_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>Liver-specific organic anion transporter 2</ns0:synonym>
          <ns0:synonym>LST-2</ns0:synonym>
          <ns0:synonym>LST2</ns0:synonym>
          <ns0:synonym>OATP-8</ns0:synonym>
          <ns0:synonym>OATP1B3</ns0:synonym>
          <ns0:synonym>OATP8</ns0:synonym>
          <ns0:synonym>Organic anion transporter 8</ns0:synonym>
          <ns0:synonym>Organic anion-transporting polypeptide 8</ns0:synonym>
          <ns0:synonym>SLC21A8</ns0:synonym>
          <ns0:synonym>Solute carrier family 21 member 8</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007032|Solute carrier organic anion transporter family member 1B3
MDQHQHLNKTAESASSEKKKTRRCNGFKMFLAALSFSYIAKALGGIIMKISITQIERRFD
ISSSLAGLIDGSFEIGNLLVIVFVSYFGSKLHRPKLIGIGCLLMGTGSILTSLPHFFMGY
YRYSKETHINPSENSTSSLSTCLINQTLSFNGTSPEIVEKDCVKESGSHMWIYVFMGNML
RGIGETPIVPLGISYIDDFAKEGHSSLYLGSLNAIGMIGPVIGFALGSLFAKMYVDIGYV
DLSTIRITPKDSRWVGAWWLGFLVSGLFSIISSIPFFFLPKNPNKPQKERKISLSLHVLK
TNDDRNQTANLTNQGKNVTKNVTGFFQSLKSILTNPLYVIFLLLTLLQVSSFIGSFTYVF
KYMEQQYGQSASHANFLLGIITIPTVATGMFLGGFIIKKFKLSLVGIAKFSFLTSMISFL
FQLLYFPLICESKSVAGLTLTYDGNNSVASHVDVPLSYCNSECNCDESQWEPVCGNNGIT
YLSPCLAGCKSSSGIKKHTVFYNCSCVEVTGLQNRNYSAHLGECPRDNTCTRKFFIYVAI
QVINSLFSATGGTTFILLTVKIVQPELKALAMGFQSMVIRTLGGILAPIYFGALIDKTCM
KWSTNSCGAQGACRIYNSVFFGRVYLGLSIALRFPALVLYIVFIFAMKKKFQGKDTKASD
NERKVMDEANLEFLNNGEHFVPSAGTDSKTCNLDMQDNAAAN</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0012544|Solute carrier organic anion transporter family member 1B3 (SLCO1B3)
ATGGACCAACATCAACATTTGAATAAAACAGCAGAGTCAGCATCTTCAGAGAAAAAGAAA
ACAAGACGCTGCAATGGATTCAAGATGTTCTTGGCAGCCCTGTCATTCAGCTATATTGCT
AAAGCACTAGGTGGAATCATTATGAAAATTTCCATCACTCAAATAGAAAGGAGATTTGAC
ATATCCTCTTCTCTTGCTGGTTTAATTGATGGAAGCTTTGAAATTGGAAATTTGCTTGTG
ATTGTATTTGTAAGTTACTTTGGATCTAAACTACACAGACCGAAGTTAATTGGAATTGGT
TGTCTCCTTATGGGAACTGGAAGTATTTTGACATCTTTACCACATTTCTTCATGGGATAT
TATAGGTATTCTAAAGAAACCCATATTAATCCATCAGAAAATTCAACATCAAGTTTATCA
ACCTGTTTAATTAATCAAACCTTATCATTCAATGGAACATCACCTGAGATAGTAGAAAAA
GATTGTGTAAAGGAATCTGGGTCACACATGTGGATCTATGTCTTCATGGGGAATATGCTT
CGTGGCATAGGGGAAACCCCCATAGTACCATTGGGGATTTCATACATTGATGATTTTGCA
AAAGAAGGACATTCTTCCTTGTATTTAGGTAGTTTGAATGCAATAGGAATGATTGGTCCA
GTCATTGGCTTTGCACTGGGATCTCTGTTTGCTAAAATGTACGTGGATATTGGATATGTA
GATCTGAGCACTATCAGAATAACTCCTAAGGACTCTCGTTGGGTTGGAGCTTGGTGGCTT
GGTTTCCTTGTGTCTGGACTATTTTCCATTATTTCTTCCATACCATTTTTTTTCTTGCCG
AAAAATCCAAATAAACCACAAAAAGAAAGAAAAATTTCACTATCATTGCATGTGCTGAAA
ACAAATGATGATAGAAATCAAACAGCTAATTTGACCAACCAAGGAAAAAATGTTACCAAA
AATGTGACTGGTTTTTTCCAGTCTTTGAAAAGCATCCTTACCAATCCCCTGTATGTTATA
TTTCTGCTTTTGACATTGTTACAAGTAAGCAGCTTTATTGGTTCTTTTACTTACGTCTTT
AAATATATGGAGCAACAGTACGGTCAGTCTGCATCTCATGCTAACTTTTTGTTGGGAATC
ATAACCATTCCTACGGTTGCAACTGGAATGTTTTTAGGAGGATTTATCATTAAAAAATTC
AAATTGTCTTTAGTTGGAATTGCCAAATTTTCATTTCTTACTTCGATGATATCCTTCTTG
TTTCAACTTCTATATTTCCCTCTAATCTGCGAAAGCAAATCAGTTGCCGGCCTAACCTTG
ACCTATGATGGAAATAATTCAGTGGCATCTCATGTAGATGTACCACTTTCTTATTGCAAC
TCAGAGTGCAATTGTGATGAAAGTCAGTGGGAACCAGTCTGTGGGAACAATGGAATAACT
TACCTGTCACCTTGTCTAGCAGGATGCAAATCCTCAAGTGGTATTAAAAAGCATACAGTG
TTTTATAACTGTAGTTGTGTGGAAGTAACTGGTCTCCAGAACAGAAATTACTCAGCACAC
TTGGGTGAATGCCCAAGAGATAATACTTGTACAAGGAAATTTTTCATCTATGTTGCAATT
CAAGTCATAAACTCTTTGTTCTCTGCAACAGGAGGTACCACATTTATCTTGTTGACTGTG
AAGATTGTTCAACCTGAATTGAAAGCACTTGCAATGGGTTTCCAGTCAATGGTTATAAGA
ACACTAGGAGGAATTCTAGCTCCAATATATTTTGGGGCTCTGATTGATAAAACATGTATG
AAGTGGTCCACCAACAGCTGTGGAGCACAAGGAGCTTGTAGGATATATAATTCCGTATTT
TTTGGAAGGGTCTACTTGGGCTTATCTATAGCTTTAAGATTCCCAGCACTTGTTTTATAT
ATTGTTTTCATTTTTGCTATGAAGAAAAAATTTCAAGGAAAAGATACCAAGGCATCGGAC
AATGAAAGAAAAGTAATGGATGAAGCAAACTTAGAATTCTTAAATAATGGTGAACATTTT
GTACCTTCTGCTGGAACAGATAGTAAAACATGTAATTTGGACATGCAAGACAATGCTGCT
GCCAACTAA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF07648</ns0:identifier>
            <ns0:name>Kazal_2</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF03137</ns0:identifier>
            <ns0:name>OATP</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>basolateral plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>bile acid transmembrane transporter activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>organic anion transmembrane transporter activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>sodium-independent organic anion transmembrane transporter activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>bile acid and bile salt transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>organic anion transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>sodium-independent organic anion transport</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:transporter>
    <ns0:transporter position="5">
      <ns0:id>BE0001066</ns0:id>
      <ns0:name>Solute carrier family 22 member 6</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="Q4U2R8" source="Swiss-Prot">
        <ns0:name>Solute carrier family 22 member 6</ns0:name>
        <ns0:general-function>Secondary active transporter that functions as a Na(+)-independent organic anion (OA)/dicarboxylate antiporter where the uptake of one molecule of OA into the cell is coupled with an efflux of one molecule of intracellular dicarboxylate such as 2-oxoglutarate or glutarate (PubMed:11669456, PubMed:11907186, PubMed:14675047, PubMed:22108572, PubMed:23832370, PubMed:28534121, PubMed:9950961). Mediates the uptake of OA across the basolateral side of proximal tubule epithelial cells, thereby contributing to the renal elimination of endogenous OA from the systemic circulation into the urine (PubMed:9887087). Functions as a biopterin transporters involved in the uptake and the secretion of coenzymes tetrahydrobiopterin (BH4), dihydrobiopterin (BH2) and sepiapterin to urine, thereby determining baseline levels of blood biopterins (PubMed:28534121). Transports prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) and may contribute to their renal excretion (PubMed:11907186). Also mediates the uptake of cyclic nucleotides such as cAMP and cGMP (PubMed:26377792). Involved in the transport of neuroactive tryptophan metabolites kynurenate (KYNA) and xanthurenate (XA) and may contribute to their secretion from the brain (PubMed:22108572, PubMed:23832370). May transport glutamate (PubMed:26377792). Also involved in the disposition of uremic toxins and potentially toxic xenobiotics by the renal organic anion secretory pathway, helping reduce their undesired toxicological effects on the body (PubMed:11669456, PubMed:14675047). Uremic toxins include the indoxyl sulfate (IS), hippurate/N-benzoylglycine (HA), indole acetate (IA), 3-carboxy-4- methyl-5-propyl-2-furanpropionate (CMPF) and urate (PubMed:14675047, PubMed:26377792). Xenobiotics include the mycotoxin ochratoxin (OTA) (PubMed:11669456). May also contribute to the transport of organic compounds in testes across the blood-testis-barrier (PubMed:35307651)</ns0:general-function>
        <ns0:specific-function>alpha-ketoglutarate transmembrane transporter activity</ns0:specific-function>
        <ns0:gene-name>SLC22A6</ns0:gene-name>
        <ns0:locus>11q12.3</ns0:locus>
        <ns0:cellular-location>Basolateral cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>10-30
136-156
165-187
191-213
225-245
249-269
338-358
369-389
396-416
426-446
456-475
485-505</ns0:transmembrane-regions>
        <ns0:signal-regions />
        <ns0:theoretical-pi>8.78</ns0:theoretical-pi>
        <ns0:molecular-weight>61815.78</ns0:molecular-weight>
        <ns0:chromosome-location>11</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:10970</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>hROAT1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>SLC22A6</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>AF057039</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>3831566</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1025</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>Q4U2R8</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>S22A6_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>hOAT1</ns0:synonym>
          <ns0:synonym>hPAHT</ns0:synonym>
          <ns0:synonym>hROAT1</ns0:synonym>
          <ns0:synonym>OAT1</ns0:synonym>
          <ns0:synonym>Organic anion transporter 1</ns0:synonym>
          <ns0:synonym>PAH transporter</ns0:synonym>
          <ns0:synonym>PAHT</ns0:synonym>
          <ns0:synonym>Renal organic anion transporter 1</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037120|Solute carrier family 22 member 6
MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCRPPADANLSKN
GGLEVWLPRDRQGQPESCLRFTSPQWGLPFLNGTEANGTGATEPCTDGWIYDNSTFPSTI
VTEWDLVCSHRALRQLAQSLYMVGVLLGAMVFGYLADRLGRRKVLILNYLQTAVSGTCAA
FAPNFPIYCAFRLLSGMALAGISLNCMTLNVEWMPIHTRACVGTLIGYVYSLGQFLLAGV
AYAVPHWRHLQLLVSAPFFAFFIYSWFFIESARWHSSSGRLDLTLRALQRVARINGKREE
GAKLSMEVLRASLQKELTMGKGQASAMELLRCPTLRHLFLCLSMLWFATSFAYYGLVMDL
QGFGVSIYLIQVIFGAVDLPAKLVGFLVINSLGRRPAQMAALLLAGICILLNGVIPQDQS
IVRTSLAVLGKGCLAASFNCIFLYTGELYPTMIRQTGMGMGSTMARVGSIVSPLVSMTAE
LYPSMPLFIYGAVPVAASAVTVLLPETLGQPLPDTVQDLESRWAPTQKEAGIYPRKGKQT
RQQQEHQKYMVPLQASAQEKNGL</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0010747|Solute carrier family 22 member 6 (SLC22A6)
ATGGCCTTTAATGACCTCCTGCAGCAGGTGGGGGGTGTCGGCCGCTTCCAGCAGATCCAG
GTCACCCTGGTGGTCCTCCCCCTGCTCCTGATGGCTTCTCACAACACCCTGCAGAACTTC
ACTGCTGCCATCCCTACCCACCACTGCCGCCCGCCTGCCGATGCCAACCTCAGCAAGAAC
GGGGGGCTGGAGGTCTGGCTGCCCCGGGACAGGCAGGGGCAGCCTGAGTCCTGCCTCCGC
TTCACCTCCCCGCAGTGGGGACTGCCCTTTCTCAATGGCACAGAAGCCAATGGCACAGGG
GCCACAGAGCCCTGCACCGATGGCTGGATCTATGACAACAGCACCTTCCCATCTACCATC
GTGACTGAGTGGGACCTTGTGTGCTCTCACAGGGCCCTACGCCAGCTGGCCCAGTCCTTG
TACATGGTGGGGGTGCTGCTCGGAGCCATGGTGTTCGGCTACCTTGCAGACAGGCTAGGC
CGCCGGAAGGTACTCATCTTGAACTACCTGCAGACAGCTGTGTCAGGGACCTGCGCAGCC
TTCGCACCCAACTTCCCCATCTACTGCGCCTTCCGGCTCCTCTCGGGCATGGCTCTGGCT
GGCATCTCCCTCAACTGCATGACACTGAATGTGGAGTGGATGCCCATTCACACACGGGCC
TGCGTGGGCACCTTGATTGGCTATGTCTACAGCCTGGGCCAGTTCCTCCTGGCTGGTGTG
GCCTACGCTGTGCCCCACTGGCGCCACCTGCAGCTACTGGTCTCTGCGCCTTTTTTTGCC
TTCTTCATCTACTCCTGGTTCTTCATTGAGTCGGCCCGCTGGCACTCCTCCTCCGGGAGG
CTGGACCTCACCCTGAGGGCCCTGCAGAGAGTCGCCCGGATCAATGGGAAGCGGGAAGAA
GGAGCCAAATTGAGTATGGAGGTACTCCGGGCCAGTCTGCAGAAGGAGCTGACCATGGGC
AAAGGCCAGGCATCGGCCATGGAGCTGCTGCGCTGCCCCACCCTCCGCCACCTCTTCCTC
TGCCTCTCCATGCTGTGGTTTGCCACTAGCTTTGCATACTATGGGCTGGTCATGGACCTG
CAGGGCTTTGGAGTCAGCATCTACCTAATCCAGGTGATCTTTGGTGCTGTGGACCTGCCT
GCCAAGCTTGTGGGCTTCCTTGTCATCAACTCCCTGGGTCGCCGGCCTGCCCAGATGGCT
GCACTGCTGCTGGCAGGCATCTGCATCCTGCTCAATGGGGTGATACCCCAGGACCAGTCC
ATTGTCCGAACCTCTCTTGCTGTGCTGGGGAAGGGTTGTCTGGCTGCCTCCTTCAACTGC
ATCTTCCTGTATACTGGGGAACTGTATCCCACAATGATCCGGCAGACAGGCATGGGAATG
GGCAGCACCATGGCCCGAGTGGGCAGCATCGTGAGCCCACTGGTGAGCATGACTGCCGAG
CTCTACCCCTCCATGCCTCTCTTCATCTACGGTGCTGTTCCTGTGGCCGCCAGCGCTGTC
ACTGTCCTCCTGCCAGAGACCCTGGGCCAGCCACTGCCAGACACGGTGCAGGACCTGGAG
AGCAGGTGGGCCCCCACTCAGAAAGAAGCAGGGATATATCCCAGGAAAGGGAAACAGACG
CGACAGCAACAAGAGCACCAGAAGTATATGGTCCCACTGCAGGCCTCAGCACAAGAGAAG
AATGGACTCTGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00083</ns0:identifier>
            <ns0:name>Sugar_tr</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>basolateral plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>caveola</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>extracellular exosome</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>chloride ion binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>organic anion transmembrane transporter activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>sodium-independent organic anion transmembrane transporter activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>alpha-ketoglutarate transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>organic anion transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>renal tubular secretion</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>sodium-independent organic anion transport</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:transporter>
    <ns0:transporter position="6">
      <ns0:id>BE0003657</ns0:id>
      <ns0:name>Multidrug and toxin extrusion protein 1</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="Q96FL8" source="Swiss-Prot">
        <ns0:name>Multidrug and toxin extrusion protein 1</ns0:name>
        <ns0:general-function>Multidrug efflux pump that functions as a H(+)/organic cation antiporter (PubMed:16330770, PubMed:17509534). Plays a physiological role in the excretion of cationic compounds including endogenous metabolites, drugs, toxins through the kidney and liver, into urine and bile respectively (PubMed:16330770, PubMed:17495125, PubMed:17509534, PubMed:17582384, PubMed:18305230, PubMed:19158817, PubMed:21128598, PubMed:24961373). Mediates the efflux of endogenous compounds such as creatinine, vitamin B1/thiamine, agmatine and estrone-3-sulfate (PubMed:16330770, PubMed:17495125, PubMed:17509534, PubMed:17582384, PubMed:18305230, PubMed:19158817, PubMed:21128598, PubMed:24961373). May also contribute to regulate the transport of cationic compounds in testis across the blood-testis-barrier (Probable)</ns0:general-function>
        <ns0:specific-function>antiporter activity</ns0:specific-function>
        <ns0:gene-name>SLC47A1</ns0:gene-name>
        <ns0:locus>17p11.2</ns0:locus>
        <ns0:cellular-location>Cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>38-58
73-93
124-144
153-173
177-197
217-237
257-276
296-316
337-357
371-391
409-429
438-458
547-567</ns0:transmembrane-regions>
        <ns0:signal-regions />
        <ns0:theoretical-pi>7.62</ns0:theoretical-pi>
        <ns0:molecular-weight>61921.585</ns0:molecular-weight>
        <ns0:chromosome-location>17</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:25588</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>SLC47A1</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>AK001709</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>7023138</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1216</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>Q96FL8</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>S47A1_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>hMATE-1</ns0:synonym>
          <ns0:synonym>MATE-1</ns0:synonym>
          <ns0:synonym>MATE1</ns0:synonym>
          <ns0:synonym>Solute carrier family 47 member 1</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007028|Multidrug and toxin extrusion protein 1
MEAPEEPAPVRGGPEATLEVRGSRCLRLSAFREELRALLVLAGPAFLVQLMVFLISFISS
VFCGHLGKLELDAVTLAIAVINVTGVSVGFGLSSACDTLISQTYGSQNLKHVGVILQRSA
LVLLLCCFPCWALFLNTQHILLLFRQDPDVSRLTQTYVTIFIPALPATFLYMLQVKYLLN
QGIVLPQIVTGVAANLVNALANYLFLHQLHLGVIGSALANLISQYTLALLLFLYILGKKL
HQATWGGWSLECLQDWASFLRLAIPSMLMLCMEWWAYEVGSFLSGILGMVELGAQSIVYE
LAIIVYMVPAGFSVAASVRVGNALGAGDMEQARKSSTVSLLITVLFAVAFSVLLLSCKDH
VGYIFTTDRDIINLVAQVVPIYAVSHLFEALACTSGGVLRGSGNQKVGAIVNTIGYYVVG
LPIGIALMFATTLGVMGLWSGIIICTVFQAVCFLGFIIQLNWKKACQQAQVHANLKVNNV
PRSGNSALPQDPLHPGCPENLEGILTNDVGKTGEPQSDQQMRQEEPLPEHPQDGAKLSRK
QLVLRRGLLLLGVFLILLVGILVRFYVRIQ</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0017174|Multidrug and toxin extrusion protein 1 (SLC47A1)
ATGGAAGCTCCTGAGGAGCCCGCGCCAGTGCGCGGAGGCCCGGAGGCCACCCTTGAGGTC
CGTGGGTCGCGCTGCTTGCGGCTGTCCGCCTTCCGAGAAGAGCTGCGGGCGCTCTTGGTC
CTGGCTGGCCCCGCGTTCTTGGTTCAGCTGATGGTGTTCCTGATCAGCTTCATAAGCTCC
GTGTTCTGTGGCCACCTGGGCAAGCTGGAGCTGGATGCAGTCACGCTGGCAATCGCGGTT
ATCAATGTCACTGGTGTCTCAGTGGGATTCGGCTTATCTTCTGCCTGTGACACCCTCATC
TCCCAGACGTACGGGAGCCAGAACCTGAAGCACGTGGGCGTGATCCTGCAGCGGAGTGCG
CTCGTCCTGCTCCTCTGCTGCTTCCCCTGCTGGGCGCTCTTTCTCAACACCCAGCACATC
CTGCTGCTCTTCAGGCAGGACCCAGATGTGTCCAGGCTTACCCAGACCTATGTCACGATC
TTCATTCCAGCTCTTCCTGCAACCTTTCTTTATATGTTACAAGTTAAATATTTGCTCAAC
CAGGGAATTGTACTGCCCCAGATCGTAACTGGAGTTGCAGCCAACCTTGTCAATGCCCTC
GCCAACTATCTGTTTCTCCATCAACTGCATCTTGGGGTGATAGGCTCTGCACTGGCAAAC
TTGATTTCCCAGTACACCCTGGCTCTACTCCTCTTTCTCTACATCCTCGGGAAAAAACTG
CATCAAGCTACATGGGGAGGCTGGTCCCTCGAGTGCCTGCAGGACTGGGCCTCCTTCCTC
CGCCTGGCCATCCCCAGCATGCTCATGCTGTGCATGGAGTGGTGGGCCTATGAGGTCGGG
AGCTTCCTCAGTGGCATCCTCGGCATGGTGGAGCTGGGCGCTCAGTCCATCGTGTATGAA
CTGGCCATCATTGTGTACATGGTCCCTGCAGGCTTCAGTGTGGCTGCCAGTGTCCGGGTA
GGAAACGCTCTGGGTGCTGGAGACATGGAGCAGGCACGGAAGTCCTCTACCGTTTCCCTG
CTGATTACAGTGCTCTTTGCTGTAGCCTTCAGTGTCCTGCTGTTAAGCTGTAAGGATCAC
GTGGGGTACATTTTTACTACCGACCGAGACATCATTAATCTGGTGGCTCAGGTGGTTCCA
ATTTATGCTGTTTCCCACCTCTTTGAAGCTCTTGCTTGCACGAGTGGTGGTGTTCTGAGG
GGGAGTGGAAATCAGAAGGTTGGAGCCATTGTGAATACCATTGGGTACTATGTGGTTGGC
CTCCCCATCGGGATCGCGCTGATGTTTGCAACCACACTTGGAGTGATGGGTCTGTGGTCA
GGGATCATCATCTGTACAGTCTTTCAAGCTGTGTGTTTTCTAGGCTTTATTATTCAGCTA
AATTGGAAAAAAGCCTGTCAGCAGGCTCAGGTACACGCCAATTTGAAAGTAAACAACGTG
CCTCGGAGTGGGAATTCTGCTCTCCCTCAGGATCCGCTTCACCCAGGGTGCCCTGAAAAC
CTTGAAGGAATTTTAACGAACGATGTTGGAAAGACAGGCGAGCCTCAGTCAGATCAGCAG
ATGCGCCAAGAAGAACCTTTGCCGGAACATCCACAGGACGGCGCTAAATTGTCCAGGAAA
CAGCTGGTGCTGCGGCGAGGGCTTCTGCTCCTGGGGGTCTTCTTAATCTTGCTGGTGGGG
ATTTTAGTGAGATTCTATGTCAGAATTCAGTGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF01554</ns0:identifier>
            <ns0:name>MatE</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>organic cation transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>transmembrane transport</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:transporter>
    <ns0:transporter position="7">
      <ns0:id>BE0004752</ns0:id>
      <ns0:name>Multidrug and toxin extrusion protein 2</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L2953</ns0:ref-id>
            <ns0:title>FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers</ns0:title>
            <ns0:url>https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm</ns0:url>
          </ns0:link>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="Q86VL8" source="Swiss-Prot">
        <ns0:name>Multidrug and toxin extrusion protein 2</ns0:name>
        <ns0:general-function>Multidrug efflux pump that functions as a H(+)/organic cation antiporter. Mediates the efflux of cationic compounds, such as the model cations, tetraethylammonium (TEA) and 1-methyl-4-phenylpyridinium (MPP+), the platinum-based drug oxaliplatin or weak bases that are positively charged at physiological pH, cimetidine, the platinum-based drugs cisplatin and oxaliplatin or the antidiabetic drug metformin. Mediates the efflux of endogenous compounds such as, creatinine, thiamine and estrone-3-sulfate. Plays a physiological role in the excretion of drugs, toxins and endogenous metabolites through the kidney</ns0:general-function>
        <ns0:specific-function>antiporter activity</ns0:specific-function>
        <ns0:gene-name>SLC47A2</ns0:gene-name>
        <ns0:locus>17p11.2</ns0:locus>
        <ns0:cellular-location>Cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>34-54
67-87
120-140
154-174
220-240
249-269
290-309
328-348
369-389
403-423
443-463
467-487
579-599</ns0:transmembrane-regions>
        <ns0:signal-regions />
        <ns0:theoretical-pi />
        <ns0:molecular-weight>65083.915</ns0:molecular-weight>
        <ns0:chromosome-location>17</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:26439</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>SLC47A2</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>1217</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>Q86VL8</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>S47A2_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>hMATE-2</ns0:synonym>
          <ns0:synonym>Kidney-specific H(+)/organic cation antiporter</ns0:synonym>
          <ns0:synonym>MATE-2</ns0:synonym>
          <ns0:synonym>MATE2</ns0:synonym>
          <ns0:synonym>Solute carrier family 47 member 2</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008601|Multidrug and toxin extrusion protein 2
MDSLQDTVALDHGGCCPALSRLVPRGFGTEMWTLFALSGPLFLFQVLTFMIYIVSTVFCG
HLGKVELASVTLAVAFVNVCGVSVGVGLSSACDTLMSQSFGSPNKKHVGVILQRGALVLL
LCCLPCWALFLNTQHILLLFRQDPDVSRLTQDYVMIFIPGLPVIFLYNLLAKYLQNQGWL
KGQEEESPFQTPGLSILHPSHSHLSRASFHLFQKITWPQVLSGVVGNCVNGVANYALVSV
LNLGVRGSAYANIISQFAQTVFLLLYIVLKKLHLETWAGWSSQCLQDWGPFFSLAVPSML
MICVEWWAYEIGSFLMGLLSVVDLSAQAVIYEVATVTYMIPLGLSIGVCVRVGMALGAAD
TVQAKRSAVSGVLSIVGISLVLGTLISILKNQLGHIFTNDEDVIALVSQVLPVYSVFHVF
EAICCVYGGVLRGTGKQAFGAAVNAITYYIIGLPLGILLTFVVRMRIMGLWLGMLACVFL
ATAAFVAYTARLDWKLAAEEAKKHSGRQQQQRAESTATRPGPEKAVLSSVATGSSPGITL
TTYSRSECHVDFFRTPEEAHALSAPTSRLSVKQLVIRRGAALGAASATLMVGLTVRILAT
RH</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0021398|Multidrug and toxin extrusion protein 2 (SLC47A2)
ATGGACAGCCTCCAGGACACAGTGGCCCTGGACCATGGGGGCTGCTGCCCTGCCCTCAGC
AGGCTGGTTCCCAGAGGCTTTGGGACTGAGATGTGGACTCTCTTTGCCCTTTCTGGACCC
CTGTTCCTGTTCCAGGTGCTGACTTTTATGATCTACATCGTGAGCACTGTGTTCTGCGGG
CACCTGGGCAAGGTGGAGCTGGCATCGGTGACCCTCGCGGTGGCCTTTGTCAATGTCTGC
GGAGTTTCTGTAGGAGTTGGTTTGTCTTCGGCATGTGACACCTTGATGTCTCAGAGCTTC
GGCAGCCCCAACAAGAAGCACGTGGGCGTGATCCTGCAGCGGGGCGCGCTGGTCCTGCTC
CTCTGCTGCCTCCCTTGCTGGGCGCTCTTCCTCAACACCCAGCACATCCTGCTGCTCTTC
CGGCAGGACCCGGACGTGTCCAGGTTGACCCAGGACTATGTAATGATTTTCATTCCAGGA
CTTCCGGTGATTTTTCTTTACAATCTGCTGGCAAAATATTTGCAAAATCAGAAGATCACC
TGGCCCCAAGTCCTCAGTGGTGTGGTGGGCAACTGTGTCAACGGTGTGGCCAACTATGCC
CTGGTTTCTGTGCTGAACCTGGGGGTCAGGGGCTCCGCCTATGCCAACATCATCTCCCAG
TTTGCACAGACCGTCTTCCTCCTTCTCTACATTGTGCTGAAGAAGCTGCACCTGGAGACG
TGGGCAGGTTGGTCCAGCCAGTGCCTGCAGGACTGGGGCCCCTTCTTCTCCCTGGCTGTC
CCCAGCATGCTCATGATCTGTGTTGAGTGGTGGGCCTATGAGATCGGGAGCTTCCTCATG
GGGCTGCTCAGTGTGGTGGATCTCTCTGCCCAGGCTGTCATCTACGAGGTGGCCACTGTG
ACCTACATGATTCCCTTGGGGCTCAGCATCGGGGTCTGTGTCCGAGTGGGGATGGCTCTG
GGGGCTGCGGATACTGTGCAGGCCAAGCGCTCGGCCGTCTCGGGCGTGCTCAGCATAGTT
GGCATTTCCCTGGTCCTGGGCACCCTGATAAGCATCCTGAAAAATCAGCTGGGGCATATT
TTTACCAATGATGAAGATGTCATTGCCCTGGTGAGCCAGGTCTTGCCGGTTTATAGTGTC
TTTCACGTGTTTGAGGCCATCTGTTGTGTCTATGGCGGAGTTCTGAGAGGAACTGGGAAG
CAGGCCTTTGGTGCCGCTGTGAATGCCATCACATATTACATCATCGGCCTACCACTGGGC
ATCCTTCTGACCTTTGTGGTCAGAATGAGAATCATGGGCCTCTGGCTGGGCATGCTGGCC
TGTGTCTTCCTGGCAACTGCTGCCTTTGTTGCTTATACTGCCCGGCTGGACTGGAAGCTT
GCTGCAGAGGAGGCTAAGAAACATTCAGGCCGGCAGCAGCAGCAGAGAGCAGAGAGCACT
GCAACCAGACCTGGGCCTGAGAAAGCAGTCCTATCTTCAGTGGCTACAGGCAGTTCCCCT
GGCATTACCTTGACAACGTATTCAAGGTCTGAGTGCCACGTGGACTTCTTCAGGACTCCA
GAGGAGGCCCACGCCCTTTCAGCTCCTACCAGCAGACTATCAGTGAAACAGCTGGTCATC
CGCCGTGGGGCTGCTCTGGGGGCGGCGTCAGCCACACTGATGGTGGGGCTCACGGTCAGG
ATCCTAGCCACCAGGCACTAG</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF01554</ns0:identifier>
            <ns0:name>MatE</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>antiporter activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>transmembrane transport</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:transporter>
    <ns0:transporter position="8">
      <ns0:id>BE0000703</ns0:id>
      <ns0:name>Bile salt export pump</ns0:name>
      <ns0:organism>Humans</ns0:organism>
      <ns0:actions>
        <ns0:action>inhibitor</ns0:action>
      </ns0:actions>
      <ns0:references>
        <ns0:articles />
        <ns0:textbooks />
        <ns0:links>
          <ns0:link>
            <ns0:ref-id>L15986</ns0:ref-id>
            <ns0:title>FDA Approved Drug Products: GAVRETO (pralsetinib) oral capsules</ns0:title>
            <ns0:url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213721s004lbl.pdf</ns0:url>
          </ns0:link>
        </ns0:links>
        <ns0:attachments />
      </ns0:references>
      <ns0:known-action>no</ns0:known-action>
      <ns0:polypeptide id="O95342" source="Swiss-Prot">
        <ns0:name>Bile salt export pump</ns0:name>
        <ns0:general-function>Catalyzes the transport of the major hydrophobic bile salts, such as taurine and glycine-conjugated cholic acid across the canalicular membrane of hepatocytes in an ATP-dependent manner, therefore participates in hepatic bile acid homeostasis and consequently to lipid homeostasis through regulation of biliary lipid secretion in a bile salts dependent manner (PubMed:15791618, PubMed:16332456, PubMed:18985798, PubMed:19228692, PubMed:20010382, PubMed:20398791, PubMed:22262466, PubMed:24711118, PubMed:29507376, PubMed:32203132). Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts (PubMed:16332456). Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion (PubMed:15901796, PubMed:18245269)</ns0:general-function>
        <ns0:specific-function>ABC-type bile acid transporter activity</ns0:specific-function>
        <ns0:gene-name>ABCB11</ns0:gene-name>
        <ns0:locus>2q31.1</ns0:locus>
        <ns0:cellular-location>Apical cell membrane</ns0:cellular-location>
        <ns0:transmembrane-regions>63-83
148-168
216-236
241-261
320-340
354-374
756-776
795-815
870-890
891-911
980-1000
1012-1032</ns0:transmembrane-regions>
        <ns0:signal-regions />
        <ns0:theoretical-pi>6.52</ns0:theoretical-pi>
        <ns0:molecular-weight>146405.83</ns0:molecular-weight>
        <ns0:chromosome-location>2</ns0:chromosome-location>
        <ns0:organism ncbi-taxonomy-id="9606">Humans</ns0:organism>
        <ns0:external-identifiers>
          <ns0:external-identifier>
            <ns0:resource>HUGO Gene Nomenclature Committee (HGNC)</ns0:resource>
            <ns0:identifier>HGNC:42</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenAtlas</ns0:resource>
            <ns0:identifier>ABCB11</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GeneCards</ns0:resource>
            <ns0:identifier>ABCB11</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Gene Database</ns0:resource>
            <ns0:identifier>AF091582</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>GenBank Protein Database</ns0:resource>
            <ns0:identifier>3873243</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>Guide to Pharmacology</ns0:resource>
            <ns0:identifier>778</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProtKB</ns0:resource>
            <ns0:identifier>O95342</ns0:identifier>
          </ns0:external-identifier>
          <ns0:external-identifier>
            <ns0:resource>UniProt Accession</ns0:resource>
            <ns0:identifier>ABCBB_HUMAN</ns0:identifier>
          </ns0:external-identifier>
        </ns0:external-identifiers>
        <ns0:synonyms>
          <ns0:synonym>7.6.2.-</ns0:synonym>
          <ns0:synonym>ATP-binding cassette sub-family B member 11</ns0:synonym>
          <ns0:synonym>BSEP</ns0:synonym>
        </ns0:synonyms>
        <ns0:amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010492|Bile salt export pump
MSDSVILRSIKKFGEENDGFESDKSYNNDKKSRLQDEKKGDGVRVGFFQLFRFSSSTDIW
LMFVGSLCAFLHGIAQPGVLLIFGTMTDVFIDYDVELQELQIPGKACVNNTIVWTNSSLN
QNMTNGTRCGLLNIESEMIKFASYYAGIAVAVLITGYIQICFWVIAAARQIQKMRKFYFR
RIMRMEIGWFDCNSVGELNTRFSDDINKINDAIADQMALFIQRMTSTICGFLLGFFRGWK
LTLVIISVSPLIGIGAATIGLSVSKFTDYELKAYAKAGVVADEVISSMRTVAAFGGEKRE
VERYEKNLVFAQRWGIRKGIVMGFFTGFVWCLIFLCYALAFWYGSTLVLDEGEYTPGTLV
QIFLSVIVGALNLGNASPCLEAFATGRAAATSIFETIDRKPIIDCMSEDGYKLDRIKGEI
EFHNVTFHYPSRPEVKILNDLNMVIKPGEMTALVGPSGAGKSTALQLIQRFYDPCEGMVT
VDGHDIRSLNIQWLRDQIGIVEQEPVLFSTTIAENIRYGREDATMEDIVQAAKEANAYNF
IMDLPQQFDTLVGEGGGQMSGGQKQRVAIARALIRNPKILLLDMATSALDNESEAMVQEV
LSKIQHGHTIISVAHRLSTVRAADTIIGFEHGTAVERGTHEELLERKGVYFTLVTLQSQG
NQALNEEDIKDATEDDMLARTFSRGSYQDSLRASIRQRSKSQLSYLVHEPPLAVVDHKST
YEEDRKDKDIPVQEEVEPAPVRRILKFSAPEWPYMLVGSVGAAVNGTVTPLYAFLFSQIL
GTFSIPDKEEQRSQINGVCLLFVAMGCVSLFTQFLQGYAFAKSGELLTKRLRKFGFRAML
GQDIAWFDDLRNSPGALTTRLATDASQVQGAAGSQIGMIVNSFTNVTVAMIIAFSFSWKL
SLVILCFFPFLALSGATQTRMLTGFASRDKQALEMVGQITNEALSNIRTVAGIGKERRFI
EALETELEKPFKTAIQKANIYGFCFAFAQCIMFIANSASYRYGGYLISNEGLHFSYVFRV
ISAVVLSATALGRAFSYTPSYAKAKISAARFFQLLDRQPPISVYNTAGEKWDNFQGKIDF
VDCKFTYPSRPDSQVLNGLSVSISPGQTLAFVGSSGCGKSTSIQLLERFYDPDQGKVMID
GHDSKKVNVQFLRSNIGIVSQEPVLFACSIMDNIKYGDNTKEIPMERVIAAAKQAQLHDF
VMSLPEKYETNVGSQGSQLSRGEKQRIAIARAIVRDPKILLLDEATSALDTESEKTVQVA
LDKAREGRTCIVIAHRLSTIQNADIIAVMAQGVVIEKGTHEELMAQKGAYYKLVTTGSPI
S</ns0:amino-acid-sequence>
        <ns0:gene-sequence format="FASTA">&gt;lcl|BSEQ0010493|Bile salt export pump (ABCB11)
ATGTCTGACTCAGTAATTCTTCGAAGTATAAAGAAATTTGGAGAGGAGAATGATGGTTTT
GAGTCAGATAAATCATATAATAATGATAAGAAATCAAGGTTACAAGATGAGAAGAAAGGT
GATGGCGTTAGAGTTGGCTTCTTTCAATTGTTTCGGTTTTCTTCATCAACTGACATTTGG
CTGATGTTTGTGGGAAGTTTGTGTGCATTTCTCCATGGAATAGCCCAGCCAGGCGTGCTA
CTCATTTTTGGCACAATGACAGATGTTTTTATTGACTACGACGTTGAGTTACAAGAACTC
CAGATTCCAGGAAAAGCATGTGTGAATAACACCATTGTATGGACTAACAGTTCCCTCAAC
CAGAACATGACAAATGGAACACGTTGTGGGTTGCTGAACATCGAGAGCGAAATGATCAAA
TTTGCCAGTTACTATGCTGGAATTGCTGTCGCAGTACTTATCACAGGATATATTCAAATA
TGCTTTTGGGTCATTGCCGCAGCTCGTCAGATACAGAAAATGAGAAAATTTTACTTTAGG
AGAATAATGAGAATGGAAATAGGGTGGTTTGACTGCAATTCAGTGGGGGAGCTGAATACA
AGATTCTCTGATGATATTAATAAAATCAATGATGCCATAGCTGACCAAATGGCCCTTTTC
ATTCAGCGCATGACCTCGACCATCTGTGGTTTCCTGTTGGGATTTTTCAGGGGTTGGAAA
CTGACCTTGGTTATTATTTCTGTCAGCCCTCTCATTGGGATTGGAGCAGCCACCATTGGT
CTGAGTGTGTCCAAGTTTACGGACTATGAGCTGAAGGCCTATGCCAAAGCAGGGGTGGTG
GCTGATGAAGTCATTTCATCAATGAGAACAGTGGCTGCTTTTGGTGGTGAGAAAAGAGAG
GTTGAAAGGTATGAGAAAAATCTTGTGTTCGCCCAGCGTTGGGGAATTAGAAAAGGAATA
GTGATGGGATTCTTTACTGGATTCGTGTGGTGTCTCATCTTTTTGTGTTATGCACTGGCC
TTCTGGTACGGCTCCACACTTGTCCTGGATGAAGGAGAATATACACCAGGAACCCTTGTC
CAGATTTTCCTCAGTGTCATAGTAGGAGCTTTAAATCTTGGCAATGCCTCTCCTTGTTTG
GAAGCCTTTGCAACTGGACGTGCAGCAGCCACCAGCATTTTTGAGACAATAGACAGGAAA
CCCATCATTGACTGCATGTCAGAAGATGGTTACAAGTTGGATCGAATCAAGGGTGAAATT
GAATTCCATAATGTGACCTTCCATTATCCTTCCAGACCAGAGGTGAAGATTCTAAATGAC
CTCAACATGGTCATTAAACCAGGGGAAATGACAGCTCTGGTAGGACCCAGTGGAGCTGGA
AAAAGTACAGCACTGCAACTCATTCAGCGATTCTATGACCCCTGTGAAGGAATGGTGACC
GTGGATGGCCATGACATTCGCTCTCTTAACATTCAGTGGCTTAGAGATCAGATTGGGATA
GTGGAGCAAGAGCCAGTTCTGTTCTCTACCACCATTGCAGAAAATATTCGCTATGGCAGA
GAAGATGCAACAATGGAAGACATAGTCCAAGCTGCCAAGGAGGCCAATGCCTACAACTTC
ATCATGGACCTGCCACAGCAATTTGACACCCTTGTTGGAGAAGGAGGAGGCCAGATGAGT
GGTGGCCAGAAACAAAGGGTAGCTATCGCCAGAGCCCTCATCCGAAATCCCAAGATTCTG
CTTTTGGACATGGCCACCTCAGCTCTGGACAATGAGAGTGAAGCCATGGTGCAAGAAGTG
CTGAGTAAGATTCAGCATGGGCACACAATCATTTCAGTTGCTCATCGCTTGTCTACGGTC
AGAGCTGCAGATACCATCATTGGTTTTGAACATGGCACTGCAGTGGAAAGAGGGACCCAT
GAAGAATTACTGGAAAGGAAAGGTGTTTACTTCACTCTAGTGACTTTGCAAAGCCAGGGA
AATCAAGCTCTTAATGAAGAGGACATAAAGGATGCAACTGAAGATGACATGCTTGCGAGG
ACCTTTAGCAGAGGGAGCTACCAGGATAGTTTAAGGGCTTCCATCCGGCAACGCTCCAAG
TCTCAGCTTTCTTACCTGGTGCACGAACCTCCATTAGCTGTTGTAGATCATAAGTCTACC
TATGAAGAAGATAGAAAGGACAAGGACATTCCTGTGCAGGAAGAAGTTGAACCTGCCCCA
GTTAGGAGGATTCTGAAATTCAGTGCTCCAGAATGGCCCTACATGCTGGTAGGGTCTGTG
GGTGCAGCTGTGAACGGGACAGTCACACCCTTGTATGCCTTTTTATTCAGCCAGATTCTT
GGGACTTTTTCAATTCCTGATAAAGAGGAACAAAGGTCACAGATCAATGGTGTGTGCCTA
CTTTTTGTAGCAATGGGCTGTGTATCTCTTTTCACCCAATTTCTACAGGGATATGCCTTT
GCTAAATCTGGGGAGCTCCTAACAAAAAGGCTACGTAAATTTGGTTTCAGGGCAATGCTG
GGGCAAGATATTGCCTGGTTTGATGACCTCAGAAATAGCCCTGGAGCATTGACAACAAGA
CTTGCTACAGATGCTTCCCAAGTTCAAGGGGCTGCCGGCTCTCAGATCGGGATGATAGTC
AATTCCTTCACTAACGTCACTGTGGCCATGATCATTGCCTTCTCCTTTAGCTGGAAGCTG
AGCCTGGTCATCTTGTGCTTCTTCCCCTTCTTGGCTTTATCAGGAGCCACACAGACCAGG
ATGTTGACAGGATTTGCCTCTCGAGATAAGCAGGCCCTGGAGATGGTGGGACAGATTACA
AATGAAGCCCTCAGTAACATCCGCACTGTTGCTGGAATTGGAAAGGAGAGGCGGTTCATT
GAAGCACTTGAGACTGAGCTGGAGAAGCCCTTCAAGACAGCCATTCAGAAAGCCAATATT
TACGGATTCTGCTTTGCCTTTGCCCAGTGCATCATGTTTATTGCGAATTCTGCTTCCTAC
AGATATGGAGGTTACTTAATCTCCAATGAGGGGCTCCATTTCAGCTATGTGTTCAGGGTG
ATCTCTGCAGTTGTACTGAGTGCAACAGCTCTTGGAAGAGCCTTCTCTTACACCCCAAGT
TATGCAAAAGCTAAAATATCAGCTGCACGCTTTTTTCAACTGCTGGACCGACAACCCCCA
ATCAGTGTATACAATACTGCAGGTGAAAAATGGGACAACTTCCAGGGGAAGATTGATTTT
GTTGATTGTAAATTTACATATCCTTCTCGACCTGACTCGCAAGTTCTGAATGGTCTCTCA
GTGTCGATTAGTCCAGGGCAGACACTGGCGTTTGTTGGGAGCAGTGGATGTGGCAAAAGC
ACTAGCATTCAGCTGTTGGAACGTTTCTATGATCCTGATCAAGGGAAGGTGATGATAGAT
GGTCATGACAGCAAAAAAGTAAATGTCCAGTTCCTCCGCTCAAACATTGGAATTGTTTCC
CAGGAACCAGTGTTGTTTGCCTGTAGCATAATGGACAATATCAAGTATGGAGACAACACC
AAAGAAATTCCCATGGAAAGAGTCATAGCAGCTGCAAAACAGGCTCAGCTGCATGATTTT
GTCATGTCACTCCCAGAGAAATATGAAACTAACGTTGGGTCCCAGGGGTCTCAACTCTCT
AGAGGGGAGAAACAACGCATTGCTATTGCTCGGGCCATTGTACGAGATCCTAAAATCTTG
CTACTAGATGAAGCCACTTCTGCCTTAGACACAGAAAGTGAAAAGACGGTGCAGGTTGCT
CTAGACAAAGCCAGAGAGGGTCGGACCTGCATTGTCATTGCCCATCGCTTGTCCACCATC
CAGAACGCGGATATCATTGCTGTCATGGCACAGGGGGTGGTGATTGAAAAGGGGACCCAT
GAAGAACTGATGGCCCAAAAAGGAGCCTACTACAAACTAGTCACCACTGGATCCCCCATC
AGTTGA</ns0:gene-sequence>
        <ns0:pfams>
          <ns0:pfam>
            <ns0:identifier>PF00005</ns0:identifier>
            <ns0:name>ABC_tran</ns0:name>
          </ns0:pfam>
          <ns0:pfam>
            <ns0:identifier>PF00664</ns0:identifier>
            <ns0:name>ABC_membrane</ns0:name>
          </ns0:pfam>
        </ns0:pfams>
        <ns0:go-classifiers>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>extracellular exosome</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>intercellular canaliculus</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>component</ns0:category>
            <ns0:description>plasma membrane</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>ATP binding</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>function</ns0:category>
            <ns0:description>canalicular bile acid transmembrane transporter activity</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>bile acid and bile salt transport</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>bile acid biosynthetic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>bile acid metabolic process</ns0:description>
          </ns0:go-classifier>
          <ns0:go-classifier>
            <ns0:category>process</ns0:category>
            <ns0:description>canalicular bile acid transport</ns0:description>
          </ns0:go-classifier>
        </ns0:go-classifiers>
      </ns0:polypeptide>
    </ns0:transporter>
  </ns0:transporters>
</ns0:drug>
</ns0:drugbank>